US20220306694A1 - Heterotandem bicyclic peptide complexes - Google Patents
Heterotandem bicyclic peptide complexes Download PDFInfo
- Publication number
- US20220306694A1 US20220306694A1 US17/655,822 US202217655822A US2022306694A1 US 20220306694 A1 US20220306694 A1 US 20220306694A1 US 202217655822 A US202217655822 A US 202217655822A US 2022306694 A1 US2022306694 A1 US 2022306694A1
- Authority
- US
- United States
- Prior art keywords
- seq
- pya
- μmol
- peg5
- bcy8928
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 221
- 125000002619 bicyclic group Chemical group 0.000 title claims abstract description 66
- 239000003446 ligand Substances 0.000 claims abstract description 92
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 90
- 210000004027 cell Anatomy 0.000 claims abstract description 50
- 201000011510 cancer Diseases 0.000 claims abstract description 48
- 210000002865 immune cell Anatomy 0.000 claims abstract description 9
- 101000604197 Homo sapiens Neuronatin Proteins 0.000 claims description 91
- 102100038816 Neuronatin Human genes 0.000 claims description 91
- 238000000034 method Methods 0.000 claims description 82
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 74
- 229920001184 polypeptide Polymers 0.000 claims description 43
- 239000002062 molecular scaffold Substances 0.000 claims description 32
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 30
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 30
- 102100035486 Nectin-4 Human genes 0.000 claims description 23
- 101710043865 Nectin-4 Proteins 0.000 claims description 22
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 21
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 claims description 20
- 239000002253 acid Substances 0.000 claims description 20
- 108010055196 EphA2 Receptor Proteins 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 15
- 210000004443 dendritic cell Anatomy 0.000 claims description 9
- 210000000822 natural killer cell Anatomy 0.000 claims description 6
- 210000004698 lymphocyte Anatomy 0.000 claims description 5
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 4
- 210000000285 follicular dendritic cell Anatomy 0.000 claims description 4
- FYBFGAFWCBMEDG-UHFFFAOYSA-N 1-[3,5-di(prop-2-enoyl)-1,3,5-triazinan-1-yl]prop-2-en-1-one Chemical compound C=CC(=O)N1CN(C(=O)C=C)CN(C(=O)C=C)C1 FYBFGAFWCBMEDG-UHFFFAOYSA-N 0.000 claims description 3
- 210000003714 granulocyte Anatomy 0.000 claims description 3
- 210000000265 leukocyte Anatomy 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 150000003863 ammonium salts Chemical class 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 210000004970 cd4 cell Anatomy 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N Arginine Chemical compound OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 117
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 94
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 84
- 239000011541 reaction mixture Substances 0.000 description 83
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 76
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 62
- 239000000203 mixture Substances 0.000 description 58
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 55
- 239000000243 solution Substances 0.000 description 48
- 238000002360 preparation method Methods 0.000 description 46
- 238000002953 preparative HPLC Methods 0.000 description 43
- 150000001875 compounds Chemical class 0.000 description 42
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 42
- 239000007787 solid Substances 0.000 description 42
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 41
- 230000002829 reductive effect Effects 0.000 description 39
- 229940024606 amino acid Drugs 0.000 description 37
- 150000001413 amino acids Chemical class 0.000 description 36
- 235000001014 amino acid Nutrition 0.000 description 35
- 238000007792 addition Methods 0.000 description 34
- 229940126214 compound 3 Drugs 0.000 description 27
- 229940125782 compound 2 Drugs 0.000 description 26
- -1 hydrobromic Chemical class 0.000 description 26
- 239000013256 coordination polymer Substances 0.000 description 25
- 239000012299 nitrogen atmosphere Substances 0.000 description 24
- VAKXPQHQQNOUEZ-UHFFFAOYSA-N 3-[4-[[bis[[1-(3-hydroxypropyl)triazol-4-yl]methyl]amino]methyl]triazol-1-yl]propan-1-ol Chemical compound N1=NN(CCCO)C=C1CN(CC=1N=NN(CCCO)C=1)CC1=CN(CCCO)N=N1 VAKXPQHQQNOUEZ-UHFFFAOYSA-N 0.000 description 22
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 22
- 125000000539 amino acid group Chemical group 0.000 description 22
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 22
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 22
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 21
- 230000015572 biosynthetic process Effects 0.000 description 20
- 239000002904 solvent Substances 0.000 description 20
- 238000003786 synthesis reaction Methods 0.000 description 20
- 230000014509 gene expression Effects 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 18
- 239000012043 crude product Substances 0.000 description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 14
- 229940125898 compound 5 Drugs 0.000 description 13
- 235000018417 cysteine Nutrition 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 239000011347 resin Substances 0.000 description 13
- 229920005989 resin Polymers 0.000 description 13
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 12
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 11
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 11
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 11
- 230000007935 neutral effect Effects 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 11
- 210000004881 tumor cell Anatomy 0.000 description 11
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 10
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 10
- 235000021314 Palmitic acid Nutrition 0.000 description 10
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 229940125904 compound 1 Drugs 0.000 description 10
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 10
- 238000011191 terminal modification Methods 0.000 description 10
- VNWKTOKETHGBQD-UHFFFAOYSA-N C Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 9
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 9
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 9
- 210000004899 c-terminal region Anatomy 0.000 description 9
- 230000008878 coupling Effects 0.000 description 9
- 238000010168 coupling process Methods 0.000 description 9
- 238000005859 coupling reaction Methods 0.000 description 9
- 230000006698 induction Effects 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- JJBRCINQXASGAI-UHFFFAOYSA-M O=COO[Na] Chemical compound O=COO[Na] JJBRCINQXASGAI-UHFFFAOYSA-M 0.000 description 8
- UFULAYFCSOUIOV-UHFFFAOYSA-O cysteaminium Chemical compound [NH3+]CCS UFULAYFCSOUIOV-UHFFFAOYSA-O 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 150000003573 thiols Chemical class 0.000 description 8
- 238000003556 assay Methods 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 125000000524 functional group Chemical group 0.000 description 7
- 230000002209 hydrophobic effect Effects 0.000 description 7
- 229960003151 mercaptamine Drugs 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 241000282414 Homo sapiens Species 0.000 description 6
- 210000000481 breast Anatomy 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 5
- 108010069514 Cyclic Peptides Proteins 0.000 description 5
- 102000001189 Cyclic Peptides Human genes 0.000 description 5
- 150000008574 D-amino acids Chemical class 0.000 description 5
- 208000017604 Hodgkin disease Diseases 0.000 description 5
- 206010025323 Lymphomas Diseases 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- NBVXSUQYWXRMNV-MICDWDOJSA-N [2H]CF Chemical compound [2H]CF NBVXSUQYWXRMNV-MICDWDOJSA-N 0.000 description 5
- 150000001350 alkyl halides Chemical class 0.000 description 5
- 150000001540 azides Chemical class 0.000 description 5
- 238000003501 co-culture Methods 0.000 description 5
- 102000012803 ephrin Human genes 0.000 description 5
- 108060002566 ephrin Proteins 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 150000003923 2,5-pyrrolediones Chemical class 0.000 description 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 4
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 4
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 4
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 4
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 4
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 4
- 150000008575 L-amino acids Chemical class 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 4
- 102000002356 Nectin Human genes 0.000 description 4
- 108060005251 Nectin Proteins 0.000 description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 description 4
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 206010042971 T-cell lymphoma Diseases 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 150000001345 alkine derivatives Chemical class 0.000 description 4
- 150000001412 amines Chemical group 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 239000000611 antibody drug conjugate Substances 0.000 description 4
- 229940049595 antibody-drug conjugate Drugs 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 125000003636 chemical group Chemical group 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000021615 conjugation Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 235000018977 lysine Nutrition 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 210000002307 prostate Anatomy 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 125000006850 spacer group Chemical group 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 3
- FABVRSFEBCDJLC-UHFFFAOYSA-N 1,2,3-tris(bromomethyl)benzene Chemical compound BrCC1=CC=CC(CBr)=C1CBr FABVRSFEBCDJLC-UHFFFAOYSA-N 0.000 description 3
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- 208000011691 Burkitt lymphomas Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 108090000369 Glutamate Carboxypeptidase II Proteins 0.000 description 3
- 101710183768 Glutamate carboxypeptidase 2 Proteins 0.000 description 3
- 206010066476 Haematological malignancy Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000638251 Homo sapiens Tumor necrosis factor ligand superfamily member 9 Proteins 0.000 description 3
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 description 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 208000034578 Multiple myelomas Diseases 0.000 description 3
- 230000006052 T cell proliferation Effects 0.000 description 3
- 230000005867 T cell response Effects 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 description 3
- 102000018594 Tumour necrosis factor Human genes 0.000 description 3
- 108050007852 Tumour necrosis factor Proteins 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000005587 bubbling Effects 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 3
- 239000000562 conjugate Substances 0.000 description 3
- 230000001461 cytolytic effect Effects 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 201000009277 hairy cell leukemia Diseases 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 150000002678 macrocyclic compounds Chemical class 0.000 description 3
- 230000036210 malignancy Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000002611 ovarian Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 230000002797 proteolythic effect Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 210000003289 regulatory T cell Anatomy 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 210000003932 urinary bladder Anatomy 0.000 description 3
- FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 description 2
- IYKLZBIWFXPUCS-VIFPVBQESA-N (2s)-2-(naphthalen-1-ylamino)propanoic acid Chemical compound C1=CC=C2C(N[C@@H](C)C(O)=O)=CC=CC2=C1 IYKLZBIWFXPUCS-VIFPVBQESA-N 0.000 description 2
- PJRFTUILPGJJIO-IBGZPJMESA-N (2s)-6-azido-2-(9h-fluoren-9-ylmethoxycarbonylamino)hexanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCCN=[N+]=[N-])C(=O)O)C3=CC=CC=C3C2=C1 PJRFTUILPGJJIO-IBGZPJMESA-N 0.000 description 2
- GOPWHXPXSPIIQZ-FQEVSTJZSA-N (4s)-4-(9h-fluoren-9-ylmethoxycarbonylamino)-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCC(O)=O)C(=O)OC(C)(C)C)C3=CC=CC=C3C2=C1 GOPWHXPXSPIIQZ-FQEVSTJZSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- DKIDEFUBRARXTE-UHFFFAOYSA-N 3-mercaptopropanoic acid Chemical compound OC(=O)CCS DKIDEFUBRARXTE-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 2
- ZRKQYPOOYZKAJT-ZSCHJXSPSA-N CCCCCCCCCCCCCCCC(O)=O.C[C@@H](C(O)=O)NCC#C Chemical compound CCCCCCCCCCCCCCCC(O)=O.C[C@@H](C(O)=O)NCC#C ZRKQYPOOYZKAJT-ZSCHJXSPSA-N 0.000 description 2
- 101100129088 Caenorhabditis elegans lys-2 gene Proteins 0.000 description 2
- 101100289894 Caenorhabditis elegans lys-7 gene Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 102000050554 Eph Family Receptors Human genes 0.000 description 2
- 108091008815 Eph receptors Proteins 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 208000033833 Myelomonocytic Chronic Leukemia Diseases 0.000 description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
- 102000056189 Neutrophil collagenases Human genes 0.000 description 2
- 108030001564 Neutrophil collagenases Proteins 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 108010059993 Vancomycin Proteins 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 150000001266 acyl halides Chemical class 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 230000001919 adrenal effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 230000001270 agonistic effect Effects 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 229940009098 aspartate Drugs 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical group NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 2
- 239000003560 cancer drug Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 230000000139 costimulatory effect Effects 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000005965 immune activity Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- CMWYAOXYQATXSI-UHFFFAOYSA-N n,n-dimethylformamide;piperidine Chemical compound CN(C)C=O.C1CCNCC1 CMWYAOXYQATXSI-UHFFFAOYSA-N 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 238000010837 poor prognosis Methods 0.000 description 2
- 238000012877 positron emission topography Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 description 2
- 229940055619 selenocysteine Drugs 0.000 description 2
- 235000016491 selenocysteine Nutrition 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical class O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- 125000002653 sulfanylmethyl group Chemical group [H]SC([H])([H])[*] 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 229960003165 vancomycin Drugs 0.000 description 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 2
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 2
- MRTPISKDZDHEQI-YFKPBYRVSA-N (2s)-2-(tert-butylamino)propanoic acid Chemical group OC(=O)[C@H](C)NC(C)(C)C MRTPISKDZDHEQI-YFKPBYRVSA-N 0.000 description 1
- PECGVEGMRUZOML-AWEZNQCLSA-N (2s)-2-amino-3,3-diphenylpropanoic acid Chemical group C=1C=CC=CC=1C([C@H](N)C(O)=O)C1=CC=CC=C1 PECGVEGMRUZOML-AWEZNQCLSA-N 0.000 description 1
- QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 description 1
- SRGOJUDAJKUDAZ-LURJTMIESA-N (2s)-2-amino-3-cyclobutylpropanoic acid Chemical group OC(=O)[C@@H](N)CC1CCC1 SRGOJUDAJKUDAZ-LURJTMIESA-N 0.000 description 1
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
- LKLLNYWECKEQIB-UHFFFAOYSA-N 1,3,5-triazinane Chemical compound C1NCNCN1 LKLLNYWECKEQIB-UHFFFAOYSA-N 0.000 description 1
- PWTGPQMQEULXFR-UHFFFAOYSA-N 1-[2,3-bis(2,5-dioxopyrrol-1-yl)phenyl]pyrrole-2,5-dione Chemical compound O=C1C=CC(=O)N1C1=CC=CC(N2C(C=CC2=O)=O)=C1N1C(=O)C=CC1=O PWTGPQMQEULXFR-UHFFFAOYSA-N 0.000 description 1
- UCKPWPPRJHUUPL-UHFFFAOYSA-N 1-[2-[2,3-bis[2-(2,5-dioxopyrrol-1-yl)ethyl]phenyl]ethyl]pyrrole-2,5-dione Chemical compound O=C1C=CC(=O)N1CCC1=CC=CC(CCN2C(C=CC2=O)=O)=C1CCN1C(=O)C=CC1=O UCKPWPPRJHUUPL-UHFFFAOYSA-N 0.000 description 1
- WHEOHCIKAJUSJC-UHFFFAOYSA-N 1-[2-[bis[2-(2,5-dioxopyrrol-1-yl)ethyl]amino]ethyl]pyrrole-2,5-dione Chemical compound O=C1C=CC(=O)N1CCN(CCN1C(C=CC1=O)=O)CCN1C(=O)C=CC1=O WHEOHCIKAJUSJC-UHFFFAOYSA-N 0.000 description 1
- PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical compound [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 1
- 108010000239 Aequorin Proteins 0.000 description 1
- 102000004400 Aminopeptidases Human genes 0.000 description 1
- 108090000915 Aminopeptidases Proteins 0.000 description 1
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical group NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 241001598984 Bromius obscurus Species 0.000 description 1
- 206010058354 Bronchioloalveolar carcinoma Diseases 0.000 description 1
- HYBDYDFYSWSJDC-UHFFFAOYSA-N C#CC.CCC(=O)CCOCCOCCOCCOCCOCCN=[N+]=[N-].CCC(=O)CCOCCOCCOCCOCCOCCn1cc(C)nn1.CN.[N-]=[N+]=NCCOCCOCCOCCOCCOCCC(=O)ON1C(=O)CCC1=O Chemical compound C#CC.CCC(=O)CCOCCOCCOCCOCCOCCN=[N+]=[N-].CCC(=O)CCOCCOCCOCCOCCOCCn1cc(C)nn1.CN.[N-]=[N+]=NCCOCCOCCOCCOCCOCCC(=O)ON1C(=O)CCC1=O HYBDYDFYSWSJDC-UHFFFAOYSA-N 0.000 description 1
- LWSFSCZULAQUKK-LRKMYQSLSA-N C#CC[C@H](N)C(=O)O.C#CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(=O)O.CCCCCCCCCCCCCCCC(=O)ON1C(=O)CCC1=O.[2H]CF Chemical compound C#CC[C@H](N)C(=O)O.C#CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(=O)O.CCCCCCCCCCCCCCCC(=O)ON1C(=O)CCC1=O.[2H]CF LWSFSCZULAQUKK-LRKMYQSLSA-N 0.000 description 1
- FEWYABJYYKPIDB-QCNSCHFVSA-N C.C.[2H]CF Chemical compound C.C.[2H]CF FEWYABJYYKPIDB-QCNSCHFVSA-N 0.000 description 1
- NICMPXLFOIVURU-IVTUVLNASA-N C.CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)C[C@@H](CCC(=O)NC)C(=O)OC(C)(C)C)C(=O)OC(C)(C)C.CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)C[C@@H](CCC(=O)O)C(=O)OC(C)(C)C)C(=O)OC(C)(C)C Chemical compound C.CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)C[C@@H](CCC(=O)NC)C(=O)OC(C)(C)C)C(=O)OC(C)(C)C.CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)C[C@@H](CCC(=O)O)C(=O)OC(C)(C)C)C(=O)OC(C)(C)C NICMPXLFOIVURU-IVTUVLNASA-N 0.000 description 1
- OZTRBWXVMXAQKW-UHFFFAOYSA-M C.O=COO[Na] Chemical compound C.O=COO[Na] OZTRBWXVMXAQKW-UHFFFAOYSA-M 0.000 description 1
- NGYQNBIAUAGJHY-RWQOXAPSSA-N C.[2H]CF Chemical compound C.[2H]CF NGYQNBIAUAGJHY-RWQOXAPSSA-N 0.000 description 1
- SLZCVTVHXOSWSA-UHFFFAOYSA-N C=C(CCOCCN(CCOCCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCN=[N+]=[N-])CCOCCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCN=[N+]=[N-])NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCN=[N+]=[N-].[N-]=[N+]=NCCOCCOCCOCCOCCOCCC(=O)ON1C(=O)CCC1=O Chemical compound C=C(CCOCCN(CCOCCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCN=[N+]=[N-])CCOCCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCN=[N+]=[N-])NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCN=[N+]=[N-].[N-]=[N+]=NCCOCCOCCOCCOCCOCCC(=O)ON1C(=O)CCC1=O SLZCVTVHXOSWSA-UHFFFAOYSA-N 0.000 description 1
- GRWIPTOCPQROQH-UHFFFAOYSA-M CC#N.O.O=COO[Na] Chemical compound CC#N.O.O=COO[Na] GRWIPTOCPQROQH-UHFFFAOYSA-M 0.000 description 1
- ZNFBUFJFWUKTQH-QFJYLQTESA-N CCCCCCCCCCCCCCCC(=O)C[C@@H](CCC(=O)N[C@@H](CCCCN=[N+]=[N-])C(=O)O)C(=O)O.CCCCCCCCCCCCCCCC(=O)C[C@@H](CCC(=O)N[C@@H](CCCCN=[N+]=[N-])C(C)=O)C(=O)O.CCl.S.S.S.S.S=PP=S Chemical compound CCCCCCCCCCCCCCCC(=O)C[C@@H](CCC(=O)N[C@@H](CCCCN=[N+]=[N-])C(=O)O)C(=O)O.CCCCCCCCCCCCCCCC(=O)C[C@@H](CCC(=O)N[C@@H](CCCCN=[N+]=[N-])C(C)=O)C(=O)O.CCl.S.S.S.S.S=PP=S ZNFBUFJFWUKTQH-QFJYLQTESA-N 0.000 description 1
- MYANSQFGQGLHLN-URYWXEGGSA-N CCCCCCCCCCCCCCCC(=O)C[C@@H](CCC(=O)N[C@@H](CCCCN=[N+]=[N-])C(=O)O)C(=O)O.CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)N[C@@H](CCCCn1cc(C)nn1)C(=O)O)C(=O)O Chemical compound CCCCCCCCCCCCCCCC(=O)C[C@@H](CCC(=O)N[C@@H](CCCCN=[N+]=[N-])C(=O)O)C(=O)O.CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)N[C@@H](CCCCn1cc(C)nn1)C(=O)O)C(=O)O MYANSQFGQGLHLN-URYWXEGGSA-N 0.000 description 1
- XOHGZEWFIFUAGF-UHPFVLSRSA-N CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)C[C@@H](CCC(=O)NC)C(=O)OC(C)(C)C)C(=O)OC(C)(C)C.CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)C[C@@H](CCC(=O)NCc1cn(CCOCCC(=O)CCC(=O)CCC(=O)CCC(=O)CCC(=O)NC)nn1)C(=O)OC(C)(C)C)C(=O)OC(C)(C)C.CNC(=O)CCOCCOCCOCCOCCOCCN=[N+]=[N-] Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)C[C@@H](CCC(=O)NC)C(=O)OC(C)(C)C)C(=O)OC(C)(C)C.CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)C[C@@H](CCC(=O)NCc1cn(CCOCCC(=O)CCC(=O)CCC(=O)CCC(=O)CCC(=O)NC)nn1)C(=O)OC(C)(C)C)C(=O)OC(C)(C)C.CNC(=O)CCOCCOCCOCCOCCOCCN=[N+]=[N-] XOHGZEWFIFUAGF-UHPFVLSRSA-N 0.000 description 1
- PLDHDSJQGSEPCH-MWHPOPNNSA-N CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)C[C@@H](CCC(=O)NCc1cn(CCOCCC(=O)CCC(=O)CCC(=O)CCC(=O)CCC(=O)NC)nn1)C(=O)O)C(=O)O.CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)C[C@@H](CCC(=O)NCc1cn(CCOCCC(=O)CCC(=O)CCC(=O)CCC(=O)CCC(=O)NC)nn1)C(=O)OC(C)(C)C)C(=O)OC(C)(C)C Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)C[C@@H](CCC(=O)NCc1cn(CCOCCC(=O)CCC(=O)CCC(=O)CCC(=O)CCC(=O)NC)nn1)C(=O)O)C(=O)O.CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)C[C@@H](CCC(=O)NCc1cn(CCOCCC(=O)CCC(=O)CCC(=O)CCC(=O)CCC(=O)NC)nn1)C(=O)OC(C)(C)C)C(=O)OC(C)(C)C PLDHDSJQGSEPCH-MWHPOPNNSA-N 0.000 description 1
- WADVTWFKUFKWKD-SCIHWSBRSA-N CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)C[C@@H](CCC(=O)O)C(=O)OC(C)(C)C)C(=O)OC(C)(C)C.CCl.S=PP=S Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)C[C@@H](CCC(=O)O)C(=O)OC(C)(C)C)C(=O)OC(C)(C)C.CCl.S=PP=S WADVTWFKUFKWKD-SCIHWSBRSA-N 0.000 description 1
- YETADYBUTQUGFC-UHFFFAOYSA-N CCCCCCCCCCCCCCCC(=O)O.CCCCCCCCCCCCCCCC(=O)ON1C(=O)CCC1=O.O=C1CCC(=O)N1O Chemical compound CCCCCCCCCCCCCCCC(=O)O.CCCCCCCCCCCCCCCC(=O)ON1C(=O)CCC1=O.O=C1CCC(=O)N1O YETADYBUTQUGFC-UHFFFAOYSA-N 0.000 description 1
- 101150091609 CD274 gene Proteins 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 108010006303 Carboxypeptidases Proteins 0.000 description 1
- 102000005367 Carboxypeptidases Human genes 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010007275 Carcinoid tumour Diseases 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 208000008334 Dermatofibrosarcoma Diseases 0.000 description 1
- 206010057070 Dermatofibrosarcoma protuberans Diseases 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000007033 Dysgerminoma Diseases 0.000 description 1
- 206010062805 Dysplastic naevus Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101150076616 EPHA2 gene Proteins 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 101710116743 Ephrin type-A receptor 2 Proteins 0.000 description 1
- 102100031983 Ephrin type-B receptor 4 Human genes 0.000 description 1
- 102100023721 Ephrin-B2 Human genes 0.000 description 1
- 108010044090 Ephrin-B2 Proteins 0.000 description 1
- 201000005231 Epithelioid sarcoma Diseases 0.000 description 1
- 208000032027 Essential Thrombocythemia Diseases 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 208000001382 Experimental Melanoma Diseases 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 description 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000003958 Glutamate Carboxypeptidase II Human genes 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical group NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- 208000023661 Haematological disease Diseases 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 description 1
- 101100407305 Homo sapiens CD274 gene Proteins 0.000 description 1
- 101000938346 Homo sapiens Ephrin type-A receptor 2 Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101000950669 Homo sapiens Mitogen-activated protein kinase 9 Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 1
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 208000006937 Hydatidiform mole Diseases 0.000 description 1
- 206010048643 Hypereosinophilic syndrome Diseases 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 1
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 102000019145 JUN kinase activity proteins Human genes 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 206010023347 Keratoacanthoma Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- OYIFNHCXNCRBQI-BYPYZUCNSA-N L-2-aminoadipic acid Chemical compound OC(=O)[C@@H](N)CCCC(O)=O OYIFNHCXNCRBQI-BYPYZUCNSA-N 0.000 description 1
- QUOGESRFPZDMMT-UHFFFAOYSA-N L-Homoarginine Natural products OC(=O)C(N)CCCCNC(N)=N QUOGESRFPZDMMT-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical compound OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 229910052765 Lutetium Inorganic materials 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 102100037809 Mitogen-activated protein kinase 9 Human genes 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000014767 Myeloproliferative disease Diseases 0.000 description 1
- 238000007126 N-alkylation reaction Methods 0.000 description 1
- GDFAOVXKHJXLEI-VKHMYHEASA-N N-methyl-L-alanine Chemical group C[NH2+][C@@H](C)C([O-])=O GDFAOVXKHJXLEI-VKHMYHEASA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- USDIEMSQPJIHLX-UHFFFAOYSA-N N=[N+]=NCCOCCN.O=C(O)CCOCCN(CCOCCC(=O)O)CCOCCC(=O)O.[N-]=[N+]=NCCOCCNC(=O)CCOCCN(CCOCCC(=O)NCCOCCN=[N+]=[N-])CCOCCC(=O)NCCOCCN=[N+]=[N-] Chemical compound N=[N+]=NCCOCCN.O=C(O)CCOCCN(CCOCCC(=O)O)CCOCCC(=O)O.[N-]=[N+]=NCCOCCNC(=O)CCOCCN(CCOCCC(=O)NCCOCCN=[N+]=[N-])CCOCCC(=O)NCCOCCN=[N+]=[N-] USDIEMSQPJIHLX-UHFFFAOYSA-N 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 241000750002 Nestor Species 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- NVNLLIYOARQCIX-MSHCCFNRSA-N Nisin Chemical compound N1C(=O)[C@@H](CC(C)C)NC(=O)C(=C)NC(=O)[C@@H]([C@H](C)CC)NC(=O)[C@@H](NC(=O)C(=C/C)/NC(=O)[C@H](N)[C@H](C)CC)CSC[C@@H]1C(=O)N[C@@H]1C(=O)N2CCC[C@@H]2C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(NCC(=O)N[C@H](C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCSC)C(=O)NCC(=O)N[C@H](CS[C@@H]2C)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CCSC)C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(N[C@H](C)C(=O)N[C@@H]3C(=O)N[C@@H](C(N[C@H](CC=4NC=NC=4)C(=O)N[C@H](CS[C@@H]3C)C(=O)N[C@H](CO)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@H](CC=3NC=NC=3)C(=O)N[C@H](C(C)C)C(=O)NC(=C)C(=O)N[C@H](CCCCN)C(O)=O)=O)CS[C@@H]2C)=O)=O)CS[C@@H]1C NVNLLIYOARQCIX-MSHCCFNRSA-N 0.000 description 1
- 108010053775 Nisin Proteins 0.000 description 1
- 208000019569 Nodular lymphocyte predominant Hodgkin lymphoma Diseases 0.000 description 1
- 108010016076 Octreotide Proteins 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 108091059809 PVRL4 Proteins 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 206010033963 Parathyroid tumour Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 241000233805 Phoenix Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010035104 Pituitary tumour Diseases 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 206010057846 Primitive neuroectodermal tumour Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 241000242680 Schistosoma mansoni Species 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 108091008035 T cell costimulatory receptors Proteins 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 102100023132 Transcription factor Jun Human genes 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 108091005906 Type I transmembrane proteins Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 201000006083 Xeroderma Pigmentosum Diseases 0.000 description 1
- UBITXOFSGXNPBW-UHFFFAOYSA-N [N-]=[N+]=NCCOCCOCCOCCOCCOCCC(=O)ON1C(=O)CCC1=O Chemical compound [N-]=[N+]=NCCOCCOCCOCCOCCOCCC(=O)ON1C(=O)CCC1=O UBITXOFSGXNPBW-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 159000000021 acetate salts Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000002355 alkine group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- UGJQDKYTAYNNBH-UHFFFAOYSA-N amino cyclopropanecarboxylate Chemical compound NOC(=O)C1CC1 UGJQDKYTAYNNBH-UHFFFAOYSA-N 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003286 aryl halide group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 229940023913 cation exchange resins Drugs 0.000 description 1
- 150000001767 cationic compounds Chemical class 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000002576 chemokine receptor CXCR4 antagonist Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229910052681 coesite Inorganic materials 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 230000004940 costimulation Effects 0.000 description 1
- 229910052906 cristobalite Inorganic materials 0.000 description 1
- 229940121384 cxc chemokine receptor type 4 (cxcr4) antagonist Drugs 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- DTPCFIHYWYONMD-UHFFFAOYSA-N decaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO DTPCFIHYWYONMD-UHFFFAOYSA-N 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003413 degradative effect Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 208000031068 ectodermal dysplasia syndrome Diseases 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 231100001129 embryonic lethality Toxicity 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 229950004930 enfortumab vedotin Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 210000003020 exocrine pancreas Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 229910052733 gallium Inorganic materials 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 230000009033 hematopoietic malignancy Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- CAKXJTDJRUEEGS-UHFFFAOYSA-N hexadecanoyl azide Chemical compound CCCCCCCCCCCCCCCC(=O)N=[N+]=[N-] CAKXJTDJRUEEGS-UHFFFAOYSA-N 0.000 description 1
- 201000000284 histiocytoma Diseases 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 229940051026 immunotoxin Drugs 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 231100000608 immunotoxin Toxicity 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910001411 inorganic cation Inorganic materials 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 201000002529 islet cell tumor Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- OHSVLFRHMCKCQY-UHFFFAOYSA-N lutetium atom Chemical compound [Lu] OHSVLFRHMCKCQY-UHFFFAOYSA-N 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 150000002669 lysines Chemical class 0.000 description 1
- 238000005710 macrocyclization reaction Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 201000005328 monoclonal gammopathy of uncertain significance Diseases 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 206010028537 myelofibrosis Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000002071 myeloproliferative effect Effects 0.000 description 1
- 210000000754 myometrium Anatomy 0.000 description 1
- ZGENBODMIMDNJM-UHFFFAOYSA-N n-[3,5-bis[(2-bromoacetyl)amino]phenyl]-2-bromoacetamide Chemical compound BrCC(=O)NC1=CC(NC(=O)CBr)=CC(NC(=O)CBr)=C1 ZGENBODMIMDNJM-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- GTWJETSWSUWSEJ-UHFFFAOYSA-N n-benzylaniline Chemical compound C=1C=CC=CC=1CNC1=CC=CC=C1 GTWJETSWSUWSEJ-UHFFFAOYSA-N 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000004309 nisin Substances 0.000 description 1
- 235000010297 nisin Nutrition 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 229960002700 octreotide Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002892 organic cations Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 description 1
- 210000003695 paranasal sinus Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 238000000059 patterning Methods 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- MLBYLEUJXUBIJJ-UHFFFAOYSA-N pent-4-ynoic acid Chemical group OC(=O)CCC#C MLBYLEUJXUBIJJ-UHFFFAOYSA-N 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N pentanoic acid group Chemical class C(CCCC)(=O)O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 239000000863 peptide conjugate Substances 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 208000037244 polycythemia vera Diseases 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 208000017805 post-transplant lymphoproliferative disease Diseases 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 210000004986 primary T-cell Anatomy 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 208000003476 primary myelofibrosis Diseases 0.000 description 1
- 150000003147 proline derivatives Chemical class 0.000 description 1
- 210000005267 prostate cell Anatomy 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 208000029817 pulmonary adenocarcinoma in situ Diseases 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 239000012070 reactive reagent Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 210000003752 saphenous vein Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 229910052682 stishovite Inorganic materials 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 108010037022 subtiligase Proteins 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013595 supernatant sample Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 229910052905 tridymite Inorganic materials 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 230000001573 trophoblastic effect Effects 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000006459 vascular development Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
- 238000012447 xenograft mouse model Methods 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
- VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Definitions
- the present invention relates to heterotandem bicyclic peptide complexes which comprise a first peptide ligand, which binds to a component present on a cancer cell, conjugated via a linker to a second peptide ligand, which binds to a component present on an immune cell.
- the invention also relates to the use of said heterotandem bicyclic peptide complexes in preventing, suppressing or treating cancer.
- Cyclic peptides are able to bind with high affinity and target specificity to protein targets and hence are an attractive molecule class for the development of therapeutics.
- several cyclic peptides are already successfully used in the clinic, as for example the antibacterial peptide vancomycin, the immunosuppressant drug cyclosporine or the anti-cancer drug octreotide (Driggers et al. (2008), Nat Rev Drug Discov 7 (7), 608-24).
- Good binding properties result from a relatively large interaction surface formed between the peptide and the target as well as the reduced conformational flexibility of the cyclic structures.
- macrocycles bind to surfaces of several hundred square angstrom, as for example the cyclic peptide CXCR4 antagonist CVX15 (400 ⁇ 2 ; Wu et al. (2007), Science 330, 1066-71), a cyclic peptide with the Arg-Gly-Asp motif binding to integrin ⁇ Vb3 (355 ⁇ 2 ) (Xiong et al. (2002), Science 296 (5565), 151-5) or the cyclic peptide inhibitor upain-1 binding to urokinase-type plasminogen activator (603 ⁇ 2 ; Zhao et al. (2007), J Struct Biol 160 (1), 1-10).
- CVX15 400 ⁇ 2 ; Wu et al. (2007), Science 330, 1066-71
- a cyclic peptide with the Arg-Gly-Asp motif binding to integrin ⁇ Vb3 355 ⁇ 2
- peptide macrocycles are less flexible than linear peptides, leading to a smaller loss of entropy upon binding to targets and resulting in a higher binding affinity.
- the reduced flexibility also leads to locking target-specific conformations, increasing binding specificity compared to linear peptides.
- MMP-8 matrix metalloproteinase 8
- the favorable binding properties achieved through macrocyclization are even more pronounced in multicyclic peptides having more than one peptide ring as for example in vancomycin, nisin and actinomycin.
- Phage display-based combinatorial approaches have been developed to generate and screen large libraries of bicyclic peptides to targets of interest (Heinis et al. (2009), Nat Chem Biol 5 (7), 502-7 and WO 2009/098450). Briefly, combinatorial libraries of linear peptides containing three cysteine residues and two regions of six random amino acids (Cys-(Xaa) 6 -Cys-(Xaa) 6 -Cys) were displayed on phage and cyclised by covalently linking the cysteine side chains to a small molecule (tris-(bromomethyl)benzene).
- heterotandem bicyclic peptide complex comprising:
- a pharmaceutical composition comprising a heterotandem bicyclic peptide complex as defined herein in combination with one or more pharmaceutically acceptable excipients.
- heterotandem bicyclic peptide complex as defined herein for use in preventing, suppressing or treating cancer.
- cancer cell includes any cell which is known to be involved in cancer. Cancer cells are created when the genes responsible for regulating cell division are damaged. Carcinogenesis is caused by mutation and epimutation of the genetic material of normal cells, which upsets the normal balance between proliferation and cell death. This results in uncontrolled cell division and the evolution of those cells by natural selection in the body. The uncontrolled and often rapid proliferation of cells can lead to benign or malignant tumours (cancer). Benign tumors do not spread to other parts of the body or invade other tissues. Malignant tumors can invade other organs, spread to distant iodations (metastasis) and become life-threatening.
- cancer cells are created when the genes responsible for regulating cell division are damaged. Carcinogenesis is caused by mutation and epimutation of the genetic material of normal cells, which upsets the normal balance between proliferation and cell death. This results in uncontrolled cell division and the evolution of those cells by natural selection in the body. The uncontrolled and often rapid proliferation of cells can lead to benign or malignant tumours (cancer). Benign tumors do not spread to other parts of the
- the cancer cell is selected from an HT1080, A549, SC-OV-3, PC3, H1376, NCI-H292, LnCap, MC38, 4T1-D02 and RKO tumor cell.
- the component present on a cancer cell is Nectin-4.
- Nectin-4 is a surface molecule that belongs to the nectin family of proteins, which comprises 4 members. Nectins are cell adhesion molecules that play a key role in various biological processes such as polarity, proliferation, differentiation and migration, for epithelial, endothelial, immune and neuronal cells, during development and adult life. They are involved in several pathological processes in humans. They are the main receptors for poliovirus, herpes simplex virus and measles virus. Mutations in the genes encoding Nectin-1 (PVRL1) or Nectin-4 (PVRL4) cause ectodermal dysplasia syndromes associated with other abnormalities. Nectin-4 is expressed during foetal development.
- PVRL1 Nectin-1
- PVRL4 Nectin-4
- Nectin-4 is a tumour-associated antigen in 50%, 49% and 86% of breast, ovarian and lung carcinomas, respectively, mostly on tumours of bad prognosis. Its expression is not detected in the corresponding normal tissues. In breast tumours, Nectin-4 is expressed mainly in triple-negative and ERBB2+ carcinomas. In the serum of patients with these cancers, the detection of soluble forms of Nectin-4 is associated with a poor prognosis. Levels of serum Nectin-4 increase during metastatic progression and decrease after treatment. These results suggest that Nectin-4 could be a reliable target for the treatment of cancer.
- Enfortumab Vedotin (ASG-22ME) is an antibody-drug conjugate (ADC) targeting Nectin-4 and is currently clinically investigated for the treatment of patients suffering from solid tumours.
- ADC antibody-drug conjugate
- the first peptide ligand comprises a Nectin-4 binding bicyclic peptide ligand.
- Nectin-4 binding bicyclic peptide ligands are disclosed in PCT Patent Application No PCT/GB2019/051740, the peptides of which are incorporated herein by reference.
- the Nectin-4 binding bicyclic peptide is selected from any of the peptides of SEQ ID NOS: 52 to 66 described herein.
- the component present on a cancer cell is EphA2.
- Eph receptor tyrosine kinases belong to a large group of receptor tyrosine kinases (RTKs), kinases that phosphorylate proteins on tyrosine residues.
- RTKs receptor tyrosine kinases
- Ephs and their membrane bound ephrin ligands ephrins
- ephrins membrane bound ephrin ligands
- Ephs and ephrins have been shown to play a role in vascular development. Knockout of EphB4 and ephrin-B2 results in a lack of the ability to remodel capillary beds into blood vessels (Poliakov et al., supra) and embryonic lethality. Persistent expression of some Eph receptors and ephrins has also been observed in newly-formed, adult micro-vessels (Brantley-Sieders et al. (2004) Curr Pharm Des 10, 3431-42; Adams (2003) J Anat 202, 105-12).
- EPH receptor A2 (ephrin type-A receptor 2) is a protein that in humans is encoded by the EPHA2 gene.
- EphA2 is upregulated in multiple cancers in man, often correlating with disease progression, metastasis and poor prognosis e.g.: breast (Zelinski et al (2001) Cancer Res. 61, 2301-2306; Zhuang et al (2010) Cancer Res. 70, 299-308; Brantley-Sieders et al (2011) PLoS One 6, e24426), lung (Brannan et al (2009) Cancer Prev Res (Phila) 2, 1039-1049; Kinch et al (2003) Clin Cancer Res. 9, 613-618; Guo et al (2013) J Thorac Oncol. 8, 301-308), gastric (Nakamura et al (2005) Cancer Sci.
- EphA2 in cancer progression is still not defined although there is evidence for interaction at numerous stages of cancer progression including tumour cell growth, survival, invasion and angiogenesis.
- Downregulation of EphA2 expression suppresses tumour cancer cell propagation (Binda et al (2012) Cancer Cell 22, 765-780), whilst EphA2 blockade inhibits VEGF induced cell migration (Hess et al (2001) Cancer Res. 61, 3250-3255), sprouting and angiogenesis (Cheng et al (2002) Mol Cancer Res. 1, 2-11; Lin et al (2007) Cancer 109, 332-40) and metastatic progression (Brantley-Sieders et al (2005) FASEB J. 19, 1884-1886).
- EphA2 An antibody drug conjugate to EphA2 has been shown to significantly diminish tumour growth in rat and mouse xenograft models (Jackson et al (2008) Cancer Research 68, 9367-9374) and a similar approach has been tried in man although treatment had to be discontinued for treatment related adverse events (Annunziata et al (2013) Invest New drugs 31, 77-84).
- the first peptide ligand comprises an EphA2 binding bicyclic peptide ligand.
- EphA2 binding bicyclic peptide ligands are disclosed in WO 2019/122860, WO 2019/122861 and WO 2019/122863, the peptides of which are incorporated herein by reference.
- the EphA2 binding bicyclic peptide is selected from any of the peptides of SEQ ID NOS: 10 to 51 described herein.
- the component present on a cancer cell is PD-L1.
- Programmed cell death 1 ligand 1 is a 290 amino acid type I transmembrane protein encoded by the CD274 gene on mouse chromosome 19 and human chromosome 9.
- PD-L1 expression is involved in evasion of immune responses involved in chronic infection, e.g., chronic viral infection (including, for example, HIV, HBV, HCV and HTLV, among others), chronic bacterial infection (including, for example, Helicobacter pylori , among others), and chronic parasitic infection (including, for example, Schistosoma mansoni ).
- PD-L1 expression has been detected in a number of tissues and cell types including T-cells, B-cells, macrophages, dendritic cells, and nonhaematopoietic cells including endothelial cells, hepatocytes, muscle cells, and placenta.
- PD-L1 expression is also involved in suppression of anti-tumour immune activity. Tumours express antigens that can be recognised by host T-cells, but immunologic clearance of tumours is rare. Part of this failure is due to immune suppression by the tumour microenvironment. PD-L1 expression on many tumours is a component of this suppressive milieu and acts in concert with other immunosuppressive signals. PD-L1 expression has been shown in situ on a wide variety of solid tumours including breast, lung, colon, ovarian, melanoma, bladder, liver, salivary, stomach, gliomas, thyroid, thymic epithelial, head, and neck (Brown J A et al. 2003 Immunol.
- the PD-1 pathway can also play a role in haematologic malignancies.
- PD-L1 is expressed on multiple myeloma cells but not on normal plasma cells (Liu J et al. 2007 Blood 110:296-304).
- PD-L1 is expressed on some primary T-cell lymphomas, particularly anaplastic large cell T lymphomas (Brown J A et al, 2003 Immunol. 170:1257-66).
- PD-1 is highly expressed on the T-cells of angioimmunoblastic lymphomas, and PD-L1 is expressed on the associated follicular dendritic cell network (Dorfman D M et al. 2006 Am. J. Surg. Pathol. 30:802-10).
- the T-cells associated with lymphocytic or histiocytic (L&H) cells express PD-1.
- Microarray analysis using a readout of genes induced by PD-1 ligation suggests that tumour-associated T-cells are responding to PD-1 signals in situ in Hodgkin lymphoma (Chemnitz J M et al. 2007 Blood 110:3226-33).
- PD-1 and PD-L1 are expressed on CD4 T-cells in HTLV-1-mediated adult T-cell leukaemia and lymphoma (Shimauchi T et al. 2007 Int. J. Cancer 121: 2585-90). These tumour cells are hyporesponsive to TCR signals.
- tumour-L1 on tumours inhibits T-cell activation and lysis of tumour cells and in some cases leads to increased tumour-specific T-cell death (Dong H et al. 2002 Nat. Med. 8:793-800; Hirano F et al. 2005 Cancer Res. 65:1089-96).
- Tumour-associated APCs can also utilise the PD-1:PD-L1 pathway to control antitumour T-cell responses.
- PD-L1 expression on a population of tumour-associated myeloid DCs is upregulated by tumour environmental factors (Curie) T J et al. 2003 Nat. Med. 9:562-67).
- Plasmacytoid dendritic cells (DCs) in the tumour-draining lymph node of B16 melanoma express IDO, which strongly activates the suppressive activity of regulatory T-cells.
- the suppressive activity of IDO-treated regulatory T-cells required cell contact with IDO-expressing DCs (Sharma M D et al. 2007 Clin. Invest. 117:2570-82).
- the first peptide ligand comprises a PD-L1 binding bicyclic peptide ligand.
- Suitable examples of PD-L1 binding bicyclic peptide ligands are disclosed in GB Patent Application Nos. 1905631.6 and 1904622.6, the peptides of which are incorporated herein by reference.
- the PD-L1 binding bicyclic peptide is selected from any of the peptides of SEQ ID NOS: 1 to 9 described herein.
- the component present on a cancer cell is prostate-specific membrane antigen (PSMA).
- PSMA prostate-specific membrane antigen
- Prostate-specific membrane antigen (also known as Glutamate carboxypeptidase II (GCPII), N-acetyl-L-aspartyl-L-glutamate peptidase I (NAALADase I) and NAAG peptidase) is an enzyme that in humans is encoded by the FOLH1 (folate hydrolase 1) gene.
- FOLH1 farnesoid alpha 1
- Human GCPII contains 750 amino acids and weighs approximately 84 kDa.
- PSMA Human PSMA is highly expressed in the prostate, roughly a hundred times greater than in most other tissues. In some prostate cancers, PSMA is the second-most upregulated gene product, with an 8- to 12-fold increase over levels in noncancerous prostate cells. Because of this high expression, PSMA is being developed as potential biomarker for therapy and imaging of some cancers. In human prostate cancer, the higher expressing tumors are associated with quicker time to progression and a greater percentage of patients suffering relapse.
- the first peptide ligand comprises a PSMA binding bicyclic peptide ligand.
- PSMA binding bicyclic peptide ligands are disclosed in GB Patent Application Nos 1820325.7 and 1912723.2 and PCT Patent Application No. PCT/EP2019/066273, the peptides of which are incorporated herein by reference.
- immune cell includes any cell within the immune system. Suitable examples include white blood cells, such as lymphocytes (e.g. T lymphocytes or T cells, B cells or natural killer cells). In one embodiment, the T cell is CD8 or CD4. In a further embodiment, the T cell is CD8. Other examples of immune cells include dendritic cells, follicular dendritic cells and granulocytes.
- the component present on an immune cell is CD137.
- CD137 is a member of the tumour necrosis factor (TNF) receptor family. Its alternative names are tumour necrosis factor receptor superfamily member 9 (TNFRSF9), 4-IBB and induced by lymphocyte activation (ILA). CD137 can be expressed by activated T cells, but to a larger extent on CD8+ than on CD4+ T cells. In addition, CD137 expression is found on dendritic cells, follicular dendritic cells, natural killer cells, granulocytes and cells of blood vessel walls at sites of inflammation. One characterized activity of CD137 is its costimulatory activity for activated T cells. Crosslinking of CD137 enhances T cell proliferation, IL-2 secretion, survival and cytolytic activity. Further, it can enhance immune activity to eliminate tumours in mice.
- TNF tumour necrosis factor
- TNFRSF9 tumour necrosis factor receptor superfamily member 9
- 4-IBB 4-IBB
- IAA lymphocyte activation
- CD137 can be expressed by activated T cells, but to a larger extent on CD8
- CD137 is a T-cell costimulatory receptor induced on TCR activation (Nam et al., Curr. Cancer Drug Targets, 5:357-363 (2005); Waits et al., Annu. Rev, Immunol., 23:23-68 (2005)). In addition to its expression on activated CD4+ and CD8+ T cells, CD137 is also expressed on CD4+CD25+ regulatory T cells, natural killer (NK) and NK-T cells, monocytes, neutrophils, and dendritic cells. Its natural ligand, CD137L, has been described on antigen-presenting cells including B cells, monocyte/macrophages, and dendritic cells (Watts et al. Annu. Rev.
- CD137 On interaction with its ligand, CD137 leads to increased TCR-induced T-cell proliferation, cytokine production, functional maturation, and prolonged CD8+ T-cell survival (Nam et al, Curr. Cancer Drug Targets, 5:357-363 (2005), Watts et d-I., Annu. Rev. Immunol, 23:23-68 (2005)).
- CD137L Activated monoclonal antibodies
- CD137L agonistic monoclonal antibodies
- mAbs agonistic monoclonal antibodies
- IL-2 and IL-15 activated NK cells express CD137, and ligation of CD137 by agonistic mAbs stimulates NK cell proliferation and IFN- ⁇ secretion, but not their cytolytic activity.
- CD137-stimulated NK cells promote the expansion of activated T cells in vitro.
- agonist mAbs against CD137 have been shown to promote rejection of cardiac and skin allografts, eradicate established tumours, broaden primary antiviral CD8+ T cell responses, and increase T cell cytolytic potential. These studies support the view that CD137 signalling promotes T cell function which may enhance immunity against tumours and infection.
- the second peptide ligand comprises a CD137 binding bicyclic peptide ligand.
- CD137 binding bicyclic peptide ligands are disclosed in WO 2019/025811, the peptides of which are incorporated herein by reference.
- the CD137 binding bicyclic peptide is selected from any of the peptides of SEQ ID NOS: 67 to 84 described herein.
- the first peptide ligand may be conjugated to the second peptide ligand via any suitable linker.
- the design of said linker will be such that the two Bicyclic peptides are presented in such a manner that they can bind unencumbered to their respective targets either alone or while simultaneously binding to both target receptors.
- the linker should permit binding to both targets simultaneously while maintaining an appropriate distance between the target cells that would lead to the desired functional outcome.
- the properties of the linker may be modulated to increase length, rigidity or solubility to optimise the desired functional outcome.
- the linker may also be designed to permit the attachment of more than one Bicycle to the same target. Increasing the valency of either binding peptide may serve to increase the affinity of the heterotandem for the target cells or may help to induce oligomerisation of one or both of the target receptors.
- the linker is selected from the following sequences: -PEG5- and TCA-[PEG 10 ] 3 .
- the first peptide ligand comprises a PD-L1 binding bicyclic peptide ligand attached to a TATA scaffold
- the second peptide ligand comprises a CD137 binding bicyclic peptide ligand attached to a TATA scaffold
- said heterotandem complex is selected from the complexes listed in Table A:
- the heterotandem bicyclic peptide complex is selected from: BCY12375 and BCY12021.
- the first peptide ligand comprises an EphA2 binding bicyclic peptide ligand attached to a TATA scaffold
- the second peptide ligand comprises a CD137 binding bicyclic peptide ligand attached to a TATA scaffold
- said heterotandem complex is selected from the complexes listed in Table B:
- the heterotandem bicyclic peptide complex is selected from: BCY13035, BCY13040, BCY13253, BCY13254, BCY13340 and BCY13342.
- the first peptide ligand comprises a Nectin-4 binding bicyclic peptide ligand attached to a TATA scaffold
- the second peptide ligand comprises a CD137 binding bicyclic peptide ligand attached to a TATA scaffold
- said heterotandem complex is selected from the complexes listed in Table C:
- the heterotandem bicyclic peptide complex is selected from: BCY11468, BCY11618, BCY11776, BCY11860, BCY12020, BCY12661 and BCY12969.
- N- or C-terminal extensions to the bicycle core sequence are added to the left or right side of the sequence, separated by a hyphen.
- an N-terminal ⁇ Ala-Sar10-Ala tail would be denoted as:
- amino acid is intended to be represented as a D-amino acid then the amino acid will be prefaced with a lower case d within square parentheses, for example [dA], [dD], [dE], [dK], [d1Nal], [dNle], etc.
- a peptide ligand refers to a peptide covalently bound to a molecular scaffold.
- such peptides comprise two or more reactive groups (i.e. cysteine residues) which are capable of forming covalent bonds to the scaffold, and a sequence subtended between said reactive groups which is referred to as the loop sequence, since it forms a loop when the peptide is bound to the scaffold.
- the peptides comprise at least three reactive groups selected from cysteine, 3-mercaptopropionic acid and/or cysteamine and form at least two loops on the scaffold.
- the molecular scaffold of the invention may be bonded to the polypeptide via functional or reactive groups on the polypeptide. These are typically formed from the side chains of particular amino acids found in the polypeptide polymer. Such reactive groups may be a cysteine side chain, a lysine side chain, or an N-terminal amine group or any other suitable reactive group, such as penicillamine. Details of suitable reactive groups may be found in WO 2009/098450.
- reactive groups of natural amino acids are the thiol group of cysteine, the amino group of lysine, the carboxyl group of aspartate or glutamate, the guanidinium group of arginine, the phenolic group of tyrosine or the hydroxyl group of serine.
- Non-natural amino acids can provide a wide range of reactive groups including an azide, a keto-carbonyl, an alkyne, a vinyl, or an aryl halide group.
- the amino and carboxyl group of the termini of the polypeptide can also serve as reactive groups to form covalent bonds to a molecular scaffold/molecular core.
- polypeptides of the invention contain at least three reactive groups. Said polypeptides can also contain four or more reactive groups. The more reactive groups are used, the more loops can be formed in the molecular scaffold.
- polypeptides with three reactive groups are generated. Reaction of said polypeptides with a molecular scaffold/molecular core having a three-fold rotational symmetry generates a single product isomer.
- the generation of a single product isomer is favourable for several reasons.
- the nucleic acids of the compound libraries encode only the primary sequences of the polypeptide but not the isomeric state of the molecules that are formed upon reaction of the polypeptide with the molecular core. If only one product isomer can be formed, the assignment of the nucleic acid to the product isomer is clearly defined. If multiple product isomers are formed, the nucleic acid cannot give information about the nature of the product isomer that was isolated in a screening or selection process.
- a single product isomer is also advantageous if a specific member of a library of the invention is synthesized.
- the chemical reaction of the polypeptide with the molecular scaffold yields a single product isomer rather than a mixture of isomers.
- polypeptides with four reactive groups are generated. Reaction of said polypeptides with a molecular scaffold/molecular core having a tetrahedral symmetry generates two product isomers. Even though the two different product isomers are encoded by one and the same nucleic acid, the isomeric nature of the isolated isomer can be determined by chemically synthesizing both isomers, separating the two isomers and testing both isomers for binding to a target ligand.
- At least one of the reactive groups of the polypeptides is orthogonal to the remaining reactive groups.
- the use of orthogonal reactive groups allows the directing of said orthogonal reactive groups to specific sites of the molecular core.
- Linking strategies involving orthogonal reactive groups may be used to limit the number of product isomers formed. In other words, by choosing distinct or different reactive groups for one or more of the at least three bonds to those chosen for the remainder of the at least three bonds, a particular order of bonding or directing of specific reactive groups of the polypeptide to specific positions on the molecular scaffold may be usefully achieved.
- the reactive groups of the polypeptide of the invention are reacted with molecular linkers wherein said linkers are capable to react with a molecular scaffold so that the linker will intervene between the molecular scaffold and the polypeptide in the final bonded state.
- amino acids of the members of the libraries or sets of polypeptides can be replaced by any natural or non-natural amino acid.
- exchangeable amino acids are the ones harbouring functional groups for cross-linking the polypeptides to a molecular core, such that the loop sequences alone are exchangeable.
- the exchangeable polypeptide sequences have either random sequences, constant sequences or sequences with random and constant amino acids.
- the amino acids with reactive groups are either located in defined positions within the polypeptide, since the position of these amino acids determines loop size.
- a polypeptide with three reactive groups has the sequence (X) 1 Y(X) m Y(X) n Y(X) o , wherein Y represents an amino acid with a reactive group, X represents a random amino acid, m and n are numbers between 3 and 6 defining the length of intervening polypeptide segments, which may be the same or different, and I and o are numbers between 0 and 20 defining the length of flanking polypeptide segments.
- thiol-mediated conjugations can be used to attach the molecular scaffold to the peptide via covalent interactions.
- these techniques may be used in modification or attachment of further moieties (such as small molecules of interest which are distinct from the molecular scaffold) to the polypeptide after they have been selected or isolated according to the present invention—in this embodiment then clearly the attachment need not be covalent and may embrace non-covalent attachment.
- thiol mediated methods may be used instead of (or in combination with) the thiol mediated methods by producing phage that display proteins and peptides bearing unnatural amino acids with the requisite chemical reactive groups, in combination small molecules that bear the complementary reactive group, or by incorporating the unnatural amino acids into a chemically or recombinantly synthesised polypeptide when the molecule is being made after the selection/isolation phase. Further details can be found in WO 2009/098450 or Heinis et al., Nat Chem Biol 2009, 5 (7), 502-7.
- the reactive groups are selected from cysteine, 3-mercaptopropionic acid and/or cysteamine residues.
- references to peptide ligands include the salt forms of said ligands.
- the salts of the present invention can be synthesized from the parent compound that contains a basic or acidic moiety by conventional chemical methods such as methods described in Pharmaceutical Salts: Properties, Selection, and Use , P. Heinrich Stahl (Editor), Camille G. Wermuth (Editor), ISBN: 3-90639-026-8, Hardcover, 388 pages, August 2002.
- such salts can be prepared by reacting the free acid or base forms of these compounds with the appropriate base or acid in water or in an organic solvent, or in a mixture of the two.
- Acid addition salts may be formed with a wide variety of acids, both inorganic and organic.
- acid addition salts include mono- or di-salts formed with an acid selected from the group consisting of acetic, 2,2-dichloroacetic, adipic, alginic, ascorbic (e.g.
- D-glucuronic D-glucuronic
- glutamic e.g. L-glutamic
- ⁇ -oxoglutaric glycolic, hippuric
- hydrohalic acids e.g. hydrobromic, hydrochloric, hydriodic
- isethionic lactic (e.g.
- salts consist of salts formed from acetic, hydrochloric, hydriodic, phosphoric, nitric, sulfuric, citric, lactic, succinic, maleic, malic, isethionic, fumaric, benzenesulfonic, toluenesulfonic, sulfuric, methanesulfonic (mesylate), ethanesulfonic, naphthalenesulfonic, valeric, propanoic, butanoic, malonic, glucuronic and lactobionic acids.
- One particular salt is the hydrochloride salt.
- Another particular salt is the acetate salt.
- a salt may be formed with an organic or inorganic base, generating a suitable cation.
- suitable inorganic cations include, but are not limited to, alkali metal ions such as Li + , Na + and K + , alkaline earth metal cations such as Ca 2+ and Mg 2+ , and other cations such as Al 3+ or Zn + .
- Suitable organic cations include, but are not limited to, ammonium ion (i.e., NH 4 + ) and substituted ammonium ions (e.g., NH 3 R + , NH 2 R 2 + , NHR 3 + , NR 4 + ).
- Examples of some suitable substituted ammonium ions are those derived from: methylamine, ethylamine, diethylamine, propylamine, dicyclohexylamine, triethylamine, butylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, benzylamine, phenylbenzylamine, choline, meglumine, and tromethamine, as well as amino acids, such as lysine and arginine.
- An example of a common quaternary ammonium ion is N(CH 3 ) 4 + .
- the compounds of the invention contain an amine function
- these may form quaternary ammonium salts, for example by reaction with an alkylating agent according to methods well known to the skilled person.
- Such quaternary ammonium compounds are within the scope of the invention.
- modified derivatives of the peptide ligands as defined herein are within the scope of the present invention.
- suitable modified derivatives include one or more modifications selected from: N-terminal and/or C-terminal modifications; replacement of one or more amino acid residues with one or more non-natural amino acid residues (such as replacement of one or more polar amino acid residues with one or more isosteric or isoelectronic amino acids; replacement of one or more non-polar amino acid residues with other non-natural isosteric or isoelectronic amino acids); addition of a spacer group; replacement of one or more oxidation sensitive amino acid residues with one or more oxidation resistant amino acid residues; replacement of one or more amino acid residues with an alanine, replacement of one or more L-amino acid residues with one or more D-amino acid residues; N-alkylation of one or more amide bonds within the bicyclic peptide ligand; replacement of one or more peptide bonds with a surrog
- the modified derivative comprises an N-terminal and/or C-terminal modification.
- the modified derivative comprises an N-terminal modification using suitable amino-reactive chemistry, and/or C-terminal modification using suitable carboxy-reactive chemistry.
- said N-terminal or C-terminal modification comprises addition of an effector group, including but not limited to a cytotoxic agent, a radiochelator or a chromophore.
- the modified derivative comprises an N-terminal modification.
- the N-terminal modification comprises an N-terminal acetyl group.
- the N-terminal cysteine group (the group referred to herein as C,) is capped with acetic anhydride or other appropriate reagents during peptide synthesis leading to a molecule which is N-terminally acetylated. This embodiment provides the advantage of removing a potential recognition point for aminopeptidases and avoids the potential for degradation of the bicyclic peptide.
- the N-terminal modification comprises the addition of a molecular spacer group which facilitates the conjugation of effector groups and retention of potency of the bicyclic peptide to its target.
- the modified derivative comprises a C-terminal modification.
- the C-terminal modification comprises an amide group.
- the C-terminal cysteine group (the group referred to herein as C ii ) is synthesized as an amide during peptide synthesis leading to a molecule which is C-terminally amidated. This embodiment provides the advantage of removing a potential recognition point for carboxypeptidase and reduces the potential for proteolytic degradation of the bicyclic peptide.
- the modified derivative comprises replacement of one or more amino acid residues with one or more non-natural amino acid residues.
- non-natural amino acids may be selected having isosteric/isoelectronic side chains which are neither recognised by degradative proteases nor have any adverse effect upon target potency.
- non-natural amino acids may be used having constrained amino acid side chains, such that proteolytic hydrolysis of the nearby peptide bond is conformationally and sterically impeded.
- these concern proline analogues, bulky sidechains, C ⁇ -disubstituted derivatives (for example, aminoisobutyric acid, Aib), and cyclo amino acids, a simple derivative being amino-cyclopropylcarboxylic acid.
- the modified derivative comprises the addition of a spacer group. In a further embodiment, the modified derivative comprises the addition of a spacer group to the N-terminal cysteine (C i ) and/or the C-terminal cysteine (C iii ).
- the modified derivative comprises replacement of one or more oxidation sensitive amino acid residues with one or more oxidation resistant amino acid residues.
- the modified derivative comprises replacement of a tryptophan residue with a naphthylalanine or alanine residue. This embodiment provides the advantage of improving the pharmaceutical stability profile of the resultant bicyclic peptide ligand.
- the modified derivative comprises replacement of one or more charged amino acid residues with one or more hydrophobic amino acid residues. In an alternative embodiment, the modified derivative comprises replacement of one or more hydrophobic amino acid residues with one or more charged amino acid residues.
- the correct balance of charged versus hydrophobic amino acid residues is an important characteristic of the bicyclic peptide ligands. For example, hydrophobic amino acid residues influence the degree of plasma protein binding and thus the concentration of the free available fraction in plasma, while charged amino acid residues (in particular arginine) may influence the interaction of the peptide with the phospholipid membranes on cell surfaces. The two in combination may influence half-life, volume of distribution and exposure of the peptide drug, and can be tailored according to the clinical endpoint. In addition, the correct combination and number of charged versus hydrophobic amino acid residues may reduce irritation at the injection site (if the peptide drug has been administered subcutaneously).
- the modified derivative comprises replacement of one or more L-amino acid residues with one or more D-amino acid residues.
- This embodiment is believed to increase proteolytic stability by steric hindrance and by a propensity of D-amino acids to stabilise ⁇ -turn conformations (Tugyi et al (2005) PNAS, 102(2), 413-418).
- the modified derivative comprises removal of any amino acid residues and substitution with alanines. This embodiment provides the advantage of removing potential proteolytic attack site(s).
- the present invention includes all pharmaceutically acceptable (radio)isotope-labeled peptide ligands of the invention, wherein one or more atoms are replaced by atoms having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number usually found in nature, and peptide ligands of the invention, wherein metal chelating groups are attached (termed “effector”) that are capable of holding relevant (radio)isotopes, and peptide ligands of the invention, wherein certain functional groups are covalently replaced with relevant (radio)isotopes or isotopically labelled functional groups.
- isotopes suitable for inclusion in the peptide ligands of the invention comprise isotopes of hydrogen, such as 2 H (D) and 3 H (T), carbon, such as 11 C, 13 C and 14 C, chlorine, such as 36 Cl, fluorine, such as 18 F, iodine, such as 123 I, 125 I and 131 I, nitrogen, such as 13 N and 15 N, oxygen, such as 15 O, 17 O and 18 O, phosphorus, such as 32 P, sulfur, such as 35 S, copper, such as 64 Cu, gallium, such as 67 Ga or 68 Ga, yttrium, such as 90 Y and lutetium, such as 177 Lu, and Bismuth, such as 213 Bi.
- hydrogen such as 2 H (D) and 3 H (T)
- carbon such as 11 C, 13 C and 14 C
- chlorine such as 36 Cl
- fluorine such as 18 F
- iodine such as 123 I, 125 I and 131 I
- nitrogen such as
- Certain isotopically-labelled peptide ligands of the invention are useful in drug and/or substrate tissue distribution studies, and to clinically assess the presence and/or absence of the Nectin-4 target on diseased tissues.
- the peptide ligands of the invention can further have valuable diagnostic properties in that they can be used for detecting or identifying the formation of a complex between a labelled compound and other molecules, peptides, proteins, enzymes or receptors.
- the detecting or identifying methods can use compounds that are labelled with labelling agents such as radioisotopes, enzymes, fluorescent substances, luminous substances (for example, luminol, luminol derivatives, luciferin, aequorin and luciferase), etc.
- labelling agents such as radioisotopes, enzymes, fluorescent substances, luminous substances (for example, luminol, luminol derivatives, luciferin, aequorin and luciferase), etc.
- the radioactive isotopes tritium, i.e. 3 H (T), and carbon-14, i.e. 14 C, are particularly useful for this purpose in view of their ease of incorporation and ready means of detection.
- Substitution with heavier isotopes such as deuterium, i.e. 2 H (D), may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements, and hence may be preferred in some circumstances.
- Isotopically-labeled compounds of peptide ligands of the invention can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples using an appropriate isotopically-labeled reagent in place of the non-labeled reagent previously employed.
- the molecular scaffold may be a small molecule, such as a small organic molecule.
- the molecular scaffold may be a macromolecule. In one embodiment, the molecular scaffold is a macromolecule composed of amino acids, nucleotides or carbohydrates.
- the molecular scaffold comprises reactive groups that are capable of reacting with functional group(s) of the polypeptide to form covalent bonds.
- the molecular scaffold may comprise chemical groups which form the linkage with a peptide, such as amines, thiols, alcohols, ketones, aldehydes, nitriles, carboxylic acids, esters, alkenes, alkynes, azides, anhydrides, succinimides, maleimides, alkyl halides and acyl halides.
- chemical groups which form the linkage with a peptide such as amines, thiols, alcohols, ketones, aldehydes, nitriles, carboxylic acids, esters, alkenes, alkynes, azides, anhydrides, succinimides, maleimides, alkyl halides and acyl halides.
- the molecular scaffold may comprise or may consist of hexahydro-1,3,5-triazine, especially 1,3,5-Triacryloylhexahydro-1,3,5-triazine (TATA), or a derivative thereof.
- TATA 1,3,5-Triacryloylhexahydro-1,3,5-triazine
- the molecular scaffold of the invention contains chemical groups that allow functional groups of the polypeptide of the encoded library of the invention to form covalent links with the molecular scaffold.
- Said chemical groups are selected from a wide range of functionalities including amines, thiols, alcohols, ketones, aldehydes, nitriles, carboxylic acids, esters, alkenes, alkynes, anhydrides, succinimides, maleimides, azides, alkyl halides and acyl halides.
- Scaffold reactive groups that could be used on the molecular scaffold to react with thiol groups of cysteines are alkyl halides (or also named halogenoalkanes or haloalkanes).
- scaffold reactive groups that are used to selectively couple compounds to cysteines in proteins are maleimides, ⁇ unsaturated carbonyl containing compounds and ⁇ -halomethylcarbonyl containing compounds.
- maleimides which may be used as molecular scaffolds in the invention include: tris-(2-maleimidoethyl)amine, tris-(2-maleimidoethyl)benzene, tris-(maleimido)benzene.
- An example of an ⁇ unsaturated carbonyl containing compound is 1,1′,1′′-(1,3,5-triazinane-1,3,5-triyl)triprop-2-en-1-one (TATA) (Angewandte Chemie, International Edition (2014), 53(6), 1602-1606).
- An example of an ⁇ -halomethylcarbonyl containing compound is N,N′,N′′-(benzene-1,3,5-triyl)tris(2-bromoacetamide).
- Selenocysteine is also a natural amino acid which has a similar reactivity to cysteine and can be used for the same reactions. Thus, wherever cysteine is mentioned, it is typically acceptable to substitute selenocysteine unless the context suggests otherwise.
- the peptides of the present invention may be manufactured synthetically by standard techniques followed by reaction with a molecular scaffold in vitro. When this is performed, standard chemistry may be used. This enables the rapid large scale preparation of soluble material for further downstream experiments or validation. Such methods could be accomplished using conventional chemistry such as that disclosed in Timmerman et al (supra).
- the invention also relates to manufacture of polypeptides or conjugates selected as set out herein, wherein the manufacture comprises optional further steps as explained below. In one embodiment, these steps are carried out on the end product polypeptide/conjugate made by chemical synthesis.
- amino acid residues in the polypeptide of interest may be substituted when manufacturing a conjugate or complex.
- Peptides can also be extended, to incorporate for example another loop and therefore introduce multiple specificities.
- the peptide may simply be extended chemically at its N-terminus or C-terminus or within the loops using orthogonally protected lysines (and analogues) using standard solid phase or solution phase chemistry.
- Standard (bio)conjugation techniques may be used to introduce an activated or activatable N- or C-terminus.
- additions may be made by fragment condensation or native chemical ligation e.g. as described in (Dawson et al. 1994. Synthesis of Proteins by Native Chemical Ligation. Science 266:776-779), or by enzymes, for example using subtiligase as described in (Chang et al. Proc Natl Acad Sci USA. 1994 Dec. 20; 91(26):12544-8 or in Hikari et al Bioorganic & Medicinal Chemistry Letters Volume 18, Issue 22, 15 Nov. 2008, Pages 6000-6003).
- the peptides may be extended or modified by further conjugation through disulphide bonds.
- This has the additional advantage of allowing the first and second peptides to dissociate from each other once within the reducing environment of the cell.
- the molecular scaffold e.g. TATA
- a further cysteine or thiol could then be appended to the N or C-terminus of the first peptide, so that this cysteine or thiol only reacted with a free cysteine or thiol of the second peptides, forming a disulfide—linked bicyclic peptide-peptide conjugate.
- composition comprising a peptide ligand as defined herein in combination with one or more pharmaceutically acceptable excipients.
- the present peptide ligands will be utilised in purified form together with pharmacologically appropriate excipients or carriers.
- these excipients or carriers include aqueous or alcoholic/aqueous solutions, emulsions or suspensions, including saline and/or buffered media.
- Parenteral vehicles include sodium chloride solution, Ringers dextrose, dextrose and sodium chloride and lactated Ringers.
- Suitable physiologically-acceptable adjuvants, if necessary to keep a polypeptide complex in suspension may be chosen from thickeners such as carboxymethylcellulose, polyvinylpyrrolidone, gelatin and alginates.
- Intravenous vehicles include fluid and nutrient replenishers and electrolyte replenishers, such as those based on Ringers dextrose. Preservatives and other additives, such as antimicrobials, antioxidants, chelating agents and inert gases, may also be present (Mack (1982) Remington's Pharmaceutical Sciences, 16th Edition).
- the peptide ligands of the present invention may be used as separately administered compositions or in conjunction with other agents. These can include antibodies, antibody fragments and various immunotherapeutic drugs, such as cylcosporine, methotrexate, adriamycin or cisplatinum and immunotoxins. Pharmaceutical compositions can include “cocktails” of various cytotoxic or other agents in conjunction with the protein ligands of the present invention, or even combinations of selected polypeptides according to the present invention having different specificities, such as polypeptides selected using different target ligands, whether or not they are pooled prior to administration.
- immunotherapeutic drugs such as cylcosporine, methotrexate, adriamycin or cisplatinum and immunotoxins.
- Pharmaceutical compositions can include “cocktails” of various cytotoxic or other agents in conjunction with the protein ligands of the present invention, or even combinations of selected polypeptides according to the present invention having different specificities, such as polypeptides selected
- the route of administration of pharmaceutical compositions according to the invention may be any of those commonly known to those of ordinary skill in the art.
- the peptide ligands of the invention can be administered to any patient in accordance with standard techniques.
- the administration can be by any appropriate mode, including parenterally, intravenously, intramuscularly, intraperitoneally, transdermally, via the pulmonary route, or also, appropriately, by direct infusion with a catheter.
- the pharmaceutical compositions according to the invention will be administered by inhalation.
- the dosage and frequency of administration will depend on the age, sex and condition of the patient, concurrent administration of other drugs, counterindications and other parameters to be taken into account by the clinician.
- the peptide ligands of this invention can be lyophilised for storage and reconstituted in a suitable carrier prior to use. This technique has been shown to be effective and art-known lyophilisation and reconstitution techniques can be employed. It will be appreciated by those skilled in the art that lyophilisation and reconstitution can lead to varying degrees of activity loss and that levels may have to be adjusted upward to compensate.
- compositions containing the present peptide ligands or a cocktail thereof can be administered for prophylactic and/or therapeutic treatments.
- an adequate amount to accomplish at least partial inhibition, suppression, modulation, killing, or some other measurable parameter, of a population of selected cells is defined as a “therapeutically-effective dose”. Amounts needed to achieve this dosage will depend upon the severity of the disease and the general state of the patient's own immune system, but generally range from 0.005 to 5.0 mg of selected peptide ligand per kilogram of body weight, with doses of 0.05 to 2.0 mg/kg/dose being more commonly used.
- compositions containing the present peptide ligands or cocktails thereof may also be administered in similar or slightly lower dosages.
- a composition containing a peptide ligand according to the present invention may be utilised in prophylactic and therapeutic settings to aid in the alteration, inactivation, killing or removal of a select target cell population in a mammal.
- the peptide ligands described herein may be used extracorporeally or in vitro selectively to kill, deplete or otherwise effectively remove a target cell population from a heterogeneous collection of cells.
- Blood from a mammal may be combined extracorporeally with the selected peptide ligands whereby the undesired cells are killed or otherwise removed from the blood for return to the mammal in accordance with standard techniques.
- heterotandem bicyclic peptide complex as defined herein for use in preventing, suppressing or treating cancer.
- cancers and their benign counterparts which may be treated (or inhibited) include, but are not limited to tumours of epithelial origin (adenomas and carcinomas of various types including adenocarcinomas, squamous carcinomas, transitional cell carcinomas and other carcinomas) such as carcinomas of the bladder and urinary tract, breast, gastrointestinal tract (including the esophagus, stomach (gastric), small intestine, colon, rectum and anus), liver (hepatocellular carcinoma), gall bladder and biliary system, exocrine pancreas, kidney, lung (for example adenocarcinomas, small cell lung carcinomas, non-small cell lung carcinomas, bronchioalveolar carcinomas and mesotheliomas), head and neck (for example cancers of the tongue, buccal cavity, larynx, pharynx, nasopharynx, tonsil, salivary glands, nasal cavity and paranasal sinuses), ovary, fallopian
- lymphoid lineage for example acute lymphocytic leukemia [ALL], chronic lymphocytic leukemia [CLL], B-cell lymphomas such as diffuse large B-cell lymphoma [DLBCL], follicular lymphoma, Burkitt's lymphoma, mantle cell lymphoma, T-cell lymphomas and leukaemias, natural killer [NK] cell lymphomas, Hodgkin's lymphomas, hairy cell leukaemia, monoclonal gammopathy of uncertain significance, plasmacytoma, multiple myeloma, and post-transplant lymphoproliferative disorders), and haematological malignancies and related conditions of myeloid lineage (for example acute myelogenousleukemia [AML], chronic myelogenousleukemia [CML], chronic myelomonoc
- the cancer is selected from a hematopoietic malignancy such as selected from: non-Hodgkin's lymphoma (NHL), Burkitt's lymphoma (BL), multiple myeloma (MM), B chronic lymphocytic leukemia (B-CLL), B and T acute lymphocytic leukemia (ALL), T cell lymphoma (TCL), acute myeloid leukemia (AML), hairy cell leukemia (HCL), Hodgkin's Lymphoma (HL), and chronic myeloid leukemia (CML).
- NHL non-Hodgkin's lymphoma
- BL Burkitt's lymphoma
- MM multiple myeloma
- B-CLL B chronic lymphocytic leukemia
- ALL T acute lymphocytic leukemia
- TCL T cell lymphoma
- AML acute myeloid leukemia
- HCL hairy cell leukemia
- HL Hodgkin
- prevention involves administration of the protective composition prior to the induction of the disease.
- suppression refers to administration of the composition after an inductive event, but prior to the clinical appearance of the disease.
- Treatment involves administration of the protective composition after disease symptoms become manifest.
- Animal model systems which can be used to screen the effectiveness of the peptide ligands in protecting against or treating the disease are available.
- the use of animal model systems is facilitated by the present invention, which allows the development of polypeptide ligands which can cross react with human and animal targets, to allow the use of animal models.
- heterotandem bicyclic peptide complexes of the invention may be prepared in accordance with the following general method:
- Palmitic acid (100.0 mg, 282.89 ⁇ mol, 1.0 eq.), compound 2 (150.0 mg, 284.84 ⁇ mol, 1.0 eq.), and DIEA (74.5 mg, 574.11 ⁇ mol, 100.0 ⁇ L, 2.0 eq.) was dissolved in DMF (2 mL). The reaction mixture was stirred at 30° C. for 2 hr. LC-MS showed compound 1 was consumed completely and one main peak with desired m/z (MW: 765.03, observed m/z: 765.22) was detected. The reaction mixture was concentrated under reduced pressure to remove solvent and produced a residue. The residue was then purified by prep-HPLC (neutral condition). Palmitic acid—PEG10-N 3 (79.0 mg, 99.41 ⁇ mol, 35.14% yield, 96.27% purity) was obtained as a white solid.
- Palmitic acid—NHS (100.0 mg, 282.89 ⁇ mol, 1.0 eq.)
- compound 2 (150.0 mg, 284.84 ⁇ mol, 1.0 eq.)
- DIEA 74.5 mg, 574.11 ⁇ mol, 100.0 ⁇ L, 2.0 eq.
- the reaction mixture was stirred at 30° C. for 2 hr.
- LC-MS showed compound 1 was consumed completely and one main peak with desired m/z (MW: 765.03, observed m/z: 765.22) was detected.
- the reaction mixture was concentrated under reduced pressure to remove solvent and produced a residue. The residue was then purified by prep-HPLC (neutral condition). Palmitic acid-PEG10-N3 (79.0 mg, 99.41 ⁇ mol, 35.14% yield, 96.27% purity) was obtained as a white solid.
- Palmitic acid-PEG10-BCY11144-PEG5-N 3 (20.0 mg, 5.72 ⁇ mol, 37.33% yield, 96.79% purity) was obtained as a white solid.
- the peptide was synthesized using standard Fmoc chemistry.
- DCM was added to a reaction vessel containing Chlorotrityl resin (1 mmol, 0.91 g, 1.10 mmol/g) and Fmoc-Lys(N3) —OH (1 eq, 395.4 mg, 1 mmol) with N 2 bubbling.
- DIEA (4.0 eq) was added dropwise and mixed for 2 hours. MeOH (2 mL) was then added and mixed for 30 min. The resin was drained and washed with DMF 5 times. Fmoc deprotection was performed by addition of 20% piperidine/DMF and mixing for 30 min. The resin was drained and washed with DMF 5 times.
- Fmoc-amino acid solution was added and mixed for 30 sec first, then add activation buffer (containing HBTU and DIEA in DMF) was added and stirred for 1 hr with continuous N2 bubbling. Deprotection and coupling was repeated until the peptide was complete.
- activation buffer containing HBTU and DIEA in DMF
- the peptide was synthesized using standard Fmoc chemistry.
- DCM was added to a reaction vessel containing chlorotrityl resin (1 mmol, 0.91 g, 1.1 mmol/g) and Fmoc- ⁇ Glu(OtBu)-OH (0.425 mg, 1 mmol, 1 eq) and the mixture stirred with N 2 bubbling.
- DIEA (4.0 eq) was added dropwise and the mixture was agitated for 2 hours. MeOH (4.6 mL) was then added and mixed for 30 min. The resin was drained and washed with DMF 5 times. 20% piperidine/DMF was added to the resin and mixed for 30 minutes. The resin was drained and washed with DMF 5 times.
- Fmoc-amino acid solution was added to the resin and mixed for 30 seconds, then activating agent and DIPEA was added and N2 bubbled through the mixture for 1 hour. Deprotection and coupling steps were repeated with the following reagents: Note:
- BCY12860-PEG5-N3 (39.7 mg, 15.02 ⁇ mol, 77.41% yield, 90.0% purity) was obtained as a white solid. MW: 2378.78, observed m/z: 1190.1 ([(M/2+H + ]), 793.5 ([(M/3+H + ]).
- BCY12865 (30.0 mg, 13.99 ⁇ mol, 1.0 eq) and compound 1 (6.1 mg, 14.11 ⁇ mol, 1.01 eq), were dissolved in 1 mL of MeCN/H 2 O (1:1), and then 1 M NaHCO 3 was added to adjust pH to 8. The mixture was stirred at 25° C. for 2 hr. LC-MS showed BCY12865 was consumed completely and one main peak with desired m/z was detected. The reaction mixture was purified by prep-HPLC (TFA condition) and compound 2 (15.6 mg, 6.32 ⁇ mol, 45.19% yield, 99.76% purity) was obtained as a white solid. Calculated MW: 2461.87, observed m/z: 1231.5 ([M/2+H] + ) and 821.3 ([M/3+H]+).
- BCY12865 (50 mg, 23.32 ⁇ mol, 1.0 eq) and compound 1 (10.5 mg, 24.28 ⁇ mol, 1.04 eq), were dissolved in 2 mL of MeCN/H 2 O (1:1), 1 M NaHCO 3 was added to adjust pH to 8. And then the mixture was stirred at 25° C. for 2 hr. LC-MS showed BCY12865 was consumed completely and one main peak with desired m/z (calculated MW: 2461.87, observed m/z: 1231.6 ([M/2+H] + ) and 821.4 ([M/3+H] + )) was detected. The reaction mixture was purified by prep-HPLC (TFA condition) and compound 2 (31.5 mg, 12.62 ⁇ mol, 54.14% yield, 98.66% purity) was obtained as a white solid.
- Culture medium referred to as R1 media
- R1 media is prepared by adding 1% FBS to RPMI-1640 (component of Promega kit CS196005). Serial dilutions of test articles in R1 are prepared in a sterile 96 well-plate. Add 25 ⁇ L per well of test articles or R1 (as a background control) to designated wells in a white cell culture plate. Tumour cells* are harvested and resuspended at a concentration of 400,000 cells/mL in R1 media. Twenty five (25) ⁇ L/well of tumour cells are added to the white cell culture plate.
- Jurkat cells (Promega kit CS196005, 0.5 mL) are thawed in the water bath and then added to 5 ml pre-warmed R1 media. Twenty five (25) ⁇ L/well of Jurkat cells are then added to the white cell culture plate. Incubate the cells and test articles for 6h at 37° C., 5% CO 2 . At the end of 6h, add 75 ⁇ L/well Bio-GloTM reagent (Promega) and incubate for 10 min before reading luminescence in a plate reader (Clariostar, BMG). The fold change relative to cells alone (Jurkat cells+ Cell line used in co-culture) is calculated and plotted in GraphPad Prism as log(agonist) vs response to determine EC50 (nM) and Fold Induction over background (Max).
- tumour cell type used in co-culture is NCI-H292 which has been shown to express Nectin-4.
- the tumour cell type used in co-culture for EphA2 is PC3.
- the tumour cell type used in co-culture for PD-L1 is RKO.
- the supernatant was transferred into pre-labeled polypropylene microcentrifuge tubes, and then quick-frozen over dry ice. The samples were stored at 70° C. or below as needed until analysis. 7.5 ⁇ L of the supernatant samples were directly injected for LC-MS/MS analysis using an Orbitrap Q Exactive in positive ion mode to determine the concentrations of Bicycle. Plasma concentration versus time data were analyzed by non-compartmental approaches using the Phoenix WinNonlin 6.3 software program. C0, CI, Vdss, T1/2, AUC(0-last), AUC(0-inf), MRT(0-last), MRT(0-inf) and graphs of plasma concentration versus time profile were reported. The pharmacokinetic parameters from the experiment are as shown in Table 4:
Abstract
The present invention relates to heterotandem bicyclic peptide complexes which comprise a first peptide ligand, which binds to a component present on a cancer cell, conjugated via a linker to a second peptide ligand, which binds to a component present on an immune cell. The invention also relates to the use of said heterotandem bicyclic peptide complexes in preventing, suppressing or treating cancer.
Description
- The present invention relates to heterotandem bicyclic peptide complexes which comprise a first peptide ligand, which binds to a component present on a cancer cell, conjugated via a linker to a second peptide ligand, which binds to a component present on an immune cell. The invention also relates to the use of said heterotandem bicyclic peptide complexes in preventing, suppressing or treating cancer.
- This application is a divisional of U.S. patent application Ser. No. 17/062,662, filed on Oct. 5, 2020, which claims the benefit of U.S. Provisional Application No. 62/910,129, filed on Oct. 3, 2019, the entire disclosures of which are hereby incorporated herein by reference.
- A Sequence Listing is being submitted electronically via EFS in the form of a text file, created Mar. 21, 2022, and named 189822_SL.txt (35,391 bytes), the contents of which are incorporated herein by reference in their entirety.
- Cyclic peptides are able to bind with high affinity and target specificity to protein targets and hence are an attractive molecule class for the development of therapeutics. In fact, several cyclic peptides are already successfully used in the clinic, as for example the antibacterial peptide vancomycin, the immunosuppressant drug cyclosporine or the anti-cancer drug octreotide (Driggers et al. (2008), Nat Rev Drug Discov 7 (7), 608-24). Good binding properties result from a relatively large interaction surface formed between the peptide and the target as well as the reduced conformational flexibility of the cyclic structures. Typically, macrocycles bind to surfaces of several hundred square angstrom, as for example the cyclic peptide CXCR4 antagonist CVX15 (400 Å2; Wu et al. (2007), Science 330, 1066-71), a cyclic peptide with the Arg-Gly-Asp motif binding to integrin αVb3 (355 Å2) (Xiong et al. (2002), Science 296 (5565), 151-5) or the cyclic peptide inhibitor upain-1 binding to urokinase-type plasminogen activator (603 Å2; Zhao et al. (2007), J Struct Biol 160 (1), 1-10).
- Due to their cyclic configuration, peptide macrocycles are less flexible than linear peptides, leading to a smaller loss of entropy upon binding to targets and resulting in a higher binding affinity. The reduced flexibility also leads to locking target-specific conformations, increasing binding specificity compared to linear peptides. This effect has been exemplified by a potent and selective inhibitor of matrix metalloproteinase 8 (MMP-8) which lost its selectivity over other MMPs when its ring was opened (Cherney et al. (1998), J Med Chem 41 (11), 1749-51). The favorable binding properties achieved through macrocyclization are even more pronounced in multicyclic peptides having more than one peptide ring as for example in vancomycin, nisin and actinomycin.
- Different research teams have previously tethered polypeptides with cysteine residues to a synthetic molecular structure (Kemp and McNamara (1985), J. Org. Chem; Timmerman et al. (2005), ChemBioChem). Meloen and co-workers had used tris(bromomethyl)benzene and related molecules for rapid and quantitative cyclisation of multiple peptide loops onto synthetic scaffolds for structural mimicry of protein surfaces (Timmerman et al. (2005), ChemBioChem). Methods for the generation of candidate drug compounds wherein said compounds are generated by linking cysteine containing polypeptides to a molecular scaffold as for example tris(bromomethyl)benzene are disclosed in WO 2004/077062 and WO 2006/078161.
- Phage display-based combinatorial approaches have been developed to generate and screen large libraries of bicyclic peptides to targets of interest (Heinis et al. (2009), Nat Chem Biol 5 (7), 502-7 and WO 2009/098450). Briefly, combinatorial libraries of linear peptides containing three cysteine residues and two regions of six random amino acids (Cys-(Xaa)6-Cys-(Xaa)6-Cys) were displayed on phage and cyclised by covalently linking the cysteine side chains to a small molecule (tris-(bromomethyl)benzene).
- According to a first aspect of the invention, there is provided a heterotandem bicyclic peptide complex comprising:
-
- (a) a first peptide ligand which binds to a component present on a cancer cell; conjugated via a linker to
- (b) a second peptide ligand which binds to a component present on an immune cell;
wherein each of said peptide ligands comprise a polypeptide comprising at least three reactive groups, separated by at least two loop sequences, and a molecular scaffold which forms covalent bonds with the reactive groups of the polypeptide such that at least two polypeptide loops are formed on the molecular scaffold, characterised in that said heterotandem bicyclic peptide complex comprises the following first and second peptide ligands:
-
Heterotandem Complex No. First Peptide Second Peptide BCY12229 [Ac]D[HArg]CSAGWLTMCQKLHLCPSH Ac-C[tBuAla]PE[D-Lys(PYA)]PYCFADPY[Nle]CA (SEQ (SEQ ID NO: 1; BCY11865) ID NO: 67; BCY8928) BCY12230 [Ac]D[HArg]CSKGWLTMCQK(Ac)LHLCPSH (SEQ ID Ac-C[tBuAla]PE[D-Lys(PYA)]PYCFADPY[Nle]CA (SEQ NO: 2; BCY11866) ID NO: 67; BCY8928) BCY12231 [Ac]D[HArg]CSAGWLTKCQK(Ac)LHLCPSH (SEQ ID Ac-C[tBuAla]PE[D-Lys(PYA)]PYCFADPY[Nle]CA (SEQ NO: 3; BCY11867) ID NO: 67; BCY8928) BCY12232 [Ac]D[HArg]CSAGWLTMCKK(Ac)LHLCPSH (SEQ ID Ac-C[tBuAla]PE[D-Lys(PYA)]PYCFADPY[Nle]CA (SEQ NO: 4; BCY11868) ID NO: 67; BCY8928) BCY12242 [Ac]D[HArg]CSAGWLTMCQK(Ac)LKLCPSH (SEQ ID Ac-C[tBuAla]PE[D-Lys(PYA)]PYCFADPY[Nle]CA (SEQ NO: 5; BCY11869) ID NO: 67; BCY8928) BCY12375 Ac-SDKCSAGWLTMCQK[PYA]LHLCPSH (SEQ ID NO: [Ac]C[tBuAla]EE(dK)PYCFADPY[Nle]C[Dap(PYA)] 6; BCY10861) (SEQ ID NO: 68; BCY12023) BCY12663 [Ac]SD[HArg]CSAGWLTMCQ[HArg]LHLCPSHK (SEQ Ac-C[tBuAla]PE[D-Lys(PYA)]PYCFADPY[Nle]CA (SEQ ID NO: 7; BCY12479) ID NO: 67; BCY8928) BCY12796 [Ac]SD[HArg]CSAGWLTMC[HArg]QLNLCPSHK (SEQ Ac-C[tBuAla]PE[D-Lys(PYA)]PYCFADPY[Nle]CA (SEQ ID NO: 8; BCY12477) ID NO: 67; BCY8928) BCY12021 Ac-SDKCSAGWLTMCQK[PYA]LHLCPSH (SEQ ID NO: [Ac]C[tBuAla]PE[dK]PYCFADPY[Nle]C[Dap(PYA)] 9; BCY10861) (SEQ ID NO: 69; BCY11144) BCY12233 [PYA]A[HArg]DC[HyP]LVNPLCLHP[dD]W[HArg]C Ac-C[tBuAla]PE[D-Lys]PYCFADPY[Nle]CA (SEQ ID (SEQ ID NO: 10; BCY11813) NO: 70; BCY8920) BCY12234 [Ac]A[HArg]DC[HyP]LVNPLCLHP[dD]W[HArg]CK(PYA) Ac-C[tBuAla]PE[D-Lys]PYCFADPY[Nle]CA (SEQ ID (SEQ ID NO: 11; BCY11814) NO: 70; BCY8920) BCY12235 [Ac]A[HArg]DC[HyP]LVNPLCLK(PYA)P[dD]W[HArg]C Ac-C[tBuAla]PE[D-Lys]PYCFADPY[Nle]CA (SEQ ID (SEQ ID NO: 12; BCY11815) NO: 70; BCY8920) BCY12236 [Ac]A[HArg]DC[HyP](PYA)VNPLCLHP[dD]W[HArg]C Ac-C[tBuAla]PE[D-Lys]PYCFADPY[Nle]CA (SEQ ID (SEQ ID NO: 13; BCY11816) NO: 70; BCY8920) BCY12237 [Ac]A[HArg]DC[HyP]LVNPLCK(PYA)HP[dD]W[HArg]C Ac-C[tBuAla]PE[D-Lys]PYCFADPY[Nle]CA (SEQ ID (SEQ ID NO: 14; BCY11817) NO: 70; BCY8920) BCY12711 A[HArg]DC[HyP]LVNPLCLHP[dD]W[HArg]C (SEQ ID [Ac]C[tBuAla]EE[dK(PYA)]PYCFADPY[Nle]C (SEQ ID NO: 15; BCY9594) NO: 71; BCY12143) BCY12712 A[HArg]DC[HyP]LVNPLCLHP[dD]W[HArg]C (SEQ ID [Ac]C[tBuAla]PE[dK(PYA)]PYCFADPY[Nle]C (SEQ ID NO: 15; BCY9594) NO: 72; BCY12149) BCY12713 A[HArg]DC[HyP]LVNPLCLHP[dD]W[HArg]C (SEQ ID [Ac]C[tBuAla]PE[dK(PYA)]PYCFANPY[Nle]C (SEQ ID NO: 15; BCY9594) NO: 73; BCY12147) BCY12714 A[HArg]DC[HyP]LVNPLCLHP[dD]W[HArg]C (SEQ ID [Ac]C[tBuAla]PE[dK(PYA)]PYCFAEPY[Nle]C (SEQ ID NO: 15; BCY9594) NO: 74; BCY12145) BCY12715 A[HArg]DC[HyP]LVNPLCLHP[dD]W[HArg]C (SEQ ID [Ac]C[tBuAla]PE[dK(PYA)]PYCFA[Aad]PY[Nle]C NO: 15; BCY9594) (SEQ ID NO: 75; BCY12146) BCY12717 A[HArg]DC[HyP]LVNPLCLHP[dD]W[HArg]C (SEQ ID [Ac]C[tBuAla]PE[dK(PYA)]PYCFADPY[Nle] NO: 15; BCY9594) [Cysteamine] (SEQ ID NO: 76; BCY12352) BCY12718 A[HArg]DC[HyP]LVNPLCLHP[dD]W[HArg]C (SEQ ID [3-mercaptopropionic NO: 15; BCY9594) acid][tBuAla]PE[dK(PYA)]PYCFADPY[Nle]C (SEQ ID NO: 77; BCY12353) BCY12719 A[HArg]DC[HyP]LVNPLCLHP[dD]W[HArg]C (SEQ ID [3-mercaptopropionic NO: 15; BCY9594) acid][tBuAla]PE[dK(PYA)]PYCFADPY[Nle] [Cysteamine] (SEQ ID NO: 78; BCY12354) BCY12720 A[HArg]DC[HyP]LVNPLCLHP[dD]W[HArg]C (SEQ ID Palmitic acid-yGly-yGlu- NO: 15; BCY9594) C[tBuAla]PE[dK(PYA)]PYCFADPY[Nle]C (SEQ ID NO: 79; BCY12360) BCY12961 [Ac]A[HArg]DC[HyP]LVNPLCLHP[dD]W[HArg]CK Ac-C[tBuAla]PE[D-Lys(PYA)]PYCFADPY[Nle]CA (SEQ (SEQ ID NO: 16; BCY12734) ID NO: 67; BCY8928) BCY12962 [Ac]A[HArg]DC[HyP]LVNPLCLKP[dD]W[HArg]C Ac-C[tBuAla]PE[D-Lys(PYA)]PYCFADPY[Nle]CA (SEQ (SEQ ID NO: 17; BCY12735) ID NO: 67; BCY8928) BCY12963 [Ac]A[HArg]DC[HyP]KVNPLCLHP[dD]W[HArg]C (SEQ Ac-C[tBuAla]PE[D-Lys(PYA)]PYCFADPY[Nle]CA (SEQ ID NO: 18; BCY12736) ID NO: 67; BCY8928) BCY12964 [Ac]A[HArg]DC[HyP]LVNPLCKHP[dD]W[HArg]C (SEQ Ac-C[tBuAla]PE[D-Lys(PYA)]PYCFADPY[Nle]CA (SEQ ID NO: 19; BCY12737) ID NO: 67; BCY8928) BCY12965 A[HArg]DC[HyP]LVNPLCLHP[dE]V[HArg]C (SEQ ID Ac-C[tBuAla]PE[D-Lys(PYA)]PYCFADPY[Nle]CA (SEQ NO: 20; BCY12738) ID NO: 67; BCY8928) BCY12966 A[HArg]EC[HyP]LVNPLCLHP[dE]V[HArg]C (SEQ ID Ac-C[tBuAla]PE[D-Lys(PYA)]PYCFADPY[Nle]CA (SEQ NO: 21; BCY12739) ID NO: 67; BCY8928) BCY13029 A[HArg]DC[HyP]LVNPLCLEP[dD]W[HArg]C (SEQ ID Ac-C[tBuAla]PE[D-Lys(PYA)]PYCFADPY[Nle]CA (SEQ NO: 22; BCY12854) ID NO: 67; BCY8928) BCY13030 A[HArg]DC[HyP]LVNPLCLHP[dD]WTC (SEQ ID NO: Ac-C[tBuAla]PE[D-Lys(PYA)]PYCFADPY[Nle]CA (SEQ 23; BCY12855) ID NO: 67; BCY8928) BCY13031 A[HArg]DC[HyP]LVNPLCLEP[dD]WTC (SEQ ID NO: Ac-C[tBuAla]PE[D-Lys(PYA)]PYCFADPY[Nle]CA (SEQ 24; BCY12856) ID NO: 67; BCY8928) BCY13032 A[HArg]DC[HyP]LVNPLCLEP[dD]WTC[dA] (SEQ ID Ac-C[tBuAla]PE[D-Lys(PYA)]PYCFADPY[Nle]CA (SEQ NO: 25; BCY12857) ID NO: 67; BCY8928) BCY13033 A[HArg]DC[HyP]LVNPLCLEP[dA]WTC (SEQ ID NO: Ac-C[tBuAla]PE[D-Lys(PYA)]PYCFADPY[Nle]CA (SEQ 26; BCY12858) ID NO: 67; BCY8928) BCY13034 A[HArg]DC[HyP]LVNPLCL[33DPA]P[dD]WTC (SEQ Ac-C[tBuAla]PE[D-Lys(PYA)]PYCFADPY[Nle]CA (SEQ ID NO: 27; BCY12859) ID NO: 67; BCY8928) BCY13035 C[HyP]LVNPLCL[33DPA]P[dD]WTC (SEQ ID NO: 28; Ac-C[tBuAla]PE[D-Lys(PYA)]PYCFADPY[Nle]CA (SEQ BCY12860) ID NO: 67; BCY8928) BCY13036 C[HyP]LVNPLCLEP[dD]WTC[dA] (SEQ ID NO: 29; Ac-C[tBuAla]PE[D-Lys(PYA)]PYCFADPY[Nle]CA (SEQ BCY12861) ID NO: 67; BCY8928) BCY13037 A[HArg]DC[HyP][Cba]VNPLCLHP[dD]W[HArg]C Ac-C[tBuAla]PE[D-Lys(PYA)]PYCFADPY[Nle]CA (SEQ (SEQ ID NO: 30; BCY12862) ID NO: 67; BCY8928) BCY13038 A[HArg]DC[HyP][Cba]VNPLCLEP[dD]WTC (SEQ ID Ac-C[tBuAla]PE[D-Lys(PYA)]PYCFADPY[Nle]CA (SEQ NO: 31; BCY12863) ID NO: 67; BCY8928) BCY13039 [dA][HArg]DC[HyP][Cba]VNPLCLEP[dD]WTC[dA] Ac-C[tBuAla]PE[D-Lys(PYA)]PYCFADPY[Nle]CA (SEQ (SEQ ID NO: 32; BCY12864) ID NO: 67; BCY8928) BCY13040 C[HyP][Cba]VNPLCL[33DPA]P[dD]WTC[dA] (SEQ ID Ac-C[tBuAla]PE[D-Lys(PYA)]PYCFADPY[Nle]CA (SEQ NO: 33; BCY12865) ID NO: 67; BCY8928) BCY13041 A[HArg]DC[HyP]LVNPLCL[33DPA]P[dD]W[HArg]C Ac-C[tBuAla]PE[D-Lys(PYA)]PYCFADPY[Nle]CA (SEQ (SEQ ID NO: 34; BCY12866) ID NO: 67; BCY8928) BCY13141 A[HArg]DC[HyP]LVNPLCLEP[dD]WTC (SEQ ID NO: [3-mercaptopropionic 24; BCY12856) acid][tBuAla]PE[dK(PYA)]PYCFADPY[Nle]C (SEQ ID NO: 77; BCY12353) BCY13142 A[HArg]DC[HyP]LVNPLCLHP[dD]W[HArg]C (SEQ ID [3-mercaptopropionic NO: 15; BCY9594) acid][tBuAla]EE[dNPYCFADPY[Nle]C (SEQ ID NO: 80; BCY13137) BCY13143 A[HArg]DC[HyP]LVNPLCLEP[dD]WTC (SEQ ID NO: [3-mercaptopropionic 24; BCY12856) acid][tBuAla]EE[dNPYCFADPY[Nle]C (SEQ ID NO: 80; BCY13137) BCY13250 A[HArg]DC[HyP]LVNPLCLHP[d1Nal]W[HArg]C (SEQ Ac-C[tBuAla]PE[D-Lys(PYA)]PYCFADPY[Nle]CA (SEQ ID NO: 35; BCY13116) ID NO: 67; BCY8928) BCY13251 A[HArg]DC[HyP]LVNPLCL[1Nal]P[dD]W[HArg]C Ac-C[tBuAla]PE[D-Lys(PYA)]PYCFADPY[Nle]CA (SEQ (SEQ ID NO: 36; BCY13117) ID NO: 67; BCY8928) BCY13252 A[HArg]DC[HyP]LVNPLCLEP[d1Nal]WTC (SEQ ID Ac-C[tBuAla]PE[D-Lys(PYA)]PYCFADPY[Nle]CA (SEQ NO: 37; BCY13118) ID NO: 67; BCY8928) BCY13253 C[HyP]LVNPLCL[1Nal]P[dD]WTC (SEQ ID NO: 38; Ac-C[tBuAla]PE[D-Lys(PYA)]PYCFADPY[Nle]CA (SEQ BCY13119) ID NO: 67; BCY8928) BCY13254 [Ac]C[HyP]LVNPLCL[33DPA]P[dD]ATTC[dK] (SEQ Ac-C[tBuAla]PE[D-Lys(PYA)]PYCFADPY[Nle]CA (SEQ ID NO: 39; BCY13120) ID NO: 67; BCY8928) BCY13255 [NMeAla][HArg]DC[HyP]LVNPLCLHP[dD]W[HArg]C Ac-C[tBuAla]PE[D-Lys(PYA)]PYCFADPY[Nle]CA (SEQ (SEQ ID NO: 40; BCY13121) ID NO: 67; BCY8928) BCY13256 [NMeAla][HArg]DC[HyP]LVNPLCLEP[dD]WTC (SEQ Ac-C[tBuAla]PE[D-Lys(PYA)]PYCFADPY[Nle]CA (SEQ ID NO: 41; BCY13122) ID NO: 67; BCY8928) BCY13257 [dA][HArg]DC[HyP][Cba]VNPLCLEP[dA]WTC[dA] Ac-C[tBuAla]PE[D-Lys(PYA)]PYCFADPY[Nle]CA (SEQ (SEQ ID NO: 42; BCY13123) ID NO: 67; BCY8928) BCY13258 [d1Nal][HArg]DC[HyP][Cba]VNPLCLEP[dA]WTC[dA] Ac-C[tBuAla]PE[D-Lys(PYA)]PYCFADPY[Nle]CA (SEQ (SEQ ID NO: 43; BCY13124) ID NO: 67; BCY8928) BCY13260 [dNEDC[HyP]LVNPLCLEP[dD]WTC (SEQ ID NO: 44; Ac-C[tBuAla]PE[D-Lys(PYA)]PYCFADPY[Nle]CA (SEQ BCY13126) ID NO: 67; BCY8928) BCY13261 [dA][dA]DC[HyP]LVNPLCLEP[dD]WTC (SEQ ID NO: Ac-C[tBuAla]PE[D-Lys(PYA)]PYCFADPY[Nle]CA (SEQ 45; BCY13127) ID NO: 67; BCY8928) BCY13262 ADC[HyP]LVNPLCLEP[dD]WTC (SEQ ID NO: 46; Ac-C[tBuAla]PE[D-Lys(PYA)]PYCFADPY[Nle]CA (SEQ BCY13128) ID NO: 67; BCY8928) BCY13264 A[HArg]DC[HyP][hGlu]VNPLCLHP[dD]W[HArg]C Ac-C[tBuAla]PE[D-Lys(PYA)]PYCFADPY[Nle]CA (SEQ (SEQ ID NO: 47; BCY13130) ID NO: 67; BCY8928) BCY13265 A[HArg]DC[HyP]LVNPLC[hGlu]HP[dD]W[HArg]C Ac-C[tBuAla]PE[D-Lys(PYA)]PYCFADPY[Nle]CA (SEQ (SEQ ID NO: 48; BCY13131) ID NO: 67; BCY8928) BCY13266 A[HArg]DC[HyP]LVNPLCL[hGlu]P[dD]W[HArg]C Ac-C[tBuAla]PE[D-Lys(PYA)]PYCFADPY[Nle]CA (SEQ (SEQ ID NO: 49; BCY13132) ID NO: 67; BCY8928) BCY13268 A[HArg]DC[HyP]LVNPLCLHP[dNle]W[HArg]C (SEQ Ac-C[tBuAla]PE[D-Lys(PYA)]PYCFADPY[Nle]CA (SEQ ID NO: 50; BCY13134) ID NO: 67; BCY8928) BCY13269 A[HArg]DC[HyP]LVNPLCL[Nle]P[dD]W[HArg]C Ac-C[tBuAla]PE[D-Lys(PYA)]PYCFADPY[Nle]CA (SEQ (SEQ ID NO: 51; BCY13135) ID NO: 67; BCY8928) BCY13340 C[HyP][Cba]VNPLCL[33DPA]P[dD]WTC[dA] (SEQ [3-mercaptopropionic ID NO: 33; BCY12865) acid][tBuAla]PE[dK(PYA)]PYCFADPY[Nle]C (SEQ ID NO: 77; BCY12353) BCY13342 C[HyP]LVNPLCL[33DPA]P[dD]WTC (SEQ ID NO: [3-mercaptopropionic 28; BCY12860) acid][tBuAla]PE[dK(PYA)]PYCFADPY[Nle]C (SEQ ID NO: 77; BCY12353) BCY11616 CP[1Nal][dD]CM[HArg]DWSTP[HyP]WC (SEQ ID NO: Ac-ACIEE(D-K)(PYA)QYCFADPY(Nle)CA (SEQ ID NO: 52; BCY8116) 81; BCY7744) BCY12238 [Ac]CP[1Nal][dK]CM[HArg]DWSTP[HyP]WC (SEQ ID Ac-C[tBuAla]PE[D-Lys(PYA)]PYCFADPY[Nle]CA (SEQ NO: 53; BCY12024) ID NO: 67; BCY8928) BCY12377 CP[1Nal][dD]CM[HArg]DWSTP[HyP]WC (SEQ ID NO: [Ac]C[tBuAla]EE[dK(PYA)]PYCFADPY[Nle]C (SEQ ID 52; BCY8116) NO: 71; BCY12143) BCY12379 CP[1Nal][dD]CM[HArg]DWSTP[HyP]WC (SEQ ID NO: [Ac]C[tBuAla]PE[dK(PYA)]PYCFADPY[Nle]C (SEQ ID 52; BCY8116) NO: 72; BCY12149) BCY12572 CP[1Nal][dD]CM[HArg]DWSTP[HyP]WC (SEQ ID NO: [Ac]C[tBuAla]PE[dK(PYA)]PYCFADPY[Nle] 52; BCY8116) [Cysteamine] (SEQ ID NO: 76; BCY12352) BCY12573 CP[1Nal][dD]CM[HArg]DWSTP[HyP]WC (SEQ ID NO: [3-mercaptopropionic 52; BCY8116) acid][tBuAla]PE[dK(PYA)]PYCFADPY[Nle]C (SEQ ID NO: 77; BCY12353) BCY12574 CP[1Nal][dD]CM[HArg]DWSTP[HyP]WC (SEQ ID NO: [3-mercaptopropionic 52; BCY8116) acid][tBuAla]PE[dK(PYA)]PYCFADPY[Nle] [Cysteamine] (SEQ ID NO: 78; BCY12354) BCY12575 CP[1Nal][dD]CM[HArg]DWSTP[HyP]WC (SEQ ID NO: Palmitic acid-yGly-yGlu- 52; BCY8116) C[tBuAla]PE[dK(PYA)]PYCFADPY[Nle]C (SEQ ID NO: 79; BCY12360) BCY12576 [3-mercaptopropionic Ac-C[tBuAla]PE[D-Lys(PYA)]PYCFADPY[Nle]CA (SEQ acid]P[1Nal][dK]CM[HArg]DWSTP[HyP]WC (SEQ ID ID NO: 67; BCY8928) NO: 54; BCY12363) BCY12577 [Ac]CP[1Nal][dK]CM[HArg]DWSTP[HyP]W Ac-C[tBuAla]PE[D-Lys(PYA)]PYCFADPY[Nle]CA (SEQ [Cysteamine] (SEQ ID NO: 55; BCY12364) ID NO: 67; BCY8928) BCY12578 [3-mercaptopropionic Ac-C[tBuAla]PE[D-Lys(PYA)]PYCFADPY[Nle]CA (SEQ acid]P[1Nal][dK]CM[HArg]DWSTP[HyP]W ID NO: 67; BCY8928) [Cysteamine] (SEQ ID NO: 56; BCY12365) BCY12579 [Ac]CP[1Nal][dK]CM[HArg]HWSTP[HyP]WC (SEQ ID Ac-C[tBuAla]PE[D-Lys(PYA)]PYCFADPY[Nle]CA (SEQ NO: 57; BCY12366) ID NO: 67; BCY8928) BCY12580 [Ac]CP[1Nal][dK]CM[HArg]EWSTP[HyP]WC (SEQ ID Ac-C[tBuAla]PE[D-Lys(PYA)]PYCFADPY[Nle]CA (SEQ NO: 58; BCY12367) ID NO: 67; BCY8928) BCY12581 CP[lNal][dE]CM[HArg]DWSTP[HyP]WC (SEQ ID NO: Ac-C[tBuAla]PE[D-Lys(PYA)]PYCFADPY[Nle]CA (SEQ 59; BCY12368) ID NO: 67; BCY8928) BCY12582 CP[lNal][dA]CM[HArg]DWSTP[HyP]WC (SEQ ID NO: Ac-C[tBuAla]PE[D-Lys(PYA)]PYCFADPY[Nle]CA (SEQ 60; BCY12369) ID NO: 67; BCY8928) BCY12583 CP[lNal][dE]CL[HArg]DWSTP[HyP]WC (SEQ ID NO: Ac-C[tBuAla]PE[D-Lys(PYA)]PYCFADPY[Nle]CA (SEQ 61; BCY12370) ID NO: 67; BCY8928) BCY12584 Palmitic-yGlu-yGlu- Ac-C[tBuAla]PE[D-Lys(PYA)]PYCFADPY[Nle]CA (SEQ CP[1Nal][dK]CM[HArg]DWSTP[HyP]WC (SEQ ID NO: ID NO: 67; BCY8928) 62; BCY12371) BCY12585 CP[1Nal][dE]CM[HArg]EWSTP[HyP]WC (SEQ ID NO: Ac-C[tBuAla]PE[D-Lys(PYA)]PYCFADPY[Nle]CA (SEQ 63; BCY12384) ID NO: 67; BCY8928) BCY12709 CP[1Nal][dD]CM[HArg]DWSTP[HyP]WC (SEQ ID NO: [Ac]C[tBuAla]PE[dK(PYA)]PYCFAD[NMeAla]Y[Nle]C 52; BCY8116) (SEQ ID NO: 82; BCY12381) BCY12710 CP[1Nal][dD]CM[HArg]DWSTP[HyP]WC (SEQ ID NO: [Ac]C[tBuAla]PE[dK(PYA)]PYCFAD[NMeDAla]Y[Nle]C 52; BCY8116) (SEQ ID NO: 83; BCY12382) BCY11468 [PYA][B-Ala]CP[1Nal][dD]CM[HArg]DWSTP[HyP]WC Ac-C[tBuAla]PE[D-Lys(PYA)]PYCFADPY[Nle]CA (SEQ (SEQ ID NO: 64; BCY11016) ID NO: 67; BCY8928) BCY11618 [PYA][B-Ala]CP[1Nal][dK]CM[HArg]DWSTP[HyP]WC Ac-C[tBuAla]PE[D-Lys]PYCFADPY[Nle]CA (SEQ ID (SEQ ID NO: 65; BCY11143) NO: 70; BCY8920) BCY11776 CP[lNal][dD]CM[HArg]DWSTP[HyP]WC (SEQ ID NO: [Ac]C[tBuAla]PE[dK]PYCFADPY[Nle]C[Dap(PYA)] 52; BCY8116) (SEQ ID NO: 69; BCY11144) BCY11860 [PYA][B-Ala]CP[1Nal][dK]CM[HArg]DWSTP[HyP]WC Ac-C[tBuAla]PE[D-Lys]PYCFADPY[Nle]CA (SEQ ID (SEQ ID NO: 65; BCY11143) NO: 70; BCY8920) BCY12020 [PYA][B-Ala]CP[1Nal][dD]CM[HArg]DWSTP[HyP]WC [Ac]C[tBuAla]PE[dK]PYCFADPY[Nle]C[Dap(PYA)] (SEQ ID NO: 64; BCY11016) (SEQ ID NO: 69; BCY11144) BCY12661 [PYA]CP[1Nal][dD]CM[HArg]DWSTP[HyP]WC (SEQ [Ac]C[tBuAla]EE(dK)PYCFADPY[Nle]C[Dap(PYA)] ID NO: 66; BCY11015) (SEQ ID NO: 68; BCY12023) BCY12969 CP[1Nal][dD]CM[HArg]DWSTP[HyP]WC (SEQ ID NO: [Ac]C[tBuAla]PE[dK(PYA)]PYCFADPY[Nle]C[1,2- 52; BCY8116) diaminoethane](SEQ ID NO: 84; BCY12358) wherein 1Nal represents 1-naphthylalanine, HArg represents homoarginine, HyP represents hydroxyproline, B-Ala represents beta-alanine, PYA represents 4-pentynoic acid, 3,3-DPA represents 3,3-diphenylalanine, Cba represents β-cyclobutyl-alanine , hGlu represents homoglutamic acid, Nle represents norleucine, NMeAla represents N-methyl-alanine, tBuAla represents t-butyl-alanine, Aad represents alpha-L-aminoadipic acid, Ac represents an acetyl group, Dap represents diaminopropionic acid, or a pharmaceutically acceptable salt thereof. - According to a further aspect of the invention, there is provided a pharmaceutical composition comprising a heterotandem bicyclic peptide complex as defined herein in combination with one or more pharmaceutically acceptable excipients.
- According to a further aspect of the invention, there is provided a heterotandem bicyclic peptide complex as defined herein for use in preventing, suppressing or treating cancer.
- First Peptide Ligands
- References herein to the term “cancer cell” includes any cell which is known to be involved in cancer. Cancer cells are created when the genes responsible for regulating cell division are damaged. Carcinogenesis is caused by mutation and epimutation of the genetic material of normal cells, which upsets the normal balance between proliferation and cell death. This results in uncontrolled cell division and the evolution of those cells by natural selection in the body. The uncontrolled and often rapid proliferation of cells can lead to benign or malignant tumours (cancer). Benign tumors do not spread to other parts of the body or invade other tissues. Malignant tumors can invade other organs, spread to distant iodations (metastasis) and become life-threatening.
- In one embodiment, the cancer cell is selected from an HT1080, A549, SC-OV-3, PC3, H1376, NCI-H292, LnCap, MC38, 4T1-D02 and RKO tumor cell.
- In one embodiment, the component present on a cancer cell is Nectin-4.
- Nectin-4 is a surface molecule that belongs to the nectin family of proteins, which comprises 4 members. Nectins are cell adhesion molecules that play a key role in various biological processes such as polarity, proliferation, differentiation and migration, for epithelial, endothelial, immune and neuronal cells, during development and adult life. They are involved in several pathological processes in humans. They are the main receptors for poliovirus, herpes simplex virus and measles virus. Mutations in the genes encoding Nectin-1 (PVRL1) or Nectin-4 (PVRL4) cause ectodermal dysplasia syndromes associated with other abnormalities. Nectin-4 is expressed during foetal development. In adult tissues its expression is more restricted than that of other members of the family. Nectin-4 is a tumour-associated antigen in 50%, 49% and 86% of breast, ovarian and lung carcinomas, respectively, mostly on tumours of bad prognosis. Its expression is not detected in the corresponding normal tissues. In breast tumours, Nectin-4 is expressed mainly in triple-negative and ERBB2+ carcinomas. In the serum of patients with these cancers, the detection of soluble forms of Nectin-4 is associated with a poor prognosis. Levels of serum Nectin-4 increase during metastatic progression and decrease after treatment. These results suggest that Nectin-4 could be a reliable target for the treatment of cancer. Accordingly, several anti-Nectin-4 antibodies have been described in the prior art. In particular, Enfortumab Vedotin (ASG-22ME) is an antibody-drug conjugate (ADC) targeting Nectin-4 and is currently clinically investigated for the treatment of patients suffering from solid tumours.
- In one embodiment, the first peptide ligand comprises a Nectin-4 binding bicyclic peptide ligand.
- Suitable examples of Nectin-4 binding bicyclic peptide ligands are disclosed in PCT Patent Application No PCT/GB2019/051740, the peptides of which are incorporated herein by reference.
- In one embodiment, the Nectin-4 binding bicyclic peptide is selected from any of the peptides of SEQ ID NOS: 52 to 66 described herein.
- In an alternative embodiment, the component present on a cancer cell is EphA2.
- Eph receptor tyrosine kinases (Ephs) belong to a large group of receptor tyrosine kinases (RTKs), kinases that phosphorylate proteins on tyrosine residues. Ephs and their membrane bound ephrin ligands (ephrins) control cell positioning and tissue organization (Poliakov et al. (2004) Dev Cell 7, 465-80). Functional and biochemical Eph responses occur at higher ligand oligomerization states (Stein et al. (1998) Genes Dev 12, 667-678).
- Among other patterning functions, various Ephs and ephrins have been shown to play a role in vascular development. Knockout of EphB4 and ephrin-B2 results in a lack of the ability to remodel capillary beds into blood vessels (Poliakov et al., supra) and embryonic lethality. Persistent expression of some Eph receptors and ephrins has also been observed in newly-formed, adult micro-vessels (Brantley-Sieders et al. (2004) Curr Pharm Des 10, 3431-42; Adams (2003) J Anat 202, 105-12).
- The de-regulated re-emergence of some ephrins and their receptors in adults also has been observed to contribute to tumor invasion, metastasis and neo-angiogenesis (Nakamoto et al. (2002) Microsc Res Tech 59, 58-67; Brantley-Sieders et al., supra). Furthermore, some Eph family members have been found to be over-expressed on tumor cells from a variety of human tumors (Brantley-Sieders et al., supra); Marme (2002) Ann Hematol 81 Suppl 2, S66; Booth et al. (2002) Nat Med 8, 1360-1).
- EPH receptor A2 (ephrin type-A receptor 2) is a protein that in humans is encoded by the EPHA2 gene.
- EphA2 is upregulated in multiple cancers in man, often correlating with disease progression, metastasis and poor prognosis e.g.: breast (Zelinski et al (2001) Cancer Res. 61, 2301-2306; Zhuang et al (2010) Cancer Res. 70, 299-308; Brantley-Sieders et al (2011) PLoS One 6, e24426), lung (Brannan et al (2009) Cancer Prev Res (Phila) 2, 1039-1049; Kinch et al (2003) Clin Cancer Res. 9, 613-618; Guo et al (2013) J Thorac Oncol. 8, 301-308), gastric (Nakamura et al (2005) Cancer Sci. 96, 42-47; Yuan et al (2009) Dig Dis Sci 54, 2410-2417), pancreatic (Mudali et al (2006) Clin Exp Metastasis 23, 357-365), prostate (Walker-Daniels et al (1999) Prostate 41, 275-280), liver (Yang et al (2009) Hepatol Res. 39, 1169-1177) and glioblastoma (Wykosky et al (2005) Mol Cancer Res. 3, 541-551; Li et al (2010) Tumour Biol. 31, 477-488).
- The full role of EphA2 in cancer progression is still not defined although there is evidence for interaction at numerous stages of cancer progression including tumour cell growth, survival, invasion and angiogenesis. Downregulation of EphA2 expression suppresses tumour cancer cell propagation (Binda et al (2012) Cancer Cell 22, 765-780), whilst EphA2 blockade inhibits VEGF induced cell migration (Hess et al (2001) Cancer Res. 61, 3250-3255), sprouting and angiogenesis (Cheng et al (2002) Mol Cancer Res. 1, 2-11; Lin et al (2007) Cancer 109, 332-40) and metastatic progression (Brantley-Sieders et al (2005) FASEB J. 19, 1884-1886).
- An antibody drug conjugate to EphA2 has been shown to significantly diminish tumour growth in rat and mouse xenograft models (Jackson et al (2008) Cancer Research 68, 9367-9374) and a similar approach has been tried in man although treatment had to be discontinued for treatment related adverse events (Annunziata et al (2013) Invest New drugs 31, 77-84).
- In one embodiment, the first peptide ligand comprises an EphA2 binding bicyclic peptide ligand.
- Suitable examples of EphA2 binding bicyclic peptide ligands are disclosed in WO 2019/122860, WO 2019/122861 and WO 2019/122863, the peptides of which are incorporated herein by reference.
- In one embodiment, the EphA2 binding bicyclic peptide is selected from any of the peptides of SEQ ID NOS: 10 to 51 described herein.
- In an alternative embodiment, the component present on a cancer cell is PD-L1.
- Programmed cell death 1 ligand 1 (PD-L1) is a 290 amino acid type I transmembrane protein encoded by the CD274 gene on mouse chromosome 19 and human chromosome 9. PD-L1 expression is involved in evasion of immune responses involved in chronic infection, e.g., chronic viral infection (including, for example, HIV, HBV, HCV and HTLV, among others), chronic bacterial infection (including, for example, Helicobacter pylori, among others), and chronic parasitic infection (including, for example, Schistosoma mansoni). PD-L1 expression has been detected in a number of tissues and cell types including T-cells, B-cells, macrophages, dendritic cells, and nonhaematopoietic cells including endothelial cells, hepatocytes, muscle cells, and placenta.
- PD-L1 expression is also involved in suppression of anti-tumour immune activity. Tumours express antigens that can be recognised by host T-cells, but immunologic clearance of tumours is rare. Part of this failure is due to immune suppression by the tumour microenvironment. PD-L1 expression on many tumours is a component of this suppressive milieu and acts in concert with other immunosuppressive signals. PD-L1 expression has been shown in situ on a wide variety of solid tumours including breast, lung, colon, ovarian, melanoma, bladder, liver, salivary, stomach, gliomas, thyroid, thymic epithelial, head, and neck (Brown J A et al. 2003 Immunol. 170:1257-66; Dong H et al. 2002 Nat. Med. 8:793-800; Hamanishi J, et al. 2007 Proc. Natl. Acad. Sci. USA 104:3360-65; Strome S E et al. 2003 Cancer Res. 63:6501-5; Inman B A et al. 2007 Cancer 109:1499-505; Konishi J et al. 2004 Clin. Cancer Res. 10:5094-100; Nakanishi J et al. 2007 Cancer Immunol. Immunother. 56:1173-82; Nomi T et al. 2007 Clin. Cancer Res. 13:2151-57; Thompson R H et al. 2004 Proc. Natl. Acad. Sci. USA 101: 17174-79; Wu C et al. 2006 Acta Histochem. 108:19-24). In addition, the expression of the receptor for PD-L1, Programmed cell death protein 1 (also known as PD-1 and CD279) is upregulated on tumour infiltrating lymphocytes, and this also contributes to tumour immunosuppression (Blank C et al. 2003 Immunol. 171:4574-81). Most importantly, studies relating PD-L1 expression on tumours to disease outcome show that PD-L1 expression strongly correlates with unfavourable prognosis in kidney, ovarian, bladder, breast, gastric, and pancreatic cancer (Hamanishi J et al. 2007 Proc. Natl. Acad. Sci. USA 104:3360-65; Inman B A et al. 2007 Cancer 109:1499-505; Konishi J et al. 2004 Clin. Cancer Res. 10:5094-100; Nakanishi J et al. 2007 Cancer Immunol. Immunother. 56:1173-82; Nomi T et al. 2007 Clin. Cancer Res. 13:2151-57; Thompson R H et al. 2004 Proc. Natl. Acad. Sci. USA 101:17174-79; Wu C et al. 2006 Acta Histochem. 108:19-24). In addition, these studies suggest that higher levels of PD-L1 expression on tumours may facilitate advancement of tumour stage and invasion into deeper tissue structures.
- The PD-1 pathway can also play a role in haematologic malignancies. PD-L1 is expressed on multiple myeloma cells but not on normal plasma cells (Liu J et al. 2007 Blood 110:296-304). PD-L1 is expressed on some primary T-cell lymphomas, particularly anaplastic large cell T lymphomas (Brown J A et al, 2003 Immunol. 170:1257-66). PD-1 is highly expressed on the T-cells of angioimmunoblastic lymphomas, and PD-L1 is expressed on the associated follicular dendritic cell network (Dorfman D M et al. 2006 Am. J. Surg. Pathol. 30:802-10). In nodular lymphocyte-predominant Hodgkin lymphoma, the T-cells associated with lymphocytic or histiocytic (L&H) cells express PD-1. Microarray analysis using a readout of genes induced by PD-1 ligation suggests that tumour-associated T-cells are responding to PD-1 signals in situ in Hodgkin lymphoma (Chemnitz J M et al. 2007 Blood 110:3226-33). PD-1 and PD-L1 are expressed on CD4 T-cells in HTLV-1-mediated adult T-cell leukaemia and lymphoma (Shimauchi T et al. 2007 Int. J. Cancer 121: 2585-90). These tumour cells are hyporesponsive to TCR signals.
- Studies in animal models demonstrate that PD-L1 on tumours inhibits T-cell activation and lysis of tumour cells and in some cases leads to increased tumour-specific T-cell death (Dong H et al. 2002 Nat. Med. 8:793-800; Hirano F et al. 2005 Cancer Res. 65:1089-96). Tumour-associated APCs can also utilise the PD-1:PD-L1 pathway to control antitumour T-cell responses. PD-L1 expression on a population of tumour-associated myeloid DCs is upregulated by tumour environmental factors (Curie) T J et al. 2003 Nat. Med. 9:562-67). Plasmacytoid dendritic cells (DCs) in the tumour-draining lymph node of B16 melanoma express IDO, which strongly activates the suppressive activity of regulatory T-cells. The suppressive activity of IDO-treated regulatory T-cells required cell contact with IDO-expressing DCs (Sharma M D et al. 2007 Clin. Invest. 117:2570-82).
- In one embodiment, the first peptide ligand comprises a PD-L1 binding bicyclic peptide ligand.
- Suitable examples of PD-L1 binding bicyclic peptide ligands are disclosed in GB Patent Application Nos. 1905631.6 and 1904622.6, the peptides of which are incorporated herein by reference.
- In one embodiment, the PD-L1 binding bicyclic peptide is selected from any of the peptides of SEQ ID NOS: 1 to 9 described herein.
- In an alternative embodiment, the component present on a cancer cell is prostate-specific membrane antigen (PSMA).
- Prostate-specific membrane antigen (PSMA) (also known as Glutamate carboxypeptidase II (GCPII), N-acetyl-L-aspartyl-L-glutamate peptidase I (NAALADase I) and NAAG peptidase) is an enzyme that in humans is encoded by the FOLH1 (folate hydrolase 1) gene. Human GCPII contains 750 amino acids and weighs approximately 84 kDa.
- Human PSMA is highly expressed in the prostate, roughly a hundred times greater than in most other tissues. In some prostate cancers, PSMA is the second-most upregulated gene product, with an 8- to 12-fold increase over levels in noncancerous prostate cells. Because of this high expression, PSMA is being developed as potential biomarker for therapy and imaging of some cancers. In human prostate cancer, the higher expressing tumors are associated with quicker time to progression and a greater percentage of patients suffering relapse.
- In one embodiment, the first peptide ligand comprises a PSMA binding bicyclic peptide ligand.
- Suitable examples of PSMA binding bicyclic peptide ligands are disclosed in GB Patent Application Nos 1820325.7 and 1912723.2 and PCT Patent Application No. PCT/EP2019/066273, the peptides of which are incorporated herein by reference.
- Second Peptide Ligands
- References herein to the term “immune cell” includes any cell within the immune system. Suitable examples include white blood cells, such as lymphocytes (e.g. T lymphocytes or T cells, B cells or natural killer cells). In one embodiment, the T cell is CD8 or CD4. In a further embodiment, the T cell is CD8. Other examples of immune cells include dendritic cells, follicular dendritic cells and granulocytes.
- In one embodiment, the component present on an immune cell is CD137.
- CD137 is a member of the tumour necrosis factor (TNF) receptor family. Its alternative names are tumour necrosis factor receptor superfamily member 9 (TNFRSF9), 4-IBB and induced by lymphocyte activation (ILA). CD137 can be expressed by activated T cells, but to a larger extent on CD8+ than on CD4+ T cells. In addition, CD137 expression is found on dendritic cells, follicular dendritic cells, natural killer cells, granulocytes and cells of blood vessel walls at sites of inflammation. One characterized activity of CD137 is its costimulatory activity for activated T cells. Crosslinking of CD137 enhances T cell proliferation, IL-2 secretion, survival and cytolytic activity. Further, it can enhance immune activity to eliminate tumours in mice.
- CD137 is a T-cell costimulatory receptor induced on TCR activation (Nam et al., Curr. Cancer Drug Targets, 5:357-363 (2005); Waits et al., Annu. Rev, Immunol., 23:23-68 (2005)). In addition to its expression on activated CD4+ and CD8+ T cells, CD137 is also expressed on CD4+CD25+ regulatory T cells, natural killer (NK) and NK-T cells, monocytes, neutrophils, and dendritic cells. Its natural ligand, CD137L, has been described on antigen-presenting cells including B cells, monocyte/macrophages, and dendritic cells (Watts et al. Annu. Rev. Immunol, 23:23-68 (2005)). On interaction with its ligand, CD137 leads to increased TCR-induced T-cell proliferation, cytokine production, functional maturation, and prolonged CD8+ T-cell survival (Nam et al, Curr. Cancer Drug Targets, 5:357-363 (2005), Watts et d-I., Annu. Rev. Immunol, 23:23-68 (2005)).
- Signalling through CD137 by either CD137L or agonistic monoclonal antibodies (mAbs) against CD137 leads to increased TCR-induced T cell proliferation, cytokine production and functional maturation, and prolonged CD8+ T cell survival. These effects result from: (1) the activation of the NF-κB, c-Jun NH2-terminal kinase/stress-activated protein kinase (JNK/SAPK), and p38 mitogen-activated protein kinase (MAPK) signalling pathways, and (2) the control of anti-apoptotic and cell cycle-related gene expression.
- Experiments performed in both CD137 and CD137L-deficient mice have additionally demonstrated the importance of CD137 costimulation in the generation of a fully competent T cell response.
- IL-2 and IL-15 activated NK cells express CD137, and ligation of CD137 by agonistic mAbs stimulates NK cell proliferation and IFN-γ secretion, but not their cytolytic activity.
- Furthermore, CD137-stimulated NK cells promote the expansion of activated T cells in vitro.
- In accordance with their costimulatory function, agonist mAbs against CD137 have been shown to promote rejection of cardiac and skin allografts, eradicate established tumours, broaden primary antiviral CD8+ T cell responses, and increase T cell cytolytic potential. These studies support the view that CD137 signalling promotes T cell function which may enhance immunity against tumours and infection.
- In one embodiment, the second peptide ligand comprises a CD137 binding bicyclic peptide ligand.
- Suitable examples of CD137 binding bicyclic peptide ligands are disclosed in WO 2019/025811, the peptides of which are incorporated herein by reference.
- In one embodiment, the CD137 binding bicyclic peptide is selected from any of the peptides of SEQ ID NOS: 67 to 84 described herein.
- Linkers
- It will be appreciated that the first peptide ligand may be conjugated to the second peptide ligand via any suitable linker. Typically the design of said linker will be such that the two Bicyclic peptides are presented in such a manner that they can bind unencumbered to their respective targets either alone or while simultaneously binding to both target receptors. Additionally, the linker should permit binding to both targets simultaneously while maintaining an appropriate distance between the target cells that would lead to the desired functional outcome. The properties of the linker may be modulated to increase length, rigidity or solubility to optimise the desired functional outcome. The linker may also be designed to permit the attachment of more than one Bicycle to the same target. Increasing the valency of either binding peptide may serve to increase the affinity of the heterotandem for the target cells or may help to induce oligomerisation of one or both of the target receptors.
- In one embodiment, the linker is selected from the following sequences: -PEG5- and TCA-[PEG10]3.
- Structural representations of these linkers are detailed below:
- Heterotandem Complexes
- In one specific embodiment, the first peptide ligand comprises a PD-L1 binding bicyclic peptide ligand attached to a TATA scaffold, the second peptide ligand comprises a CD137 binding bicyclic peptide ligand attached to a TATA scaffold and said heterotandem complex is selected from the complexes listed in Table A:
-
TABLE A (PD-L1:CD137; 1:1) Complex PD-L1 BCY Attachment CD137 BCY Attachment No. No. Point Linker No. Point BCY12229 BCY11865 Lys9 Peg5 BCY8928 dLys(PYA)4 BCY12230 BCY11866 Lys2 Peg5 BCY8928 dLys(PYA)4 BCY12231 BCY11867 Lys7 Peg5 BCY8928 dLys(PYA)4 BCY12232 BCY11868 Lys8 Peg5 BCY8928 dLys(PYA)4 BCY12242 BCY11869 Lys11 Peg5 BCY8928 dLys(PYA)4 BCY12375 BCY10861 Lys(PYA)9 Peg5 BCY12023 dLys4 BCY12663 BCY12479 C-term Lys Peg5 BCY8928 dLys(PYA)4 BCY12796 BCY12477 C-term Lys Peg5 BCY8928 dLys(PYA)4 BCY12021 BCY10861 Lys(PYA)9 Peg5 BCY11144 dLys4 - In one embodiment, the heterotandem bicyclic peptide complex is selected from: BCY12375 and BCY12021.
- In one specific embodiment, the first peptide ligand comprises an EphA2 binding bicyclic peptide ligand attached to a TATA scaffold, the second peptide ligand comprises a CD137 binding bicyclic peptide ligand attached to a TATA scaffold and said heterotandem complex is selected from the complexes listed in Table B:
-
TABLE B (EphA2:CD137; 1:1) Complex EphA2 BCY Attachment CD137 BCY Attachment No. No. Point Linker No. Point BCY12233 BCY11813 N-term PYA Peg5 BCY8920 dLys4 BCY12234 BCY11814 C-term Lys(PYA) Peg5 BCY8920 dLys4 BCY12235 BCY11815 Lys(PYA) 8 Peg5 BCY8920 dLys4 BCY12236 BCY11816 Lys(PYA)2 Peg5 BCY8920 dLys4 BCY12237 BCY11817 Lys(PYA)7 Peg5 BCY8920 dLys4 BCY12711 BCY9594 N-terminus Peg5 BCY12143 dLys (PYA)4 BCY12712 BCY9594 N-terminus Peg5 BCY12149 dLys (PYA)4 BCY12713 BCY9594 N-terminus Peg5 BCY12147 dLys (PYA)4 BCY12714 BCY9594 N-terminus Peg5 BCY12145 dLys (PYA)4 BCY12715 BCY9594 N-terminus Peg5 BCY12146 dLys (PYA)4 BCY12717 BCY9594 N-terminus Peg5 BCY12352 dLys (PYA)4 BCY12718 BCY9594 N-terminus Peg5 BCY12353 dLys (PYA)4 BCY12719 BCY9594 N-terminus Peg5 BCY12354 dLys (PYA)4 BCY12720 BCY9594 N-terminus Peg5 BCY12360 dLys (PYA)4 BCY12961 BCY12734 C-term Lys Peg5 BCY8928 dLys (PYA)4 BCY12962 BCY12735 Lys8 Peg5 BCY8928 dLys (PYA)4 BCY12963 BCY12736 Lys2 Peg5 BCY8928 dLys (PYA)4 BCY12964 BCY12737 Lys7 Peg5 BCY8928 dLys (PYA)4 BCY12965 BCY12738 N-terminus Peg5 BCY8928 dLys (PYA)4 BCY12966 BCY12739 N-terminus Peg5 BCY8928 dLys (PYA)4 BCY13029 BCY12854 N-terminus Peg5 BCY8928 dLys (PYA)4 BCY13030 BCY12855 N-terminus Peg5 BCY8928 dLys (PYA)4 BCY13031 BCY12856 N-terminus Peg5 BCY8928 dLys (PYA)4 BCY13032 BCY12857 N-terminus Peg5 BCY8928 dLys (PYA)4 BCY13033 BCY12858 N-terminus Peg5 BCY8928 dLys (PYA)4 BCY13034 BCY12859 N-terminus Peg5 BCY8928 dLys (PYA)4 BCY13035 BCY12860 N-terminus Peg5 BCY8928 dLys (PYA)4 BCY13036 BCY12861 N-terminus Peg5 BCY8928 dLys (PYA)4 BCY13037 BCY12862 N-terminus Peg5 BCY8928 dLys (PYA)4 BCY13038 BCY12863 N-terminus Peg5 BCY8928 dLys (PYA)4 BCY13039 BCY12864 N-terminus Peg5 BCY8928 dLys (PYA)4 BCY13040 BCY12865 N-terminus Peg5 BCY8928 dLys (PYA)4 BCY13041 BCY12866 N-terminus Peg5 BCY8928 dLys (PYA)4 BCY13141 BCY12856 N-terminus Peg5 BCY12353 dLys (PYA)4 BCY13142 BCY9594 N-terminus Peg5 BCY13137 dLys (PYA)4 BCY13143 BCY12856 N-terminus Peg5 BCY13137 dLys (PYA)4 BCY13250 BCY13116 N-terminus Peg5 BCY8928 dLys (PYA)4 BCY13251 BCY13117 N-terminus Peg5 BCY8928 dLys (PYA)4 BCY13252 BCY13118 N-terminus Peg5 BCY8928 dLys (PYA)4 BCY13253 BCY13119 N-terminus Peg5 BCY8928 dLys (PYA)4 BCY13254 BCY13120 C-term dLys Peg5 BCY8928 dLys (PYA)4 BCY13255 BCY13121 N-terminus Peg5 BCY8928 dLys (PYA)4 BCY13256 BCY13122 N-terminus Peg5 BCY8928 dLys (PYA)4 BCY13257 BCY13123 N-terminus Peg5 BCY8928 dLys (PYA)4 BCY13258 BCY13124 N-terminus Peg5 BCY8928 dLys (PYA)4 BCY13260 BCY13126 N-terminus Peg5 BCY8928 dLys (PYA)4 BCY13261 BCY13127 N-terminus Peg5 BCY8928 dLys (PYA)4 BCY13262 BCY13128 N-terminus Peg5 BCY8928 dLys (PYA)4 BCY13264 BCY13130 N-terminus Peg5 BCY8928 dLys (PYA)4 BCY13265 BCY13131 N-terminus Peg5 BCY8928 dLys (PYA)4 BCY13266 BCY13132 N-terminus Peg5 BCY8928 dLys (PYA)4 BCY13268 BCY13134 N-terminus Peg5 BCY8928 dLys (PYA)4 BCY13269 BCY13135 N-terminus Peg5 BCY8928 dLys (PYA)4 BCY13340 BCY12865 N-terminus Peg5 BCY12353 dLys (PYA)4 BCY13342 BCY12860 N-terminus Peg5 BCY12353 dLys (PYA)4 - In one embodiment, the heterotandem bicyclic peptide complex is selected from: BCY13035, BCY13040, BCY13253, BCY13254, BCY13340 and BCY13342.
- In one specific embodiment, the first peptide ligand comprises a Nectin-4 binding bicyclic peptide ligand attached to a TATA scaffold, the second peptide ligand comprises a CD137 binding bicyclic peptide ligand attached to a TATA scaffold and said heterotandem complex is selected from the complexes listed in Table C:
-
TABLE C (Nectin-4:CD137; 1:1) Complex Nectin-4 BCY Attachment CD137 BCY Attachment No. No. Point Linker No. Point BCY11616 BCY8116 N-terminus Peg5 BCY7744 dLys(PYA)4 BCY12238 BCY12024 dLys3 Peg5 BCY8928 dLys(PYA)4 BCY12377 BCY8116 N-terminus Peg5 BCY12143 dLys(PYA)4 BCY12379 BCY8116 N-terminus Peg5 BCY12149 dLys(PYA)4 BCY12572 BCY8116 N-terminus Peg5 BCY12352 dLys(PYA)4 BCY12573 BCY8116 N-terminus Peg5 BCY12353 dLys(PYA)4 BCY12574 BCY8116 N-terminus Peg5 BCY12354 dLys(PYA)4 BCY12575 BCY8116 N-terminus Peg5 BCY12360 dLys(PYA)4 BCY12576 BCY12363 dLys3 Peg5 BCY8928 dLys(PYA)4 BCY12577 BCY12364 dLys3 Peg5 BCY8928 dLys(PYA)4 BCY12578 BCY12365 dLys3 Peg5 BCY8928 dLys(PYA)4 BCY12579 BCY12366 dLys3 Peg5 BCY8928 dLys(PYA)4 BCY12580 BCY12367 dLys3 Peg5 BCY8928 dLys(PYA)4 BCY12581 BCY12368 N-terminus Peg5 BCY8928 dLys(PYA)4 BCY12582 BCY12369 N-terminus Peg5 BCY8928 dLys(PYA)4 BCY12583 BCY12370 N-terminus Peg5 BCY8928 dLys(PYA)4 BCY12584 BCY12371 dLys3 Peg5 BCY8928 dLys(PYA)4 BCY12585 BCY12384 N-terminus Peg5 BCY8928 dLys(PYA)4 BCY12709 BCY8116 N-terminus Peg5 BCY12381 dLys(PYA)4 BCY12710 BCY8116 N-terminus Peg5 BCY12382 dLys(PYA)4 BCY11468 BCY11016 N-term PYA TCA-[Peg10]3 BCY8928 dLys(PYA)4 BCY11618 BCY11143 N-term PYA Peg5 BCY8920 dLys4 BCY11776 BCY8116 N-terminus Peg5 BCY11144 C-term Dap(PYA) BCY11860 BCY11143 N-term PYA Peg5 BCY8920 dLys4 BCY12020 BCY11016 N-term PYA Peg5 BCY11144 C-term Dap(PYA) BCY12661 BCY11015 N-term PYA Peg5 BCY12023 dLys4 BCY12969 BCY8116 N-terminus Peg5 BCY12358 dLys(PYA)4 - In one embodiment, the heterotandem bicyclic peptide complex is selected from: BCY11468, BCY11618, BCY11776, BCY11860, BCY12020, BCY12661 and BCY12969.
- Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art, such as in the arts of peptide chemistry, cell culture and phage display, nucleic acid chemistry and biochemistry. Standard techniques are used for molecular biology, genetic and biochemical methods (see Sambrook et al., Molecular Cloning: A Laboratory Manual, 3rd ed., 2001, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.; Ausubel et al., Short Protocols in Molecular Biology (1999) 4th ed., John Wiley & Sons, Inc.), which are incorporated herein by reference.
- Nomenclature
- Molecular Format
- N- or C-terminal extensions to the bicycle core sequence are added to the left or right side of the sequence, separated by a hyphen. For example, an N-terminal βAla-Sar10-Ala tail would be denoted as:
-
- βAla-Sar10-A-(SEQ ID NO: X).
- Inversed Peptide Sequences
- In light of the disclosure in Nair et al (2003) J Immunol 170(3), 1362-1373, it is envisaged that the peptide sequences disclosed herein would also find utility in their retro-inverso form. For example, the sequence is reversed (i.e. N-terminus becomes C-terminus and vice versa) and their stereochemistry is likewise also reversed (i.e. D-amino acids become L-amino acids and vice versa). For the avoidance of doubt, references to amino acids either as their full name or as their amino acid single or three letter codes are intended to be represented herein as L-amino acids unless otherwise stated. If such an amino acid is intended to be represented as a D-amino acid then the amino acid will be prefaced with a lower case d within square parentheses, for example [dA], [dD], [dE], [dK], [d1Nal], [dNle], etc.
- Peptide Ligands
- A peptide ligand, as referred to herein, refers to a peptide covalently bound to a molecular scaffold. Typically, such peptides comprise two or more reactive groups (i.e. cysteine residues) which are capable of forming covalent bonds to the scaffold, and a sequence subtended between said reactive groups which is referred to as the loop sequence, since it forms a loop when the peptide is bound to the scaffold. In the present case, the peptides comprise at least three reactive groups selected from cysteine, 3-mercaptopropionic acid and/or cysteamine and form at least two loops on the scaffold.
- Reactive Groups
- The molecular scaffold of the invention may be bonded to the polypeptide via functional or reactive groups on the polypeptide. These are typically formed from the side chains of particular amino acids found in the polypeptide polymer. Such reactive groups may be a cysteine side chain, a lysine side chain, or an N-terminal amine group or any other suitable reactive group, such as penicillamine. Details of suitable reactive groups may be found in WO 2009/098450.
- Examples of reactive groups of natural amino acids are the thiol group of cysteine, the amino group of lysine, the carboxyl group of aspartate or glutamate, the guanidinium group of arginine, the phenolic group of tyrosine or the hydroxyl group of serine. Non-natural amino acids can provide a wide range of reactive groups including an azide, a keto-carbonyl, an alkyne, a vinyl, or an aryl halide group. The amino and carboxyl group of the termini of the polypeptide can also serve as reactive groups to form covalent bonds to a molecular scaffold/molecular core.
- The polypeptides of the invention contain at least three reactive groups. Said polypeptides can also contain four or more reactive groups. The more reactive groups are used, the more loops can be formed in the molecular scaffold.
- In a preferred embodiment, polypeptides with three reactive groups are generated. Reaction of said polypeptides with a molecular scaffold/molecular core having a three-fold rotational symmetry generates a single product isomer. The generation of a single product isomer is favourable for several reasons. The nucleic acids of the compound libraries encode only the primary sequences of the polypeptide but not the isomeric state of the molecules that are formed upon reaction of the polypeptide with the molecular core. If only one product isomer can be formed, the assignment of the nucleic acid to the product isomer is clearly defined. If multiple product isomers are formed, the nucleic acid cannot give information about the nature of the product isomer that was isolated in a screening or selection process. The formation of a single product isomer is also advantageous if a specific member of a library of the invention is synthesized. In this case, the chemical reaction of the polypeptide with the molecular scaffold yields a single product isomer rather than a mixture of isomers.
- In another embodiment, polypeptides with four reactive groups are generated. Reaction of said polypeptides with a molecular scaffold/molecular core having a tetrahedral symmetry generates two product isomers. Even though the two different product isomers are encoded by one and the same nucleic acid, the isomeric nature of the isolated isomer can be determined by chemically synthesizing both isomers, separating the two isomers and testing both isomers for binding to a target ligand.
- In one embodiment of the invention, at least one of the reactive groups of the polypeptides is orthogonal to the remaining reactive groups. The use of orthogonal reactive groups allows the directing of said orthogonal reactive groups to specific sites of the molecular core. Linking strategies involving orthogonal reactive groups may be used to limit the number of product isomers formed. In other words, by choosing distinct or different reactive groups for one or more of the at least three bonds to those chosen for the remainder of the at least three bonds, a particular order of bonding or directing of specific reactive groups of the polypeptide to specific positions on the molecular scaffold may be usefully achieved.
- In another embodiment, the reactive groups of the polypeptide of the invention are reacted with molecular linkers wherein said linkers are capable to react with a molecular scaffold so that the linker will intervene between the molecular scaffold and the polypeptide in the final bonded state.
- In some embodiments, amino acids of the members of the libraries or sets of polypeptides can be replaced by any natural or non-natural amino acid. Excluded from these exchangeable amino acids are the ones harbouring functional groups for cross-linking the polypeptides to a molecular core, such that the loop sequences alone are exchangeable. The exchangeable polypeptide sequences have either random sequences, constant sequences or sequences with random and constant amino acids. The amino acids with reactive groups are either located in defined positions within the polypeptide, since the position of these amino acids determines loop size.
- In one embodiment, a polypeptide with three reactive groups has the sequence (X)1Y(X)mY(X)nY(X)o, wherein Y represents an amino acid with a reactive group, X represents a random amino acid, m and n are numbers between 3 and 6 defining the length of intervening polypeptide segments, which may be the same or different, and I and o are numbers between 0 and 20 defining the length of flanking polypeptide segments.
- Alternatives to thiol-mediated conjugations can be used to attach the molecular scaffold to the peptide via covalent interactions. Alternatively these techniques may be used in modification or attachment of further moieties (such as small molecules of interest which are distinct from the molecular scaffold) to the polypeptide after they have been selected or isolated according to the present invention—in this embodiment then clearly the attachment need not be covalent and may embrace non-covalent attachment. These methods may be used instead of (or in combination with) the thiol mediated methods by producing phage that display proteins and peptides bearing unnatural amino acids with the requisite chemical reactive groups, in combination small molecules that bear the complementary reactive group, or by incorporating the unnatural amino acids into a chemically or recombinantly synthesised polypeptide when the molecule is being made after the selection/isolation phase. Further details can be found in WO 2009/098450 or Heinis et al., Nat Chem Biol 2009, 5 (7), 502-7.
- In one embodiment, the reactive groups are selected from cysteine, 3-mercaptopropionic acid and/or cysteamine residues.
- Pharmaceutically Acceptable Salts
- It will be appreciated that salt forms are within the scope of this invention, and references to peptide ligands include the salt forms of said ligands.
- The salts of the present invention can be synthesized from the parent compound that contains a basic or acidic moiety by conventional chemical methods such as methods described in Pharmaceutical Salts: Properties, Selection, and Use, P. Heinrich Stahl (Editor), Camille G. Wermuth (Editor), ISBN: 3-90639-026-8, Hardcover, 388 pages, August 2002. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with the appropriate base or acid in water or in an organic solvent, or in a mixture of the two.
- Acid addition salts (mono- or di-salts) may be formed with a wide variety of acids, both inorganic and organic. Examples of acid addition salts include mono- or di-salts formed with an acid selected from the group consisting of acetic, 2,2-dichloroacetic, adipic, alginic, ascorbic (e.g. L-ascorbic), L-aspartic, benzenesulfonic, benzoic, 4-acetamidobenzoic, butanoic, (+) camphoric, camphor-sulfonic, (+)-(1S)-camphor-10-sulfonic, capric, caproic, caprylic, cinnamic, citric, cyclamic, dodecylsulfuric, ethane-1,2-disulfonic, ethanesulfonic, 2-hydroxyethanesulfonic, formic, fumaric, galactaric, gentisic, glucoheptonic, D-gluconic, glucuronic (e.g. D-glucuronic), glutamic (e.g. L-glutamic), α-oxoglutaric, glycolic, hippuric, hydrohalic acids (e.g. hydrobromic, hydrochloric, hydriodic), isethionic, lactic (e.g. (+)-L-lactic, (±)-DL-lactic), lactobionic, maleic, malic, (−)-L-malic, malonic, (±)-DL-mandelic, methanesulfonic, naphthalene-2-sulfonic, naphthalene-1,5-disulfonic, 1-hydroxy-2-naphthoic, nicotinic, nitric, oleic, orotic, oxalic, palmitic, pamoic, phosphoric, propionic, pyruvic, L-pyroglutamic, salicylic, 4-amino-salicylic, sebacic, stearic, succinic, sulfuric, tannic, (+)-L-tartaric, thiocyanic, p-toluenesulfonic, undecylenic and valeric acids, as well as acylated amino acids and cation exchange resins.
- One particular group of salts consists of salts formed from acetic, hydrochloric, hydriodic, phosphoric, nitric, sulfuric, citric, lactic, succinic, maleic, malic, isethionic, fumaric, benzenesulfonic, toluenesulfonic, sulfuric, methanesulfonic (mesylate), ethanesulfonic, naphthalenesulfonic, valeric, propanoic, butanoic, malonic, glucuronic and lactobionic acids. One particular salt is the hydrochloride salt. Another particular salt is the acetate salt.
- If the compound is anionic, or has a functional group which may be anionic (e.g., —COOH may be —COO−), then a salt may be formed with an organic or inorganic base, generating a suitable cation. Examples of suitable inorganic cations include, but are not limited to, alkali metal ions such as Li+, Na+ and K+, alkaline earth metal cations such as Ca2+ and Mg2+, and other cations such as Al3+ or Zn+. Examples of suitable organic cations include, but are not limited to, ammonium ion (i.e., NH4 +) and substituted ammonium ions (e.g., NH3R+, NH2R2 +, NHR3 +, NR4 +). Examples of some suitable substituted ammonium ions are those derived from: methylamine, ethylamine, diethylamine, propylamine, dicyclohexylamine, triethylamine, butylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, benzylamine, phenylbenzylamine, choline, meglumine, and tromethamine, as well as amino acids, such as lysine and arginine. An example of a common quaternary ammonium ion is N(CH3)4 +.
- Where the compounds of the invention contain an amine function, these may form quaternary ammonium salts, for example by reaction with an alkylating agent according to methods well known to the skilled person. Such quaternary ammonium compounds are within the scope of the invention.
- Modified Derivatives
- It will be appreciated that modified derivatives of the peptide ligands as defined herein are within the scope of the present invention. Examples of such suitable modified derivatives include one or more modifications selected from: N-terminal and/or C-terminal modifications; replacement of one or more amino acid residues with one or more non-natural amino acid residues (such as replacement of one or more polar amino acid residues with one or more isosteric or isoelectronic amino acids; replacement of one or more non-polar amino acid residues with other non-natural isosteric or isoelectronic amino acids); addition of a spacer group; replacement of one or more oxidation sensitive amino acid residues with one or more oxidation resistant amino acid residues; replacement of one or more amino acid residues with an alanine, replacement of one or more L-amino acid residues with one or more D-amino acid residues; N-alkylation of one or more amide bonds within the bicyclic peptide ligand; replacement of one or more peptide bonds with a surrogate bond; peptide backbone length modification; substitution of the hydrogen on the alpha-carbon of one or more amino acid residues with another chemical group, modification of amino acids such as cysteine, lysine, glutamate/aspartate and tyrosine with suitable amine, thiol, carboxylic acid and phenol-reactive reagents so as to functionalise said amino acids, and introduction or replacement of amino acids that introduce orthogonal reactivities that are suitable for functionalisation, for example azide or alkyne-group bearing amino acids that allow functionalisation with alkyne or azide-bearing moieties, respectively.
- In one embodiment, the modified derivative comprises an N-terminal and/or C-terminal modification. In a further embodiment, wherein the modified derivative comprises an N-terminal modification using suitable amino-reactive chemistry, and/or C-terminal modification using suitable carboxy-reactive chemistry. In a further embodiment, said N-terminal or C-terminal modification comprises addition of an effector group, including but not limited to a cytotoxic agent, a radiochelator or a chromophore.
- In a further embodiment, the modified derivative comprises an N-terminal modification. In a further embodiment, the N-terminal modification comprises an N-terminal acetyl group. In this embodiment, the N-terminal cysteine group (the group referred to herein as C,) is capped with acetic anhydride or other appropriate reagents during peptide synthesis leading to a molecule which is N-terminally acetylated. This embodiment provides the advantage of removing a potential recognition point for aminopeptidases and avoids the potential for degradation of the bicyclic peptide.
- In an alternative embodiment, the N-terminal modification comprises the addition of a molecular spacer group which facilitates the conjugation of effector groups and retention of potency of the bicyclic peptide to its target.
- In a further embodiment, the modified derivative comprises a C-terminal modification. In a further embodiment, the C-terminal modification comprises an amide group. In this embodiment, the C-terminal cysteine group (the group referred to herein as Cii) is synthesized as an amide during peptide synthesis leading to a molecule which is C-terminally amidated. This embodiment provides the advantage of removing a potential recognition point for carboxypeptidase and reduces the potential for proteolytic degradation of the bicyclic peptide.
- In one embodiment, the modified derivative comprises replacement of one or more amino acid residues with one or more non-natural amino acid residues. In this embodiment, non-natural amino acids may be selected having isosteric/isoelectronic side chains which are neither recognised by degradative proteases nor have any adverse effect upon target potency.
- Alternatively, non-natural amino acids may be used having constrained amino acid side chains, such that proteolytic hydrolysis of the nearby peptide bond is conformationally and sterically impeded. In particular, these concern proline analogues, bulky sidechains, Cα-disubstituted derivatives (for example, aminoisobutyric acid, Aib), and cyclo amino acids, a simple derivative being amino-cyclopropylcarboxylic acid.
- In one embodiment, the modified derivative comprises the addition of a spacer group. In a further embodiment, the modified derivative comprises the addition of a spacer group to the N-terminal cysteine (Ci) and/or the C-terminal cysteine (Ciii).
- In one embodiment, the modified derivative comprises replacement of one or more oxidation sensitive amino acid residues with one or more oxidation resistant amino acid residues. In a further embodiment, the modified derivative comprises replacement of a tryptophan residue with a naphthylalanine or alanine residue. This embodiment provides the advantage of improving the pharmaceutical stability profile of the resultant bicyclic peptide ligand.
- In one embodiment, the modified derivative comprises replacement of one or more charged amino acid residues with one or more hydrophobic amino acid residues. In an alternative embodiment, the modified derivative comprises replacement of one or more hydrophobic amino acid residues with one or more charged amino acid residues. The correct balance of charged versus hydrophobic amino acid residues is an important characteristic of the bicyclic peptide ligands. For example, hydrophobic amino acid residues influence the degree of plasma protein binding and thus the concentration of the free available fraction in plasma, while charged amino acid residues (in particular arginine) may influence the interaction of the peptide with the phospholipid membranes on cell surfaces. The two in combination may influence half-life, volume of distribution and exposure of the peptide drug, and can be tailored according to the clinical endpoint. In addition, the correct combination and number of charged versus hydrophobic amino acid residues may reduce irritation at the injection site (if the peptide drug has been administered subcutaneously).
- In one embodiment, the modified derivative comprises replacement of one or more L-amino acid residues with one or more D-amino acid residues. This embodiment is believed to increase proteolytic stability by steric hindrance and by a propensity of D-amino acids to stabilise β-turn conformations (Tugyi et al (2005) PNAS, 102(2), 413-418).
- In one embodiment, the modified derivative comprises removal of any amino acid residues and substitution with alanines. This embodiment provides the advantage of removing potential proteolytic attack site(s).
- It should be noted that each of the above mentioned modifications serve to deliberately improve the potency or stability of the peptide. Further potency improvements based on modifications may be achieved through the following mechanisms:
-
- Incorporating hydrophobic moieties that exploit the hydrophobic effect and lead to lower off rates, such that higher affinities are achieved;
- Incorporating charged groups that exploit long-range ionic interactions, leading to faster on rates and to higher affinities (see for example Schreiber et al, Rapid, electrostatically assisted association of proteins (1996), Nature Struct. Biol. 3, 427-31); and
- Incorporating additional constraint into the peptide, by for example constraining side chains of amino acids correctly such that loss in entropy is minimal upon target binding, constraining the torsional angles of the backbone such that loss in entropy is minimal upon target binding and introducing additional cyclisations in the molecule for identical reasons.
- (for reviews see Gentilucci et al, Curr. Pharmaceutical Design, (2010), 16, 3185-203, and Nestor et al, Curr. Medicinal Chem (2009), 16, 4399-418).
- Isotopic Variations
- The present invention includes all pharmaceutically acceptable (radio)isotope-labeled peptide ligands of the invention, wherein one or more atoms are replaced by atoms having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number usually found in nature, and peptide ligands of the invention, wherein metal chelating groups are attached (termed “effector”) that are capable of holding relevant (radio)isotopes, and peptide ligands of the invention, wherein certain functional groups are covalently replaced with relevant (radio)isotopes or isotopically labelled functional groups.
- Examples of isotopes suitable for inclusion in the peptide ligands of the invention comprise isotopes of hydrogen, such as 2H (D) and 3H (T), carbon, such as 11C, 13C and 14C, chlorine, such as 36Cl, fluorine, such as 18F, iodine, such as 123I, 125I and 131I, nitrogen, such as 13N and 15N, oxygen, such as 15O, 17O and 18O, phosphorus, such as 32P, sulfur, such as 35S, copper, such as 64Cu, gallium, such as 67Ga or 68Ga, yttrium, such as 90Y and lutetium, such as 177Lu, and Bismuth, such as 213Bi.
- Certain isotopically-labelled peptide ligands of the invention, for example, those incorporating a radioactive isotope, are useful in drug and/or substrate tissue distribution studies, and to clinically assess the presence and/or absence of the Nectin-4 target on diseased tissues. The peptide ligands of the invention can further have valuable diagnostic properties in that they can be used for detecting or identifying the formation of a complex between a labelled compound and other molecules, peptides, proteins, enzymes or receptors. The detecting or identifying methods can use compounds that are labelled with labelling agents such as radioisotopes, enzymes, fluorescent substances, luminous substances (for example, luminol, luminol derivatives, luciferin, aequorin and luciferase), etc. The radioactive isotopes tritium, i.e. 3H (T), and carbon-14, i.e. 14C, are particularly useful for this purpose in view of their ease of incorporation and ready means of detection.
- Substitution with heavier isotopes such as deuterium, i.e. 2H (D), may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements, and hence may be preferred in some circumstances.
- Substitution with positron emitting isotopes, such as 11C, 18F, 15O and 13N, can be useful in Positron Emission Topography (PET) studies for examining target occupancy.
- Isotopically-labeled compounds of peptide ligands of the invention can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples using an appropriate isotopically-labeled reagent in place of the non-labeled reagent previously employed.
- Molecular Scaffold
- Molecular scaffolds are described in, for example, WO 2009/098450 and references cited therein, particularly WO 2004/077062 and WO 2006/078161.
- As noted in the foregoing documents, the molecular scaffold may be a small molecule, such as a small organic molecule.
- In one embodiment, the molecular scaffold may be a macromolecule. In one embodiment, the molecular scaffold is a macromolecule composed of amino acids, nucleotides or carbohydrates.
- In one embodiment, the molecular scaffold comprises reactive groups that are capable of reacting with functional group(s) of the polypeptide to form covalent bonds.
- The molecular scaffold may comprise chemical groups which form the linkage with a peptide, such as amines, thiols, alcohols, ketones, aldehydes, nitriles, carboxylic acids, esters, alkenes, alkynes, azides, anhydrides, succinimides, maleimides, alkyl halides and acyl halides.
- In one embodiment, the molecular scaffold may comprise or may consist of hexahydro-1,3,5-triazine, especially 1,3,5-Triacryloylhexahydro-1,3,5-triazine (TATA), or a derivative thereof.
- The molecular scaffold of the invention contains chemical groups that allow functional groups of the polypeptide of the encoded library of the invention to form covalent links with the molecular scaffold. Said chemical groups are selected from a wide range of functionalities including amines, thiols, alcohols, ketones, aldehydes, nitriles, carboxylic acids, esters, alkenes, alkynes, anhydrides, succinimides, maleimides, azides, alkyl halides and acyl halides.
- Scaffold reactive groups that could be used on the molecular scaffold to react with thiol groups of cysteines are alkyl halides (or also named halogenoalkanes or haloalkanes).
- Examples include bromomethylbenzene or iodoacetamide. Other scaffold reactive groups that are used to selectively couple compounds to cysteines in proteins are maleimides, αβ unsaturated carbonyl containing compounds and α-halomethylcarbonyl containing compounds. Examples of maleimides which may be used as molecular scaffolds in the invention include: tris-(2-maleimidoethyl)amine, tris-(2-maleimidoethyl)benzene, tris-(maleimido)benzene. An example of an αβ unsaturated carbonyl containing compound is 1,1′,1″-(1,3,5-triazinane-1,3,5-triyl)triprop-2-en-1-one (TATA) (Angewandte Chemie, International Edition (2014), 53(6), 1602-1606). An example of an α-halomethylcarbonyl containing compound is N,N′,N″-(benzene-1,3,5-triyl)tris(2-bromoacetamide). Selenocysteine is also a natural amino acid which has a similar reactivity to cysteine and can be used for the same reactions. Thus, wherever cysteine is mentioned, it is typically acceptable to substitute selenocysteine unless the context suggests otherwise.
- Synthesis
- The peptides of the present invention may be manufactured synthetically by standard techniques followed by reaction with a molecular scaffold in vitro. When this is performed, standard chemistry may be used. This enables the rapid large scale preparation of soluble material for further downstream experiments or validation. Such methods could be accomplished using conventional chemistry such as that disclosed in Timmerman et al (supra).
- Thus, the invention also relates to manufacture of polypeptides or conjugates selected as set out herein, wherein the manufacture comprises optional further steps as explained below. In one embodiment, these steps are carried out on the end product polypeptide/conjugate made by chemical synthesis.
- Optionally amino acid residues in the polypeptide of interest may be substituted when manufacturing a conjugate or complex.
- Peptides can also be extended, to incorporate for example another loop and therefore introduce multiple specificities.
- To extend the peptide, it may simply be extended chemically at its N-terminus or C-terminus or within the loops using orthogonally protected lysines (and analogues) using standard solid phase or solution phase chemistry. Standard (bio)conjugation techniques may be used to introduce an activated or activatable N- or C-terminus. Alternatively additions may be made by fragment condensation or native chemical ligation e.g. as described in (Dawson et al. 1994. Synthesis of Proteins by Native Chemical Ligation. Science 266:776-779), or by enzymes, for example using subtiligase as described in (Chang et al. Proc Natl Acad Sci USA. 1994 Dec. 20; 91(26):12544-8 or in Hikari et al Bioorganic & Medicinal Chemistry Letters Volume 18, Issue 22, 15 Nov. 2008, Pages 6000-6003).
- Alternatively, the peptides may be extended or modified by further conjugation through disulphide bonds. This has the additional advantage of allowing the first and second peptides to dissociate from each other once within the reducing environment of the cell. In this case, the molecular scaffold (e.g. TATA) could be added during the chemical synthesis of the first peptide so as to react with the three cysteine groups; a further cysteine or thiol could then be appended to the N or C-terminus of the first peptide, so that this cysteine or thiol only reacted with a free cysteine or thiol of the second peptides, forming a disulfide—linked bicyclic peptide-peptide conjugate.
- Similar techniques apply equally to the synthesis/coupling of two bicyclic and bispecific macrocycles, potentially creating a tetraspecific molecule.
- Furthermore, addition of other functional groups or effector groups may be accomplished in the same manner, using appropriate chemistry, coupling at the N- or C-termini or via side chains. In one embodiment, the coupling is conducted in such a manner that it does not block the activity of either entity.
- Pharmaceutical Compositions
- According to a further aspect of the invention, there is provided a pharmaceutical composition comprising a peptide ligand as defined herein in combination with one or more pharmaceutically acceptable excipients.
- Generally, the present peptide ligands will be utilised in purified form together with pharmacologically appropriate excipients or carriers. Typically, these excipients or carriers include aqueous or alcoholic/aqueous solutions, emulsions or suspensions, including saline and/or buffered media. Parenteral vehicles include sodium chloride solution, Ringers dextrose, dextrose and sodium chloride and lactated Ringers. Suitable physiologically-acceptable adjuvants, if necessary to keep a polypeptide complex in suspension, may be chosen from thickeners such as carboxymethylcellulose, polyvinylpyrrolidone, gelatin and alginates.
- Intravenous vehicles include fluid and nutrient replenishers and electrolyte replenishers, such as those based on Ringers dextrose. Preservatives and other additives, such as antimicrobials, antioxidants, chelating agents and inert gases, may also be present (Mack (1982) Remington's Pharmaceutical Sciences, 16th Edition).
- The peptide ligands of the present invention may be used as separately administered compositions or in conjunction with other agents. These can include antibodies, antibody fragments and various immunotherapeutic drugs, such as cylcosporine, methotrexate, adriamycin or cisplatinum and immunotoxins. Pharmaceutical compositions can include “cocktails” of various cytotoxic or other agents in conjunction with the protein ligands of the present invention, or even combinations of selected polypeptides according to the present invention having different specificities, such as polypeptides selected using different target ligands, whether or not they are pooled prior to administration.
- The route of administration of pharmaceutical compositions according to the invention may be any of those commonly known to those of ordinary skill in the art. For therapy, the peptide ligands of the invention can be administered to any patient in accordance with standard techniques. The administration can be by any appropriate mode, including parenterally, intravenously, intramuscularly, intraperitoneally, transdermally, via the pulmonary route, or also, appropriately, by direct infusion with a catheter. Preferably, the pharmaceutical compositions according to the invention will be administered by inhalation. The dosage and frequency of administration will depend on the age, sex and condition of the patient, concurrent administration of other drugs, counterindications and other parameters to be taken into account by the clinician.
- The peptide ligands of this invention can be lyophilised for storage and reconstituted in a suitable carrier prior to use. This technique has been shown to be effective and art-known lyophilisation and reconstitution techniques can be employed. It will be appreciated by those skilled in the art that lyophilisation and reconstitution can lead to varying degrees of activity loss and that levels may have to be adjusted upward to compensate.
- The compositions containing the present peptide ligands or a cocktail thereof can be administered for prophylactic and/or therapeutic treatments. In certain therapeutic applications, an adequate amount to accomplish at least partial inhibition, suppression, modulation, killing, or some other measurable parameter, of a population of selected cells is defined as a “therapeutically-effective dose”. Amounts needed to achieve this dosage will depend upon the severity of the disease and the general state of the patient's own immune system, but generally range from 0.005 to 5.0 mg of selected peptide ligand per kilogram of body weight, with doses of 0.05 to 2.0 mg/kg/dose being more commonly used. For prophylactic applications, compositions containing the present peptide ligands or cocktails thereof may also be administered in similar or slightly lower dosages.
- A composition containing a peptide ligand according to the present invention may be utilised in prophylactic and therapeutic settings to aid in the alteration, inactivation, killing or removal of a select target cell population in a mammal. In addition, the peptide ligands described herein may be used extracorporeally or in vitro selectively to kill, deplete or otherwise effectively remove a target cell population from a heterogeneous collection of cells. Blood from a mammal may be combined extracorporeally with the selected peptide ligands whereby the undesired cells are killed or otherwise removed from the blood for return to the mammal in accordance with standard techniques.
- Therapeutic Uses
- According to a further aspect of the invention, there is provided a heterotandem bicyclic peptide complex as defined herein for use in preventing, suppressing or treating cancer.
- Examples of cancers (and their benign counterparts) which may be treated (or inhibited) include, but are not limited to tumours of epithelial origin (adenomas and carcinomas of various types including adenocarcinomas, squamous carcinomas, transitional cell carcinomas and other carcinomas) such as carcinomas of the bladder and urinary tract, breast, gastrointestinal tract (including the esophagus, stomach (gastric), small intestine, colon, rectum and anus), liver (hepatocellular carcinoma), gall bladder and biliary system, exocrine pancreas, kidney, lung (for example adenocarcinomas, small cell lung carcinomas, non-small cell lung carcinomas, bronchioalveolar carcinomas and mesotheliomas), head and neck (for example cancers of the tongue, buccal cavity, larynx, pharynx, nasopharynx, tonsil, salivary glands, nasal cavity and paranasal sinuses), ovary, fallopian tubes, peritoneum, vagina, vulva, penis, cervix, myometrium, endometrium, thyroid (for example thyroid follicular carcinoma), adrenal, prostate, skin and adnexae (for example melanoma, basal cell carcinoma, squamous cell carcinoma, keratoacanthoma, dysplastic naevus); haematological malignancies (i.e. leukemias, lymphomas) and premalignant haematological disorders and disorders of borderline malignancy including haematological malignancies and related conditions of lymphoid lineage (for example acute lymphocytic leukemia [ALL], chronic lymphocytic leukemia [CLL], B-cell lymphomas such as diffuse large B-cell lymphoma [DLBCL], follicular lymphoma, Burkitt's lymphoma, mantle cell lymphoma, T-cell lymphomas and leukaemias, natural killer [NK] cell lymphomas, Hodgkin's lymphomas, hairy cell leukaemia, monoclonal gammopathy of uncertain significance, plasmacytoma, multiple myeloma, and post-transplant lymphoproliferative disorders), and haematological malignancies and related conditions of myeloid lineage (for example acute myelogenousleukemia [AML], chronic myelogenousleukemia [CML], chronic myelomonocyticleukemia [CMML], hypereosinophilic syndrome, myeloproliferative disorders such as polycythaemia vera, essential thrombocythaemia and primary myelofibrosis, myeloproliferative syndrome, myelodysplastic syndrome, and promyelocyticleukemia); tumours of mesenchymal origin, for example sarcomas of soft tissue, bone or cartilage such as osteosarcomas, fibrosarcomas, chondrosarcomas, rhabdomyosarcomas, leiomyosarcomas, liposarcomas, angiosarcomas, Kaposi's sarcoma, Ewing's sarcoma, synovial sarcomas, epithelioid sarcomas, gastrointestinal stromal tumours, benign and malignant histiocytomas, and dermatofibrosarcomaprotuberans; tumours of the central or peripheral nervous system (for example astrocytomas, gliomas and glioblastomas, meningiomas, ependymomas, pineal tumours and schwannomas); endocrine tumours (for example pituitary tumours, adrenal tumours, islet cell tumours, parathyroid tumours, carcinoid tumours and medullary carcinoma of the thyroid); ocular and adnexal tumours (for example retinoblastoma); germ cell and trophoblastic tumours (for example teratomas, seminomas, dysgerminomas, hydatidiform moles and choriocarcinomas); and paediatric and embryonal tumours (for example medulloblastoma, neuroblastoma, Wilms tumour, and primitive neuroectodermal tumours); or syndromes, congenital or otherwise, which leave the patient susceptible to malignancy (for example Xeroderma Pigmentosum).
- In a further embodiment, the cancer is selected from a hematopoietic malignancy such as selected from: non-Hodgkin's lymphoma (NHL), Burkitt's lymphoma (BL), multiple myeloma (MM), B chronic lymphocytic leukemia (B-CLL), B and T acute lymphocytic leukemia (ALL), T cell lymphoma (TCL), acute myeloid leukemia (AML), hairy cell leukemia (HCL), Hodgkin's Lymphoma (HL), and chronic myeloid leukemia (CML).
- References herein to the term “prevention” involves administration of the protective composition prior to the induction of the disease. “Suppression” refers to administration of the composition after an inductive event, but prior to the clinical appearance of the disease. “Treatment” involves administration of the protective composition after disease symptoms become manifest.
- Animal model systems which can be used to screen the effectiveness of the peptide ligands in protecting against or treating the disease are available. The use of animal model systems is facilitated by the present invention, which allows the development of polypeptide ligands which can cross react with human and animal targets, to allow the use of animal models.
- The invention is further described below with reference to the following examples.
- In general, the heterotandem bicyclic peptide complexes of the invention may be prepared in accordance with the following general method:
- A mixture of Bicycle 1 (1.0 eq.) and NHS-PEG5-N3 (1.6 eq.) is dissolved in MeCN/H2O (1:1), and the pH of the solution adjusted to 8 by dropwise addition of NaHCO3 (0.1 M). The reaction mixture is stirred at 30° C. for 2 hr then concentrated under reduced pressure to remove solvent.
- The residue is then purified by prep-HPLC to give intermediate 2.
- A mixture of intermediate 2 (1.0 eq) and Bicycle2 (1.0 eq) are dissolved in t-BuOH/H2O (1:1), and then CuSO4 (1.0 eq), VcNa (2.3 eq), and THPTA (1.0 eq) are added. Finally, 0.2 M NH4HCO3 is added to adjust pH to 8. The reaction mixture is stirred at 40° C. for 16 hr under N2 atmosphere. The reaction mixture was directly purified by prep-HPLC.
- More detailed experimental for selected heterotandem bicyclic peptide complexes of the invention are provided herein below:
-
- Procedure for Preparation of Palmitic Acid—PEG10-N3
- A mixture of Palmitic acid (100.0 mg, 282.89 μmol, 1.0 eq.), compound 2 (150.0 mg, 284.84 μmol, 1.0 eq.), and DIEA (74.5 mg, 574.11 μmol, 100.0 μL, 2.0 eq.) was dissolved in DMF (2 mL). The reaction mixture was stirred at 30° C. for 2 hr. LC-MS showed compound 1 was consumed completely and one main peak with desired m/z (MW: 765.03, observed m/z: 765.22) was detected. The reaction mixture was concentrated under reduced pressure to remove solvent and produced a residue. The residue was then purified by prep-HPLC (neutral condition). Palmitic acid—PEG10-N3 (79.0 mg, 99.41 μmol, 35.14% yield, 96.27% purity) was obtained as a white solid.
- Procedure for Preparation of Palmitic Acid—PEG10-BCY12023
- A mixture of compound 3 (50.0 mg, 22.07 μmol, 1.0 eq.), compound 2 (17.0 mg, 22.22 μmol, 1.0 eq.), and THPTA (10.0 mg, 23.02 μmol, 1.0 eq.) was dissolved in t-BuOH/H2O (1:1, 1 mL, pre-degassed and purged with N2 for 3 times), and then CuSO4 (0.4 M, 56.0 μL, 1.0 eq.) and VcNa (10.0 mg, 50.48 μmol, 2.3 eq.) were added under N2. The pH of this solution was adjusted to 8 by dropwise addition of 0.2 M NH4HCO3 (in 1:1 t-BuOH/H2O), and the solution turned to light yellow. The reaction mixture was stirred at 40° C. for 2 hr under N2 atmosphere. LC-MS showed Palmitic acid—PEG10-N3 was remand and one main peak with desired m/z (calculated MW: 3030.60, observed m/z: 1010.35 ([M/3+H]+)) was detected. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The crude product was purified by prep-HPLC (TFA condition), and Palmitic acid—PEG10-BCY12023 (43.0 mg, 13.97 μmol, 63.30% yield, 98.46% purity) was obtained as a white solid.
- Procedure for Preparation of Palmitic Acid—PEG10-BCY12023-PEG5-N3
- A mixture of compound 5 (43.0 mg, 14.19 μmol, 1.0 eq.), compound 6 (10.0 mg, 23.13 μmol, 1.6 eq.) was dissolved in MeCN/H2O (1:1, 1 mL), and then the pH of this solution was adjusted to 8 by dropwise addition of NaHCO3 (0.1 M). The reaction mixture was stirred at 30° C. for 2 hr. LC-MS showed compound 5 was consumed completely and one main peak with desired m/z (MW: 3347.94, observed m/z: 1673.7 ([(M/2+H+]), 1115.9 ([(M/3+H+])) was detected. The reaction mixture was concentrated under reduced pressure to remove solvent and produced a residue. The residue was then purified by prep-HPLC (neutral condition). Palmitic acid—PEG10-BCY12023-PEG5-N3 (16.0 mg, 4.43 μmol, 31.25% yield, 92.78% purity) was obtained as a white solid.
- Procedure for Preparation of BCY12375
- A mixture of compound 7 (8.0 mg, 2.39 μmol, 1.0 eq.), compound 8 (6.5 mg, 2.39 μmol, 1.0 eq.), and THPTA (1.1 mg, 2.53 μmol, 1.0 eq.) was dissolved in t-BuOH/H2O (1:1, 1 mL, pre-degassed and purged with N2 for 3 times), and then CuSO4 (0.4 M, 6.0 μL, 1.0 eq.) and VcNa (1.0 mg, 5.05 μmol, 2.1 eq.) were added under N2. The pH of this solution was adjusted to 8 by dropwise addition of 0.2 M NH4HCO3 (in 1:1 t-BuOH/H2O), and the solution turned to light yellow. The reaction mixture was stirred at 40° C. for 16 hr under N2 atmosphere. LC-MS showed compound 7 was remand and one main peak with desired m/z (calculated MW: 6064.08, observed m/z: 1516.4 ([M/4+H]+), 1212.8 ([M/5+H]+)) was detected. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The crude product was purified by prep-HPLC (TFA condition), and BCY12375 (6.2 mg, 0.99 μmol, 41.62% yield, 97.27% purity) was obtained as a white solid.
-
- Procedure for Preparation of Palmitic Acid—PEG10-BCY11144
- A mixture of compound 3 (160.0 mg, 69.45 μmol, 1.0 eq.), compound 4 (56.0 mg, 72.20 μmol, 1.0 eq.), and THPTA (35.0 mg, 80.55 μmol, 1.1 eq.) was dissolved in t-BuOH/H2O (1:1, 2 mL, pre-degassed and purged with N2 for 3 times), and then CuSO4 (0.4 M, 56.0 μL, 1.0 eq.) and VcNa (30.0 mg, 151.43 μmol, 2.2 eq.) were added under N2. The pH of this solution was adjusted to 8 by dropwise addition of 0.2 M NH4HCO3 (in 1:1 t-BuOH/H2O), and the solution turned to light yellow. The reaction mixture was stirred at 40° C. for 16 hr under N2 atmosphere. LC-MS showed one main peak with desired m/z (calculated MW: 3068.70, observed m/z: 1533.81 ([M/2+H]+), 1023.43 ([M/3+H]+)) was detected. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The crude product was purified by prep-HPLC (TFA condition), and Palmitic acid—PEG10-BCY11144 (150.0 mg, 46.83 μmol, 67.42% yield, 95.80% purity) was obtained as a white solid.
- Procedure for Preparation of Palmitic Acid—PEG10-BCY11144-PEG5-N3
- A mixture of compound 5 (47.0 mg, 15.32 μmol, 1.0 eq.), compound 6 (7.0 mg, 16.19 μmol, 1.0 eq.), and DIEA (3.0 mg, 22.97 μmol, 4.0 μL, 1.5 eq.) was dissolved in DMF (1 mL). The reaction mixture was stirred at 30° C. for 2 hr. LC-MS showed compound 5 was consumed completely and one main peak with desired m/z (MW: 3386.03, observed m/z: 1693.21 ([M/2+H]+), 1129.13 ([M/3+H]+)) was detected. The reaction mixture was concentrated under reduced pressure to remove solvent and produced a residue. The residue was then purified by prep-HPLC (neutral condition). Palmitic acid—PEG10-BCY11144-PEG5-N3 (20.0 mg, 5.72 μmol, 37.33% yield, 96.79% purity) was obtained as a white solid.
- Procedure for Preparation of BCY12021
- A mixture of compound 7 (10.0 mg, 2.95 μmol, 1.0 eq.), compound 8 (8.2 mg, 3.02 μmol, 1.0 eq.), and THPTA (1.5 mg, 3.45 μmol, 1.1 eq.) was dissolved in t-BuOH/H2O (1:1, 1 mL, pre-degassed and purged with N2 3 times), and then CuSO4 (0.4 M, 8.0 μL, 1.0 eq.) and VcNa (1.5 mg, 7.57 μmol, 2.5 eq.) were added under N2. The pH of this solution was adjusted to 8 by dropwise addition of 0.2 M NH4HCO3 (in 1:1 t-BuOH/H2O), and the solution turned to light yellow. The reaction mixture was stirred at 40° C. for 16 hr under N2 atmosphere. LC-MS showed one main peak with desired m/z (calculated MW: 6102.17, observed m/z: 1525.17 ([M/4+H]+), 1221.3 ([M/5+H]+)). The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The crude product was purified by prep-HPLC (TFA condition), and BCY12021 (6.6 mg, 1.02 μmol, 34.62% yield, 94.54% purity) was obtained as a white solid.
-
- Procedure for Preparation of COM113
- A mixture of compound 1 (50.0 mg, 124.4 μmol, 1.0 eq), EDCl (95.4 mg, 497.7 μmol, 4.0 eq), HOBt (55.5 mg, 410.6 μmol, 3.3 eq), and DMAP (15.2 mg, 124.4 μmol, 1.0 eq) was dissolved in 2 mL DMF, and then DIEA (134.9 mg, 1.04 mmol, 181.8 μL, 8.4 eq) was added to generate a homogenous solution. Next, compound 2 (200.0 mg, 379.8 μmol, 3.05 eq) dissolved in DMF (2 mL) was added to this solution dropwise. The reaction mixture was stirred at 30° C. for 16 hr. LC-MS showed compound 1 was consumed completely and one main peak with desired m/z (MW: 1891.19, observed m/z: 945.8600 ([M/2+H+]) and 612.4400 ([(M−3H2O)/3+H+])) was detected. The reaction mixture was directly purified by prep-HPLC (TFA condition), resulting in COM113 (161 mg, 85.67 μmol, 68% yield) as a yellow oil after lyophilization.
- Procedure for Preparation of COM113-BCY8928
- COM113 (50.0 mg, 26.44 μmol, 1.0 eq) and BCY8928 (53.0 mg, 23.9 μmol, 0.9 eq) were first dissolved in 2 mL of t-BuOH/H2O (1:1), and then CuSO4 (0.4 M, 66.1 μL, 1.0 eq), VcNa (10.5 mg, 53.0 μmol, 2.0 eq) and THPTA (23.0 mg, 52.93 μmol, 2.0 eq) was added. Finally, 1 M NH4HCO3 was added to adjust pH to 8. All solvents were degassed and purged with N2 for 3 times. The reaction mixture was stirred at 30° C. for 16 hr under N2 atmosphere. LC-MS showed one main peak with desired m/z (calculated MW: 4108.77 observed m/z: 1369.97 ([M/3+H]+)). The reaction mixture was purified by prep-HPLC (TFA condition) and Compound 2 (14.0 mg, 3.21 μmol, 12.14% yield, 94.16% purity) was obtained as a white solid.
- Procedure for Preparation of Palmitic Acid NHS Ester
- To a solution of palmitic acid (500 mg, 1.95 mmol, 586.85 μL, 1.0 eq), 1-hydroxypyrrolidine-2,5-dione (250 mg, 2.17 mmol, 1.11 eq) in DCM (5 mL) was added with EDCl (747.60 mg, 3.90 mmol, 2.0 eq). The mixture was stirred at 30° C. for 16 hr. TLC indicated Reactant 1 was consumed completely and one new spot formed. The reaction was clean according to TLC. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, DCM: MeOH=0 to 100:1). The desired product was dried to obtain Palmitic acid NHS ester (0.68 g, 1.92 mmol, 98.65% yield) as a white solid.
- Procedure for Preparation of Palmitic Acid—Propargylalanine
- To a solution of compound 3 (120 mg, 339.47 μmol, 1.0 eq) and compound 4 (57.60 mg, 509.20 μmol, 1.5 eq) in DMF (6 mL) was added DIEA (131.62 mg, 1.02 mmol, 177.39 μL, 3.0 eq) and DMAP (41.47 mg, 339.47 μmol, 1.0 eq). The mixture was stirred at 40° C. for 16 hr. LC-MS showed Reactant 3 was consumed completely and one main peak with desired m/z or desired mass was detected. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (TFA condition). Palmitic acid-Propargylalanine (90 mg, 256.03 μmol, 75.42% yield) was obtained as a white solid.
- Procedure for Preparation of COM113-BCY8928-Palmitic Acid
- Compound 2 (14.0 mg, 3.41 μmol, 1.0 eq) and Compound 3 (1.1 mg, 3.13 μmol, 0.9 eq) were first dissolved in 2 mL of t-BuOH/H2O (1:1), and then CuSO4 (0.4 M, 10.0 μL, 1.1 eq), VcNa (2.0 mg, 10.1 μmol, 2.9 eq) and THPTA (2.0 mg, 4.6 μmol, 1.3 eq) was added. Finally 0.2 M NH4HCO3 was added to adjust pH to 8. All solvents here were degassed and purged with N2 for 3 times. The reaction mixture was stirred at 35° C. for 16 hr under N2 atmosphere. LC-MS showed one main peak with desired m/z (calculated MW: 4460.29, observed m/z: 1486.92 ([M/3+H]+), 1115.58 ([M/4+H]+), 895.83 ([M/5+H]+)). The reaction mixture was purified by prep-HPLC (TFA condition) and Compound 4 (5.9 mg, 1.28 μmol, 37.66% yield, 97.0% purity) was obtained as a white solid.
- Procedure for Preparation of BCY11468
- Compound 4 (5.9 mg, 1.32 μmol, 1.0 eq) and BCY11016 (3.0 mg, 1.29 μmol, 1 eq) were first dissolved in 2 mL of t-BuOH/H2O (1:1), and then CuSO4 (0.4 M, 8.0 μL, 2.4 eq), VcNa 2.0 mg, 7.6 eq) and THPTA (2.0 mg, 3.5 eq) was added. Finally, 1 M NH4HCO3 was added to adjust pH to 8. All solvents were degassed and purged with N2 3 times. The reaction mixture was stirred at 30° C. for 16 hr under N2 atmosphere. LC-MS showed one main peak with desired m/z (calculated MW: 6783.93, observed m/z: 1131.7 ([M/6+H]+)). The reaction mixture was purified by prep-HPLC (TFA condition) and BCY11468 (2.2 mg, 0.312 μmol, 23.57% yield, 96.16% purity) was obtained as a white solid.
-
- Procedure for Preparation of BCY8920-PEG5-N3
- A mixture of BCY8920 (50.0 mg, 23.39 μmol, 1.0 eq.), compound 2 (10.2 mg, 23.51 μmol, 1.01 eq.) and NaHCO3 (2.0 mg, 24.8 μmol, 1.0 eq.) was dissolved in MeCN/H2O (1:1, 2 mL). The reaction mixture was stirred at 40° C. for 2 hr, until LC-MS showed BCY8920 was consumed completely and one main peak with desired m/z (calculated MW: 2454.83, observed m/z: 1227.67 ([M/2+H]+) and 818.74 ([M/3+H]+)) was detected. The reaction mixture was then concentrated under reduced pressure to remove solvent and produced a residue, following by purification by prep-HPLC (TFA condition). BCY8920-PEG5-N3 (25 mg, 9.70 μmol, 41.47% yield, 95.26% purity) was obtained as a white solid.
- Procedure for Preparation of BCY11143-dK (Palmitic Acid)
- A mixture of BCY11143 (30.0 mg, 12.84 μmol, 1.0 eq.), compound 5 (5.0 mg, 14.12 μmol, 1.1 eq.), DIEA (1.7 mg, 12.84 μmol, 2.2 μL, 1.0 eq.) and DMAP (1.6 mg, 12.84 μmol, 1.0 eq.) was dissolved in DMF. The reaction mixture was stirred at 40° C. for 2 hr under N2 atmosphere. LC-MS showed one main peak with desired m/z (calculated MW: 2575.14, observed m/z: 1287.68 ([M/2+H+])) was detected. The reaction mixture was filtered and concentrated under reduced pressure to give a residue, which was then purified by prep-HPLC (TFA condition). BCY11143-dK(palmitic acid) (18.3 mg, 6.95 μmol, 54.17% yield, 97.86% purity) was obtained as a white solid.
- Procedure for Preparation of BCY11618
- A mixture of compound 3 (5 mg, 2.04 μmol, 1.0 eq.), compound 6 (5.8 mg, 2.3 μmol, 1.1 eq.), and THPTA (0.9 mg, 2.07 μmol, 1.0 eq.) was dissolved in t-BuOH/H2O (1:1, 1 mL, pre-degassed and purged with N2 for 3 times), and then CuSO4 (0.4 M, 5.1 μL, 1.0 eq.) and VcNa (0.4 M, 5.1 μL, 1.0 eq.) were added under N2. The pH of this solution was adjusted to 8 by dropwise addition of 0.2 M NH4HCO3 (in 1:1 t-BuOH/H2O), and the solution turned to light yellow. The reaction mixture was stirred at 40° C. for 6 hr under N2 atmosphere. LC-MS showed compound 3 was consumed completely and one main peak with desired m/z (calculated MW: 5029.97, observed m/z: 1257.8 ([M/4+H]+) and 1006.6 ([M/5+H]+)) was detected. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The crude product was purified by prep-HPLC (TFA condition), and BCY11618 (5.3 mg, 1.0 μmol, 49.15% yield, 95% purity) was obtained as a white solid.
-
- Procedure for preparation of BCY8116-Peg5-N3
- A mixture of BCY8116 (50.0 mg, 23.39 μmol, 1.0 eq.), compound 2 (10.2 mg, 23.51 μmol, 1.01 eq.) and NaHCO3 (2.0 mg, 24.8 μmol, 1.0 eq.) was dissolved in MeCN/H2O (1:1, 2 mL). The reaction mixture was stirred at 25° C. for 1 hr until LC-MS showed BCY8116 was consumed completely and one main peak with desired m/z (calculated MW: 2454.83, observed m/z: 1227.67 ([M/2+H+]), 818.74 ([M/3+H+])) was detected. The reaction mixture was then concentrated under reduced pressure to remove solvent and produced a residue, following by purification by prep-HPLC (TFA condition). Compound 3 (25.0 mg, 9.70 μmol, 41.47% yield, 95.26% purity) was obtained as a white solid.
- Procedure for Preparation of Compound BCY11144-dK (Palmitic Acid)
- A mixture of BCY11144 (50.0 mg, 21.7 μmol, 1.0 eq.), compound 5 (8.5 mg, 23.87 μmol, 1.1 eq.), DIEA (2.81 mg, 21.7 μmol, 4.0 μL, 1.0 eq.) and DMAP (2.7 mg, 21.7 μmol, 1.0 eq.) was dissolved in DMF. The reaction mixture was stirred at 25° C. for 2 hr under N2 atmosphere. LC-MS showed compound 3 was consumed completely and one main peak with desired m/z (calculated MW: 2542.08, observed m/z: 1271.7 ([M/2+H+])) was detected. The reaction mixture was filtered and concentrated under reduced pressure to give a residue, which was then purified by prep-HPLC (TFA condition). Compound 6 (18.3 mg, 6.95 μmol, 54.17% yield, 96.68% purity) was obtained as a white solid.
- Procedure for Preparation of BCY11776
- A mixture of compound 3 (10 mg, 4.0 μmol, 1.0 eq.), compound 6 (11.2 mg, 4.4 μmol, 1.1 eq.), and THPTA (1.8 mg, 1.0 eq.) was dissolved in t-BuOH/H2O (1:1, 1 mL, pre-degassed and purged with N2 for 3 times), and then CuSO4 (0.4 M, 5.1 μL, 1 eq.) and VcNa (0.4 M, 5.1 μL, 1 eq.) were added under N2. The pH of this solution was adjusted to 8 by dropwise addition of 0.2 M NH4HCO3 (in 1:1 t-BuOH/H2O), and the solution turned to light yellow. The reaction mixture was stirred at 40° C. for 6 hr under N2 atmosphere. LC-MS showed compound 3 was consumed completely and one main peak with desired m/z (calculated MW: 5031.9, observed m/z: 1258.52 ([M/4+H+])), 1006.7 ([M/5+H+])) was detected. The reaction mixture was filtered and concentrated under reduced pressure to give a residue.
- The crude product was purified by prep-HPLC (TFA condition), and BCY11776 (12.5 mg, 2.4 μmol, 60.11% yield, 96.6% purity) was obtained as a white solid.
-
- Procedure for Preparation of BCY8920-Peg5-BCY11143
- A mixture of BCY8920-PEG5-N3 (20.0 mg, 8.15 μmol, 1.0 eq.), compound 2 (21.0 mg, 8.96 μmol, 1.1 eq.), and THPTA (0.4 M, 21.0 μL, 1.0 eq.) was dissolved in t-BuOH/H2O (1:1, 1 mL, pre-degassed and purged with N2 for 3 times), and then CuSO4 (0.4 M, 21.0 μL, 1.0 eq.) and VcNa (0.4 M, 21.0 μL, 1.0 eq.) were added under N2. The pH of this solution was adjusted to 8 by dropwise addition of 0.2 M NH4HCO3 (in 1:1 t-BuOH/H2O), and the solution turned to light yellow. The reaction mixture was stirred at 40° C. for 4 hr under N2 atmosphere. LC-MS showed compound 1 was consumed completely and one main peak with desired m/z (calculated MW: 4791.56, observed m/z: 1597.28 ([M/3+H]+), 1198.18 ([M/4+H]+)) was detected. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The crude product was purified by prep-HPLC (TFA condition), and BCY8920-Peg5-BCY11143 (22.5 mg, 4.25 μmol, 52.13% yield, 90.44% purity) was obtained as a white solid.
- Procedure for Preparation of BCY11860
- A mixture of compound 3 (5.0 mg, 1.04 μmol, 1.0 eq.), compound 4 (1.08 mg, 1.15 μmol, 1.1 eq.), and DIEA (0.4 M, 1.04 μmol, 3.0 μL, 1.0 eq.) and DMAP (0.2 mg, 1.04 μmol, 1.0 eq.) was dissolved in DMF (1.0 mL). The reaction mixture was stirred at 30° C. for 2 hr. LC-MS showed compound 3 was consumed completely and one main peak with desired m/z (MW: 5617.56, observed m/z: 1404.56 ([(M/4+H+])) was detected. The reaction mixture was concentrated under reduced pressure to remove solvent and produced a residue. The residue was then purified by prep-HPLC (neutral condition). BCY11860 (2.9 mg, 0.48 μmol, 45.86% yield, 92.70% purity) was obtained as a white solid.
-
- Procedure for Preparation of Palmitic Acid—PEG10-N3
- A mixture of Palmitic acid—NHS (100.0 mg, 282.89 μmol, 1.0 eq.), compound 2 (150.0 mg, 284.84 μmol, 1.0 eq.), and DIEA (74.5 mg, 574.11 μmol, 100.0 μL, 2.0 eq.) was dissolved in DMF (2 mL). The reaction mixture was stirred at 30° C. for 2 hr. LC-MS showed compound 1 was consumed completely and one main peak with desired m/z (MW: 765.03, observed m/z: 765.22) was detected. The reaction mixture was concentrated under reduced pressure to remove solvent and produced a residue. The residue was then purified by prep-HPLC (neutral condition). Palmitic acid-PEG10-N3 (79.0 mg, 99.41 μmol, 35.14% yield, 96.27% purity) was obtained as a white solid.
- Procedure for Preparation of Palmitic Acid—PEG10-BCY11144
- A mixture of compound 3 (160.0 mg, 69.45 μmol, 1.0 eq.), compound 2 (56.0 mg, 72.20 μmol, 1.0 eq.), and THPTA (35.0 mg, 80.55 μmol, 1.1 eq.) was dissolved in t-BuOH/H2O (1:1, 2 mL, pre-degassed and purged with N2 3 times), and then CuSO4 (0.4 M, 56.0 μL, 1.0 eq.) and VcNa (30.0 mg, 151.43 μmol, 2.2 eq.) were added under N2. The pH of this solution was adjusted to 8 by dropwise addition of 0.2 M NH4HCO3 (in 1:1 t-BuOH/H2O), and the solution turned to light yellow. The reaction mixture was stirred at 40° C. for 16 hr under N2 atmosphere. LC-MS showed one main peak with desired m/z (calculated MW: 3068.70, observed m/z: 1533.81 ([M/2+H]+), 1023.43 ([M/3+H]+)). The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The crude product was purified by prep-HPLC (TFA condition), and Palmitic acid-PEG10-BCY11144 (150.0 mg, 46.83 μmol, 67.42% yield, 95.80% purity) was obtained as a white solid.
- Procedure for Preparation of Palmitic Acid-PEG10-BCY11144-PEG5-N3
- A mixture of compound 5 (47.0 mg, 15.32 μmol, 1.0 eq.), compound 6 (7.0 mg, 16.19 μmol, 1.1 eq.), and DIEA (3.0 mg, 22.97 μmol, 4.0 μL, 1.5 eq.) was dissolved in DMF (1 mL). The reaction mixture was stirred at 30° C. for 2 hr. LC-MS showed compound 5 was consumed completely and one main peak with desired m/z (MW: 3386.03, observed m/z: 1693.21 ([M/2+H]+), 1129.13 ([M/3+H]+)) was detected. The reaction mixture was concentrated under reduced pressure to remove solvent and produced a residue. The residue was then purified by prep-HPLC (neutral condition). Palmitic acid-PEG10-BCY11144-PEG5-N3 (20.0 mg, 5.72 μmol, 37.33% yield, 96.79% purity) was obtained as a white solid.
- Procedure for Preparation of BCY12020
- A mixture of compound 7 (50.0 mg, 14.77 μmol, 1.0 eq.), compound 8 (35.0 mg, 15.06 μmol, 1.0 eq.), and THPTA (10.0 mg, 23.02 μmol, 1.5 eq.) was dissolved in t-BuOH/H2O (1:1, 2 mL, pre-degassed and purged with N2 for 3 times), and then CuSO4 (0.4 M, 38.0 μL, 1.0 eq.) and VcNa (6.5 mg, 32.81 μmol, 2.2 eq.) were added under N2. The pH of this solution was adjusted to 8 by dropwise addition of 0.2 M NH4HCO3 (in 1:1 t-BuOH/H2O), and the solution turned to light yellow. The reaction mixture was stirred at 40° C. for 16 hr under N2 atmosphere. LC-MS showed one main peak with desired m/z (calculated MW: 5709.68, observed m/z: 1902.80 ([M/3+H]+), 1427.56 ([M/4+H]+)). The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The crude product was purified by prep-HPLC (TFA condition), and BCY12020 (54.8 mg, 9.49 μmol, 64.24% yield, 98.83% purity) was obtained as a white solid.
-
- Procedure for Preparation of Compound 2
- The peptide was synthesized using standard Fmoc chemistry. DCM was added to a reaction vessel containing Chlorotrityl resin (1 mmol, 0.91 g, 1.10 mmol/g) and Fmoc-Lys(N3) —OH (1 eq, 395.4 mg, 1 mmol) with N2 bubbling. DIEA (4.0 eq) was added dropwise and mixed for 2 hours. MeOH (2 mL) was then added and mixed for 30 min. The resin was drained and washed with DMF 5 times. Fmoc deprotection was performed by addition of 20% piperidine/DMF and mixing for 30 min. The resin was drained and washed with DMF 5 times. For chain elongation, Fmoc-amino acid solution was added and mixed for 30 sec first, then add activation buffer (containing HBTU and DIEA in DMF) was added and stirred for 1 hr with continuous N2 bubbling. Deprotection and coupling was repeated until the peptide was complete.
-
# Materials Coupling reagents 1 Fmoc-Lys(N3) -OH (1 eq) DIEA(4.0 eq) 2 Fmoc-γGlu(OtBu)-OH (3 eq) HBTU(2.85 eq) and DIEA(6.0 eq) 3 Palmitic acid (3 eq) HBTU(2.85 eq) and DIEA(6.0 eq) - After last amino acid coupling, the resin was washed with MeOH 3 times, and then dried under vacuum. 10 ml of cleavage cocktail (95% TFA/2.5% TIS/2.5%-H2O) was added to the flask containing the side-chain protected peptide at room temperature and this was stirred for 1 hour. The resin was filtered and the filtrate concentrated to remove the solvent. The crude peptide was lyophilized to give the final product Compound 2 (palmitic acid azide) (200 mg, 97.78% purity, 37.06% yield). Calculated MW: 539.72, observed m/z: 540.4 ([M+H]+).
- Procedure for Preparation of BCY12023-Palmitic Acid Azide
- A mixture of compound 1 (40.0 mg, 17.66 μmol, 1.0 eq.), compound 2 (9.5 mg, 17.66 μmol, 1.0 eq.), and THPTA (8.0 mg, 17.66 μmol, 1.0 eq.) was dissolved in t-BuOH/H2O (1:1, 1 mL, pre-degassed and purged with N2 for 3 times), and then CuSO4 (0.4 M, 45.0 μL, 1.0 eq.) and VcNa (8.0 mg, 35.33 μmol, 2.0 eq.) were added under N2. The pH of this solution was adjusted to 8 by dropwise addition of 0.2 M NH4HCO3 (in 1:1 t-BuOH/H2O), and the solution turned to light yellow. The reaction mixture was stirred at 40° C. for 4 hr under N2 atmosphere. LC-MS showed compound 1 was consumed completely and one main peak with desired m/z (calculated MW: 2804.30, observed m/z: 1402.8 ([M/2+H]+), 935.9 ([M/3+H]+)) was detected. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The crude product was purified by prep-HPLC (TFA condition), and BCY12023-palmitic acid azide (35.0 mg, 12.11 μmol, 68.54% yield, 97.00% purity) was obtained as a white solid.
- Procedure for Preparation of BCY12023-Palmitic Acid—PEG5-N3
- A mixture of compound 3 (35.0 mg, 12.48 μmol, 1.0 eq.), compound 4 (5.4 mg, 12.48 μmol, 1.0 eq.) was dissolved in MeCN/H2O (1:1, 1 mL), and then the pH of this solution was adjusted to 8 by dropwise addition of NaHCO3 (0.1 M). The reaction mixture was stirred at 30° C. for 2 hr. LC-MS showed compound 3 was consumed completely and one main peak with desired m/z (MW: 3121.63, observed m/z: 1561.2 ([(M/2+H]+)) was detected. The reaction mixture was concentrated under reduced pressure to remove solvent and produced a residue. The residue was then purified by prep-HPLC (neutral condition). BCY12023-palmitic acid-PEG5-N3 (11.4 mg, 3.46 μmol, 27.71% yield, 94.70% purity) was obtained as a white solid.
- Procedure for Preparation of BCY12661
- A mixture of compound 5 (11.4 mg, 3.65 μmol, 1.0 eq.), compound 6 (8.3 mg, 3.65 μmol, 1.0 eq.), and THPTA (1.6 mg, 3.65 μmol, 1.0 eq.) was dissolved in t-BuOH/H2O (1:1, 1 mL, pre-degassed and purged with N2 3 times), and then CuSO4 (0.4 M, 10.0 μL, 1.1 eq.) and VcNa (1.5 mg, 7.30 μmol, 2.0 eq.) were added under N2. The pH of this solution was adjusted to 8 by dropwise addition of 0.2 M NH4HCO3 (in 1:1 t-BuOH/H2O), and the solution turned to light yellow. The reaction mixture was stirred at 40° C. for 4 hr under N2 atmosphere. LC-MS showed compound 3 was consumed completely and one main peak with desired m/z (calculated MW: 5374.21, observed m/z: 1344.5 ([M/4+H]+)) was detected. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The crude product was purified by prep-HPLC (TFA condition), and BCY12661 (9.8 mg, 19.63 μmol, 48.73% yield, 97.60% purity) was obtained as a white solid.
-
- General Procedure for Preparation of Compound 1
- The peptide was synthesized using standard Fmoc chemistry. DCM was added to a reaction vessel containing chlorotrityl resin (1 mmol, 0.91 g, 1.1 mmol/g) and Fmoc-γGlu(OtBu)-OH (0.425 mg, 1 mmol, 1 eq) and the mixture stirred with N2 bubbling. DIEA (4.0 eq) was added dropwise and the mixture was agitated for 2 hours. MeOH (4.6 mL) was then added and mixed for 30 min. The resin was drained and washed with DMF 5 times. 20% piperidine/DMF was added to the resin and mixed for 30 minutes. The resin was drained and washed with DMF 5 times. Fmoc-amino acid solution was added to the resin and mixed for 30 seconds, then activating agent and DIPEA was added and N2 bubbled through the mixture for 1 hour. Deprotection and coupling steps were repeated with the following reagents: Note:
-
# Materials Coupling reagents 1 Fmoc-Glu-OtBu (1 eq) DIEA(4.0 eq) 2 Fmoc-Glu-OtBu (3 eq) HBTU(2.85 eq) and DIEA(6.0 eq) 3 Palmitic acid (3 eq) HBTU(2.85 eq) and DIEA(6.0 eq) - After coupling of Palmitic acid, the resin was washed 3 times with MeOH and then dried under vacuum. The peptide was cleaved from the resin by addition of 20% HFIP/80% DCM at room temperature and the mixture stirred for 1 hour. This procedure was repeated once more then the resin was filtered and the filtrate concentrated to remove the solvent. The crude peptide was lyophilized to give the final product (280 mg, 84.80% purity, 44.67% yield). Calculated MW: 626.8, observed m/z: 627.4 ([M+H]+)
- General Procedure for Preparation of Compound 3
- To a solution of compound 2 (15.8 mg, 25.1 μmol, 1.1 eq) in DMF (0.5 mL) was added EDCl (4.4 mg, 22.8 μmol, 1.0 eq) and stirred for 10 min. Then HOSu (2.9 mg, 25.1 μmol, 1.1 eq) and DIEA (8.8 mg, 68.5 μmol, 11.9 μL, 3 eq) were added to the mixture. The mixture was stirred for 16 hr at 25° C. Then BCY12358 (50.0 mg, 22.8 μmol, 1.0 eq) in DMF (0.5 mL) was added to the mixture and this was stirred at 25° C. for another 4 hr. LC-MS showed BCY12358 was consumed completely and one main peak with desired m/z (Calculated MW: 2798.42, observed m/z: 1399.6 [M/2+H]+) was detected. The reaction mixture was purified by prep-HPLC (A: 0.075% TFA in H2O, B: ACN) to give compound 3 (21.9 mg, 7.83 μmol, 34.3% yield) as a white solid.
- General Procedure for Preparation of Compound 5
- A mixture of compound 4 (20.0 mg, 8.03 μmol, 1.0 eq), compound 3 (22.5 mg, 8.03 μmol, 1.0 eq) and THPTA (4.0 mg, 9.21 μmol, 1.15 eq) in t-BuOH (0.5 mL) and H2O (0.5 mL) was degassed and purged with N2 3 times, and then CuSO4 (0.4 M, 20.1 μL, 1.0 eq), VcNa (0.4 M, 40.2 μL, 2.0 eq) and NH4HCO3 (0.2 M, 80.4 μL, 2.0 eq) were added to the mixture. The mixture was stirred at 30° C. for 2 hr under N2 atmosphere. LC-MS showed compound 4 was consumed completely and one main peak with desired m/z (Calculated MW: 5288.25, observed m/z: 1322.3 [M/4+H]+, 1763.8 [M/3+H]+) was detected. EDTA (0.5 M, 20.0 μL) was added to the reaction mixture. The reaction mixture was concentrated under reduced pressure to give a crude product compound 5 (42.0 mg, crude) as gray solid and used into the next step without further purification.
- General Procedure for Preparation of BCY12969
- To a solution of compound 5 (42.0 mg, 8.22 μmol, 1.0 eq) in DCM (0.25 mL) was added TFA (3.37 μmol, 0.25 mL, 458.6 eq) dropwise. The mixture was stirred at 30° C. for 1 hr. LC-MS showed compound 5 was consumed completely and one main peak with desired m/z (Calculated MW: 5176.04, observed m/z: 1035.7 [M/5+H]+, 1294.9 [M/4+H]+, 1726.8 [M/3+H]+) was detected. The reaction mixture was concentrated under reduced pressure to give residue. The residue was purified by prep-HPLC (A: 0.075% TFA in H2O, B: ACN) to give BCY12969 (2.6 mg, 0.48 μmol, 5.85% yield, 92.4% purity) as a white solid.
-
- Procedure for Preparation of BCY12860-PEG5-N3
- A mixture of BCY12860 (40.0 mg, 19.40 μmol, 1.0 eq.), compound 2 (10.0 mg, 21.34 μmol, 1.1 eq.) was dissolved in MeCN/H2O (1:1, 1 mL), and then the pH of this solution was adjusted to 8 by dropwise addition of NaHCO3 (0.1 M). The reaction mixture was stirred at 25° C. for 1 hr. LC-MS showed a peak with desired m/z. The reaction mixture was concentrated under reduced pressure to remove solvent and produced a residue. The residue was then purified by prep-HPLC (neutral condition). BCY12860-PEG5-N3 (39.7 mg, 15.02 μmol, 77.41% yield, 90.0% purity) was obtained as a white solid. MW: 2378.78, observed m/z: 1190.1 ([(M/2+H+]), 793.5 ([(M/3+H+]).
- Procedure for Preparation of BCY13035
- A mixture of compound 3 (39.7 mg, 16.69 μmol, 1.0 eq.), BCY8928 (41.0 mg, 18.36 μmol, 1.1 eq.), and THPTA (0.4 M, 55 μL, 1.3 eq.) was dissolved in t-BuOH/H2O (1:1, 1 mL, pre-degassed and purged with N2 3 times), and then CuSO4 (0.4 M, 55 μL, 1.3 eq.) and VcNa (0.4 M, 109 μL, 2.6 eq.) were added under N2. The pH of this solution was adjusted to 8 by dropwise addition of 0.2 M NH4HCO3 (in 1:1 t-BuOH/H2O), and the solution turned to light yellow. The reaction mixture was stirred at 40° C. for 2 hr under N2 atmosphere. LC-MS showed compound 3 was consumed completely and one main peak with desired m/z was detected. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The crude product was purified by prep-HPLC (TFA condition), and BCY13035 (42.0 mg, 8.85 μmol, 53.04% yield, 96.41% purity) was obtained as a white solid. Calculated MW: 4596.37, observed m/z: 1532.9 ([M/3+H]+), 1149.9 ([M/4+H]+).
-
- Procedure for Preparation of BCY12865-PEG5-N3
- BCY12865 (30.0 mg, 13.99 μmol, 1.0 eq) and compound 1 (6.1 mg, 14.11 μmol, 1.01 eq), were dissolved in 1 mL of MeCN/H2O (1:1), and then 1 M NaHCO3 was added to adjust pH to 8. The mixture was stirred at 25° C. for 2 hr. LC-MS showed BCY12865 was consumed completely and one main peak with desired m/z was detected. The reaction mixture was purified by prep-HPLC (TFA condition) and compound 2 (15.6 mg, 6.32 μmol, 45.19% yield, 99.76% purity) was obtained as a white solid. Calculated MW: 2461.87, observed m/z: 1231.5 ([M/2+H]+) and 821.3 ([M/3+H]+).
- Procedure for Preparation of BCY13040
- Compound 2 (15.6 mg, 6.34 μmol, 1.0 eq) and BCY8928 (14.5 mg, 6.54 μmol, 1.03 eq) were first dissolved in 2 mL of t-BuOH/H2O (1:1), and then CuSO4 (0.4 M, 16 μL, 1.01 eq), VcNa (3.0 mg, 15.14 μmol, 2.39 eq) and THPTA (3 mg, 6.90 μmol, 1.09 eq) were added. Finally, 1 M NH4HCO3 was added to adjust the pH to 8. All solvents were degassed and purged with N2 3 times. The reaction mixture was stirred at 40° C. for 16 hr under N2 atmosphere. LC-MS showed Compound 2 was consumed completely and one main peak with desired m/z was detected. The reaction mixture was purified by prep-HPLC (TFA condition) and BCY13040 (15.8 mg, 3.31 μmol, 52.27% yield, 98.1% purity) was obtained as a white solid. Calculated MW: 4679.45, observed m/z: 1560.8 ([M/3+H]+), 1170.9 ([M/4+H]+), 936.6 ([M/5+H]+).
-
- Procedure for Preparation of BCY13119-PEG5-N3
- A mixture of BCY13119 (35.0 mg, 17.20 μmol, 1.0 eq.), compound 2 (7.8 mg, 18.06 μmol, 1.05 eq.) was dissolved in MeCN/H2O (1:1, 1 mL), and then the pH of this solution was adjusted to 8 by dropwise addition of NaHCO3 (0.1 M). The reaction mixture was stirred at 25° C. for 1 hr. LC-MS showed one main peak with desired m/z (MW: 2352.74, observed m/z: 1177.4 ([(M/2+H+])) was detected. The reaction mixture was concentrated under reduced pressure to remove solvent and produced a residue. The residue was then purified by prep-HPLC (neutral condition). BCY13119-PEG5-N3 (25.7 mg, 9.97 μmol, 58.0% yield, 91.3% purity) was obtained as a white solid.
- Procedure for Preparation of BCY13253
- A mixture of compound 3 (25.7 mg, 10.92 μmol, 1.0 eq.), compound 2 (26.6 mg, 12.02 μmol, 1.1 eq.), and THPTA (5.7 mg, 13.11 μmol, 1.2 eq.) was dissolved in t-BuOH/H2O (1:1, 1 mL, pre-degassed and purged with N2 3 times), and then CuSO4 (0.4 M, 33.0 μL, 1.2 eq.) and VcNa (5.2 mg, 26.21 μmol, 2.4 eq.) were added under N2. The pH of this solution was adjusted to 8 by dropwise addition of 0.2 M NH4HCO3 (in 1:1 t-BuOH/H2O), and the solution turned to light yellow. The reaction mixture was stirred at 25° C. for 2 hr under N2 atmosphere. LC-MS showed compound 3 was consumed completely and one main peak with desired m/z (calculated MW: 4570.32, observed m/z: 1143.4 ([M/4+H]+), 914.9 ([M/5+H]+)) was detected. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The crude product was purified by prep-HPLC (TFA condition), and BCY13253 (17.5 mg, 3.67 μmol, 33.58% yield, 95.8% purity) was obtained as a white solid.
-
- Procedure for Preparation of BCY13120-PEG5-N3
- A mixture of BCY13120 (40.0 mg, 17.92 μmol, 1.0 eq.), compound 2 (8.5 mg, 19.72 μmol, 1.1 eq.) was dissolved in MeCN/H2O (1:1, 1 mL), and then the pH of this solution was adjusted to 8 by dropwise addition of NaHCO3 (0.1 M). The reaction mixture was stirred at 25° C. for 1 hr. LC-MS showed BCY13120 was consumed completely and one main peak with desired m/z (MW: 2548.99, observed m/z: 1275.3 ([(M/2+H+])) was detected. The reaction mixture was concentrated under reduced pressure to remove solvent and produced a residue. The residue was then purified by prep-HPLC (neutral condition). BCY13120-PEG5-N3 (27.3 mg, 10.46 μmol, 58.38% yield, 97.7% purity) was obtained as a white solid.
- Procedure for Preparation of BCY13254
- A mixture of compound 3 (27.3 mg, 10.71 μmol, 1.0 eq.), compound 2 (26.1 mg, 11.78 μmol, 1.1 eq.), and THPTA (5.6 mg, 12.85 μmol, 1.2 eq.) was dissolved in t-BuOH/H2O (1:1, 1 mL, pre-degassed and purged with N2 3 times). CuSO4 (0.4 M, 33.0 μL, 1.2 eq.) and VcNa (5.2 mg, 26.24 μmol, 2.4 eq.) were added under N2. The pH of this solution was adjusted to 8 by dropwise addition of 0.2 M NH4HCO3 (in 1:1 t-BuOH/H2O), and the solution turned to light yellow. The reaction mixture was stirred at 25° C. for 2 hr under N2 atmosphere. LC-MS showed compound 3 was consumed completely and one main peak with desired m/z (calculated MW: 4766.58, observed m/z: 1192.5 ([M/4+H]+), 954.1 ([M/5+H]+)) was detected. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The crude product was purified by prep-HPLC (TFA condition), and BCY13254 (36.5 mg, 7.49 μmol, 69.92% yield, 97.8% purity) was obtained as a white solid.
-
- Procedure for Preparation of BCY12865-PEG5-N3
- BCY12865 (50 mg, 23.32 μmol, 1.0 eq) and compound 1 (10.5 mg, 24.28 μmol, 1.04 eq), were dissolved in 2 mL of MeCN/H2O (1:1), 1 M NaHCO3 was added to adjust pH to 8. And then the mixture was stirred at 25° C. for 2 hr. LC-MS showed BCY12865 was consumed completely and one main peak with desired m/z (calculated MW: 2461.87, observed m/z: 1231.6 ([M/2+H]+) and 821.4 ([M/3+H]+)) was detected. The reaction mixture was purified by prep-HPLC (TFA condition) and compound 2 (31.5 mg, 12.62 μmol, 54.14% yield, 98.66% purity) was obtained as a white solid.
- Procedure for Preparation of BCY13340
- A mixture of compound 2 (31.5 mg, 12.80 μmol, 1.0 eq.), BCY12353 (27 mg, 12.92 μmol, 1.0 eq), and THPTA (5.7 mg, 13.12 μmol, 1.0 eq) was dissolved in t-BuOH/H2O (1:1, 2 mL, pre-degassed and purged with N2 3 times), and then CuSO4 (0.4 M, 32 μL, 1.0 eq) and VcNa (5.1 mg, 25.74 μmol, 2.0 eq) were added under N2. The pH of this solution was adjusted to 8 by dropwise addition of 0.2 M NH4HCO3 (in 1:1 t-BuOH/H2O), and the solution turned to light yellow. The reaction mixture was stirred at 40° C. for 1 hr under N2 atmosphere. LC-MS showed compound 2 was completely consumed and one main peak with desired m/z (calculated MW: 4551.32, observed m/z: 1517.7 ([M/3+H]+) and 1138.6 ([M/4+H]+)) was detected. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The crude product was purified by prep-HPLC (TFA condition), and BCY13340 (34.7 mg, 7.62 μmol, 59.59% yield, 89.59% purity) was obtained as a white solid.
-
- Procedure for Preparation of BCY12860-PEG5-N3
- A mixture of BCY12860 (28.0 mg, 13.58 μmol, 1.0 eq.) and compound 2 (6.5 mg, 14.94 μmol, 1.1 eq.) was dissolved in MeCN/H2O (1:1, 1 mL), and then the pH of this solution was adjusted to 8 by dropwise addition of NaHCO3 (0.1 M). The reaction mixture was stirred at 25° C. for 1 hr. LC-MS showed BCY12860 was consumed completely and one main peak with desired m/z (MW: 2378.78, observed m/z: 1190.2 ([(M/2+H+])) was detected. The reaction mixture was concentrated under reduced pressure to remove solvent and produced a residue. The residue was then purified by prep-HPLC (neutral condition). BCY12860-PEG5-N3 (20.7 mg, 8.41 μmol, 61.95% yield, 96.7% purity) was obtained as a white solid.
- Procedure for preparation of BCY13342
- A mixture of compound 3 (20.7 mg, 8.70 μmol, 1.0 eq.), compound 4 (19.0 mg, 9.14 μmol, 1.05 eq.), and THPTA (5.0 mg, 11.31 μmol, 1.3 eq.) was dissolved in t-BuOH/H2O (1:1, 1 mL, pre-degassed and purged with N2 for 3 times), and then CuSO4 (0.4 M, 28.3 μL, 1.3 eq.) and VcNa (4.5 mg, 22.62 μmol, 2.6 eq.) were added under N2. The pH of this solution was adjusted to 8 by dropwise addition of 0.2 M NH4HCO3 (in 1:1 t-BuOH/H2O), and the solution turned to light yellow. The reaction mixture was stirred at 25° C. for 2 hr under N2 atmosphere. LC-MS showed compound 3 was consumed completely and one main peak with desired m/z (calculated MW: 4468.24, observed m/z: 1118.6 ([M/4+H]+)) was detected. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The crude product was purified by prep-HPLC (TFA condition), and BCY13342 (21.7 mg, 4.60 μmol, 52.85% yield, 94.7% purity) was obtained as a white solid.
- The following heterotandem bicyclic peptide complexes of the invention were analysed using mass spectrometry and HPLC. HPLC setup was as follows:
-
- Mobile Phase: A: 0.1% TFA in H2O B: 0.1% TFA in ACN
- Flow: 1.0 ml/min
- Column: Gemini-NX C18 5 um 110A 150*4.6 mm
- Instrument: Agilent 1200 HPLC-BE(1-614)
- Gradients used are described in the table below:
-
Analytical Method Gradient Description A 25-55% B over 20 minutes B 40-70% B over 20 minutes C 45-75% B over 20 minutes D 30-60% B over 20 minutes E 45-75% B over 20 minutes F 50-80% B over 20 min 50° C. G 35-65% B over 20 minutes H 20-50% B over 20 minutes
and the data was generated as follows: -
HPLC Complex Retention Analytical ID Analytical Data - Mass Spectrometry Time (min) Method BCY12229 calculated MW: 5125.93, observed m/z: 12.039 A 1281.50 ([M/4 + H]+ BCY12230 calculated MW: 5225.06, observed m/z: 12.085 A 1306.62([M/4 + H]+), 1045.0([M/5 + H]+) BCY12231 calculated MW: 5159.01, observed m/z: 10.359 A 1720.76 ([M/3 + H]+), 1291.72 ([M/4 + H]+) BCY12232 calculated MW: 5168.02, observed m/z: 12.121 A 1722.4([M/3 + H]+), 1291.4 ([M/4 + H]+) BCY12242 calculated MW: 5159.00, observed m/z: 13.173 A 1719.17([M/3 + H]+), 1289.84([M/4 + H]+) BCY12375 calculated MW: 6064.08, observed m/z: 10.493 B 1516.4([M/4 + H]+), 1212.8([M/5 + H]+) BCY12663 calculated MW: 5383.22, observed m/z: 10.346 A 1795.0([M/3 + H]+), 1346.7 ([M/4 + H]+) BCY12796 calculated MW: 5360.18, observed m/z: 11.529 A 1787.7([M/3 + H]+), 1341.0([M/4 + H]+) BCY12021 calculated MW: 6102.17, observedm/z: 6.822 C 1525.17([M/4 + H]+), 1221.3([M/5 + H]+) BCY12233 calculated MW: 4935.71, observed m/z: 10.834 A 1234.16 ([M/4 + H]+) BCY12234 calculated MW: 5105.92, observed m/z: 10.58 A 1276.87([M/4 + H]+), 1021.80([M/5 + H]+) BCY12235 calculated MW: 4968.78, observed m/z: 12.165 A 1655.4([M/3 + H]+), 1242.83([M/4 + H]+) BCY12236 calculated MW: 4992.76, observed m/z: 10.023 A 1248.4([M/4 + H]+) BCY12237 calculated MW: 4992.76, observed m/z: 10.091 A 1248.70([M/4 + H]+), 998.70([M/5 + H]+) BCY12711 calculated MW: 4896.6, observed m/z: 11.23 A 1633.1 ([M/3 + H]+), 1225.2([M/4 + H]+) BCY12712 calculated MW: 4864.63, observed m/z: 11.006 A 1622.6([M/3 + H]+), 1217.6([M/4 + H]+) BCY12713 calculated MW: 4863.65, observed m/z: 10.851 A 1621.8([M/3 + H]+), 1217.0([M/4 + H]+) BCY12714 calculated MW: 4878.67, observed m/z: 10.824 A 1626.9([M/3 + H]+), 1220.5([M/4 + H]+) BCY12715 calculated MW: 4892.70, observed m/z: 10.859 A 1631.6([M/3 + H]+), 1223.7([M/4 + H]+) BCY12717 calculated MW: 4821.61, observed m/z: 11.37 A 1607.8([M/3 + H]+), 1206.0([M/4 + H]+) BCY12718 calculated MW: 4807.58, observed m/z: 11.527 A 1603.5([M/3 + H]+), 1202.9([M/4 + H]+) BCY12719 Calculated MW: 4764.57, observed m/z: 15.353 H 1192.0 [M/4 + H]+, 1589.0 [M/3 + H]+ BCY12720 Calculated MW: 5319.25, observed m/z: 9.285 B 1065.1 [M/5 + H]+, 1331.0 [M/4 + H]+, 1773.9 [M/3 + H]+ BCY12961 Calculated MW: 5105.93, observed m/z: 10.958 A 1022.0 [M/5 + H]+, 1277.5 [M/4 + H]+, 1703.0 [M/3 + H]+ BCY12962 Calculated MW: 4968.79, observed m/z: 12.517 A 994.9 [M/5 + H]+, 1243.3 [M/4 + H]+, 1656.7 [M/3 + H]+ BCY12963 Calculated MW: 4992.76, observed m/z: 10.437 A 1249.0 [M/4 + H]+, 1664.9 [M/3 + H]+) BCY12964 Calculated MW: 4992.78, observed m/z: 10.445 A 999.6 [M/5 + H]+, 1249.3 [M/4 + H]+, 1665.3 [M/3 + H]+ BCY12965 Calculated MW: 4949.75, observed m/z: 11.302 A 990.6 [M/5 + H]+, 1238.1 [M/4 + H]+, 1650.4 [M/3 + H]+ BCY12966 Calculated MW: 4963.78, observed m/z: 11.138 A 993.8 [M/5 + H]+, 1241.7 [M/4 + H]+ BCY13029 calculated MW: 4927.69, observed m/z: 11.74 A 1643.7 ([M/3 + H]+), 1233.1 ([M/4 + H]+) BCY13030 calculated MW: 4866.62, observed m/z: 11.393 A 1622.7 ([M/3 + H]+), 1217.2 ([M/4 + H]+), 974.0 ([M/5 + H]+) BCY13031 calculated MW: 4858.59, observed m/z: 10.381 D 1619.9 ([M/3 + H]+), 1215.1 ([M/4 + H]+) BCY13032 calculated MW: 4929.67, observed m/z: 13.144 A 1643.9([M/3 + H]+), 1233.3([M/4 + H]+) BCY13033 calculated MW: 4814.57, observed m/z: 13.497 A 1606.0([M/3 + H]+), 1204.2 ([M/4 + H]+), 963.6 ([M/5 + H]+) BCY13034 calculated MW: 4952.75, observed m/z: 12.207 G 1651.5([M/3 + H]+), 1239.0([M/4 + H]+) BCY13035 calculated MW: 4596.37, observed m/z: 8.083 C 1532.9([M/3 + H]+), 1149.9 ([M/4 + H]+)) BCY13036 calculated MW: 4573.29, observed m/z: 12.387 D 1525.4([M/3 + H]+) and 1143.9([M/4 + H]+) BCY13037 calculated MW: 4947.74, observed m/z: 11.699 A 1650.4([M/3 + H]+), 1238.0 ([M/4 + H]+) BCY13038 calculated MW: 4870.60, observed m/z: 10.747 D 1624.2([M/3 + H]+), 1218.5 ([M/4 + H]+) BCY13039 calculated MW: 4914.67, observed m/z: 10.542 D 1648.5([M/3 + H]+), 1235.9 ([M/4 + H]+) BCY13040 calculated MW: 4679.45, observed m/z: 14.688 G 1560.8 ([M/3 + H]+), 1170.9 ([M/4 + H]+), 936.6 ([M/5 + H]+) BCY13041 calculated MW: 5021.86, observed m/z: 9.609 G 1674.4 ([M/3 + H]+), 1256.1 ([M/4 + H]+), 1005.2 ([M/5 + H]+ BCY11616 calculated MW: 4827.46, observed m/z: 12.538 A 1609.7([M/3 + H]+), 1207.5([M/4 + H]+) BCY12238 calculated MW: 4763.50, observed m/z: 14.249 A 1587.84 ([M/3 + H]+), 1191.37([M/4 + H]+) BCY12377 calculated MW: 4668.32, observed m/z: 14.304 A 1556.1 ([M/3 + H]+), 1167.0([M/4 + H]+) BCY12379 calculated MW: 4636.32, observed m/z: 10.779 D 1159.8([M/4 + H]+) BCY12572 calculated MW: 4593.29, observed m/z: 11.303 D 1531.7([M/3 + H]+), 1148.8([M/4 + H]+) BCY12573 calculated MW: 4579.27, observed m/z: 14.454 A 1526.8([M/3 + H]+) BCY12574 calculated MW: 4536.24, observed m/z: 11.959 D 1512.9([M/3 + H]+) BCY12575 calculated MW: 5090.92, observed m/z: 9.868 C 1698.3([M/3 + H]+), 1273.9([M/4 + H]+) BCY12576 (calculated MW: 4705.47, observed m/z: 11.383 D 1568.7 ([M/3 + H]+), 1177.3([M/4 + H]+) BCY12577 Calculated MW: 4719.51, observed m/z: 10.953 D 1180.8 [M/4 + H]+, 1574.2 [M/3 + H]+) BCY12578 Calculated MW: 4662.45, observed m/z: 11.906 D 1165.9 [M/4 + H]+, 1554.8 [M/3 + H]+ BCY12579 calculated MW: 4784.57, observed m/z: 12.811 A 1595.7([M/3 + H]+), 1197.0([M/4 + H]+) BCY12580 calculated MW: 4776.56, observed m/z: 14.107 A 1592.2 ([M/3 + H]+) BCY12581 calculated MW: 4721.43, observed m/z: 10.776 D 1574.2 ([M/3 + H]+) and 1181.1 ([M/4 + H]+) BCY12582 calculated MW: 4663.39, observed m/z: 11.002 D 1555.5 ([M/3 + H]+)) BCY12583 calculated MW: 4703.38, observed m/z: 11.017 D 1568.6 ([M/3 + H]+), 1176.2([M/4 + H]+) BCY12584 Calculated MW: 5217.13, observed m/z: 12.954 B 1305.1 [M/4 + H]+, 1739.8 [M/3 + H]+) BCY12585 calculated MW: 4735.45, observed m/z: 14.077 A 1578.8 ([M/3 + H]+ BCY12709 Calculated MW: 4624.32, observed m/z: 10.749 D 925.5 [M/5 + H]+, 1156.7 [M/4 + H]+, 1541.8 [M/3 + H]+) BCY12710 Calculated MW: 4624.32, observed m/z: 13.832 A 925.6 [M/5 + H]+, 1157.3 [M/4 + H]+, 1541.9 [M/3 + H]+ BCY11468 calculated MW: 6783.93, observed m/z: 10.29 B 1131.7([M/6 + H]+ BCY11618 calculated MW: 5029.97, observed m/z: 8.89 E 1257.8([M/4 + H]+) and 1006.6([M/5 + H]+ BCY11776 calculated MW: 5031.91, observed m/z: 12.598 E 1258.52([M/4 + H]+) and 1006.7([M/5 + H]+) BCY11860 m/z (MW: 5617.56, observed m/z: 10.166 F 1404.56 ([(M/4 + H+]) BCY12020 calculated MW: 5709.68, observed m/z: 14.108 B 1902.80([M/3 + H]+), 1427.56([M/4 + H]+ BCY12661 calculated MW: 5374.21, observed m/z: 12.408 B 1344.5 ([M/4 + H]+) BCY12969 Calculated MW: 5176.04, observed m/z: 13.147 B 1035.7 [M/5 + H]+, 1294.9 [M/4 + H]+, 1726.8 [M/3 + H]+) - 1. CD137 Reporter Assay Co-Culture with Tumour Cells
- Culture medium, referred to as R1 media, is prepared by adding 1% FBS to RPMI-1640 (component of Promega kit CS196005). Serial dilutions of test articles in R1 are prepared in a sterile 96 well-plate. Add 25 μL per well of test articles or R1 (as a background control) to designated wells in a white cell culture plate. Tumour cells* are harvested and resuspended at a concentration of 400,000 cells/mL in R1 media. Twenty five (25) μL/well of tumour cells are added to the white cell culture plate. Jurkat cells (Promega kit CS196005, 0.5 mL) are thawed in the water bath and then added to 5 ml pre-warmed R1 media. Twenty five (25) μL/well of Jurkat cells are then added to the white cell culture plate. Incubate the cells and test articles for 6h at 37° C., 5% CO2. At the end of 6h, add 75 μL/well Bio-Glo™ reagent (Promega) and incubate for 10 min before reading luminescence in a plate reader (Clariostar, BMG). The fold change relative to cells alone (Jurkat cells+ Cell line used in co-culture) is calculated and plotted in GraphPad Prism as log(agonist) vs response to determine EC50 (nM) and Fold Induction over background (Max).
- The tumour cell type used in co-culture is NCI-H292 which has been shown to express Nectin-4. The tumour cell type used in co-culture for EphA2 is PC3. The tumour cell type used in co-culture for PD-L1 is RKO.
- A summary of the fold induction induced by Nectin-4/CD137 heterotandem peptides in the CD137 reporter coculture assay with NCI-H292 cells is shown in Table 1. All compounds are compared to plate control BCY10000 which has an average EC50 of 1.1±0.5 nM and Emax of 28±11 fold over background.
-
TABLE 1 Fold induction induced by Nectin-4/CD137 heterotandem bicyclic peptide complexes in a CD137 reporter assay Fold improvement in Fold improvement in EC50 over BCY10000 Emax over BCY10000 Complex ID on same plate on same plate BCY11616 0.21 1.22 BCY12377 0.78 1.37 BCY12379 0.91 1.29 BCY12572 0.35 1.67 BCY12573 0.74 1.34 BCY12574 0.22 0.77 BCY12575 0.73 0.35 BCY12576 0.23 1.45 BCY12577 0.25 1.06 BCY12578 0.05 0.93 BCY12579 0.29 1.07 BCY12580 0.64 0.97 BCY12581 1.35 0.88 BCY12582 1.69 1.32 BCY12583 0.60 1.47 BCY12585 1.31 1.50 BCY12709 0.08 2.15 BCY12710 0.16 1.41 BCY11468 0.45 0.68 BCY11618 0.09 2.59 BCY11776 0.05 0.07 BCY11860 0.29 1.53 BCY12020 0.15 0.48 BCY12661 0.34 0.50 - A summary of the fold induction induced by EphA2/CD137 heterotandem peptides in the CD137 reporter coculture assay with PC3 cells is shown in Table 2. All compounds are compared to plate control BCY9173 which has an average EC50 of 0.54 nM and Emax of 42 fold over background.
-
TABLE 2 Fold induction induced by EphA2/CD137 heterotandem bicyclic peptide complexes in a CD137 reporter assay Fold improvement in Fold improvement in EC50 over BCY9173 Emax over BCY9173 Complex ID Cell line on same plate on same plate BCY12233 PC3 1.0 0.9 BCY12234 PC3 1.0 0.8 BCY12235 PC3 1.1 0.8 BCY12236 PC3 1.4 0.8 BCY12237 PC3 1.0 0.8 - A summary of the fold induction induced by PD-L1/CD137 heterotandem peptides in the CD137 reporter coculture assay with RKO cells is shown in Table 3.
-
TABLE 3 Fold induction induced by PD-L1/CD137 heterotandem bicyclic peptide complexes in a CD137 reporter assay Fold Induction Bicycle ID EC50(nM) over background BCY12229 18 8 BCY12230 46 10 BCY12242 20 13 BCY12375 22 3 - Male SD Rats were dosed with 2 mg/kg of each heterotandem Bicycle peptide complex formulated in 25 mM Histidine HCl, 10% sucrose pH 7. Serial bleeding (about 80 μL blood/time point) was performed via submadibular or saphenous vein at each time point. All blood samples were immediately transferred into prechilled microcentrifuge tubes containing 2 μL K2-EDTA (0.5M) as anti-coagulant and placed on wet ice. Blood samples were immediately processed for plasma by centrifugation at approximately 4° C., 3000 g. The precipitant including internal standard was immediately added into the plasma, mixed well and centrifuged at 12,000 rpm, 4° C. for 10 minutes. The supernatant was transferred into pre-labeled polypropylene microcentrifuge tubes, and then quick-frozen over dry ice. The samples were stored at 70° C. or below as needed until analysis. 7.5 μL of the supernatant samples were directly injected for LC-MS/MS analysis using an Orbitrap Q Exactive in positive ion mode to determine the concentrations of Bicycle. Plasma concentration versus time data were analyzed by non-compartmental approaches using the Phoenix WinNonlin 6.3 software program. C0, CI, Vdss, T1/2, AUC(0-last), AUC(0-inf), MRT(0-last), MRT(0-inf) and graphs of plasma concentration versus time profile were reported. The pharmacokinetic parameters from the experiment are as shown in Table 4:
-
TABLE 4 Pharmacokinetic Parameters in SD Rats Dosing Dose Clp Compound Route (mg/kg) T½(h) Vdss (L/kg) (ml/min/kg) BCY12234 IV Inf 2.0 0.42 0.95 26 BCY13035 IV Inf 3.0 1.5 0.63 11 BCY13040 IV Inf 3.0 1.6 0.63 10
Claims (21)
1-16. (canceled)
17. A method of preventing, suppressing or treating a cancer, which comprises administering to a patient in need thereof a heterotandem bicyclic peptide complex comprising:
(a) a first peptide ligand which binds to a component present on a cancer cell; conjugated via a linker to
(b) a second peptide ligand which binds to a component present on an immune cell; wherein each of said peptide ligands comprise a polypeptide comprising at least three reactive groups, separated by at least two loop sequences, and a molecular scaffold which forms covalent bonds with the reactive groups of the polypeptide such that at least two polypeptide loops are formed on the molecular scaffold, characterized in that said heterotandem bicyclic peptide complex comprises the following first and second peptide ligands:
18. The method of claim 17 , wherein the immune cell is selected from: white blood cells, lymphocytes, CD8 cells, CD4 cells, dendritic cells, follicular dendritic cells and granulocytes.
19. The method of claim 17 , wherein the second peptide ligand comprises a CD137 binding bicyclic peptide ligand.
20. The method of claim 19 , wherein the CD137 binding bicyclic peptide ligand is selected from any of the peptides of SEQ ID NOS: 67 to 84.
21. The method of claim 17 , wherein the first peptide ligand comprises a Nectin-4 binding bicyclic peptide ligand.
22. The method of claim 21 , wherein the Nectin-4 binding bicyclic peptide ligand is selected from any of the peptides of SEQ ID NOS: 52 to 66.
23. The method of claim 21 , wherein the heterotandem bicyclic peptide complex is selected from BCY11468, BCY11618, BCY11776, BCY11860, BCY12020, BCY12661 and BCY12969.
24. The method of claim 17 , wherein the first peptide ligand comprises an EphA2 binding bicyclic peptide ligand.
25. The method of claim 24 , wherein the EphA2 binding bicyclic peptide ligand is selected from any of the peptides of SEQ ID NOS: 10 to 51.
26. The method of claim 24 , wherein the heterotandem bicyclic peptide complex is selected from BCY13035, BCY13040, BCY13253, BCY13254, BCY13340 and BCY13342.
27. The method of claim 17 , wherein the first peptide ligand comprises a PD-L1 binding bicyclic peptide ligand.
28. The method of claim 27 , wherein the PD-L1 binding bicyclic peptide ligand is selected from any of the peptides of SEQ ID NOS: 1 to 9.
29. The method of claim 27 , wherein the heterotandem bicyclic peptide complex is selected from BCY12375 and BCY12021.
30. The method of claim 17 , wherein the molecular scaffold is 1,1′,1″-(1,3,5-triazinane-1,3,5-triyl)triprop-2-en-1-one (TATA).
31. The method of claim 17 , wherein the pharmaceutically acceptable salt is selected from the free acid or the sodium, potassium, calcium, or ammonium salt.
33. The method of claim 20 , wherein the CD137 binding bicyclic peptide ligand is SEQ ID NO: 77.
34. The method of claim 25 , wherein the EphA2 binding bicyclic peptide ligand is SEQ ID NO: 33.
35. The method of claim 26 , wherein the heterotandem bicyclic peptide complex is BCY13340.
36. The method of claim 18 , wherein the lymphocytes are selected from T lymphocytes or T cells, B cells, or natural killer cells.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/655,822 US20220306694A1 (en) | 2019-10-03 | 2022-03-22 | Heterotandem bicyclic peptide complexes |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962910129P | 2019-10-03 | 2019-10-03 | |
US17/062,662 US11332500B2 (en) | 2019-10-03 | 2020-10-05 | Heterotandem bicyclic peptide complexes |
US17/655,822 US20220306694A1 (en) | 2019-10-03 | 2022-03-22 | Heterotandem bicyclic peptide complexes |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/062,662 Division US11332500B2 (en) | 2019-10-03 | 2020-10-05 | Heterotandem bicyclic peptide complexes |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220306694A1 true US20220306694A1 (en) | 2022-09-29 |
Family
ID=72811890
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/062,662 Active US11332500B2 (en) | 2019-10-03 | 2020-10-05 | Heterotandem bicyclic peptide complexes |
US17/655,822 Abandoned US20220306694A1 (en) | 2019-10-03 | 2022-03-22 | Heterotandem bicyclic peptide complexes |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/062,662 Active US11332500B2 (en) | 2019-10-03 | 2020-10-05 | Heterotandem bicyclic peptide complexes |
Country Status (5)
Country | Link |
---|---|
US (2) | US11332500B2 (en) |
EP (1) | EP4038096A1 (en) |
JP (1) | JP2022551607A (en) |
CN (1) | CN114867753A (en) |
WO (1) | WO2021064428A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11833211B2 (en) | 2017-12-19 | 2023-12-05 | Bicycletx Limited | Methods of suppression and treatment of disease comprising administering bicycle peptide ligands specific for EphA2 |
US11912792B2 (en) | 2018-06-22 | 2024-02-27 | Bicycletx Limited | Bicyclic peptide ligands specific for nectin-4 |
US11970553B2 (en) | 2019-07-30 | 2024-04-30 | Bicycletx Limited | Heterotandem bicyclic peptide complex |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111032678A (en) | 2017-06-26 | 2020-04-17 | 拜西克尔德有限公司 | Bicyclic peptide ligands with detectable moieties and uses thereof |
EP3661948B1 (en) | 2017-08-04 | 2022-06-01 | BicycleTx Limited | Bicyclic peptide ligands specific for cd137 |
GB201721265D0 (en) | 2017-12-19 | 2018-01-31 | Bicyclerd Ltd | Bicyclic peptide ligands specific for EphA2 |
SG11202007678QA (en) | 2018-02-23 | 2020-09-29 | Bicycletx Ltd | Multimeric bicyclic peptide ligands |
MX2020010444A (en) | 2018-04-04 | 2021-01-08 | Bicycletx Ltd | Heterotandem bicyclic peptide complexes. |
GB201810316D0 (en) | 2018-06-22 | 2018-08-08 | Bicyclerd Ltd | Peptide ligands for binding to EphA2 |
KR20220007098A (en) | 2019-05-09 | 2022-01-18 | 바이사이클티엑스 리미티드 | Bicyclic peptide ligand specific for OX40 |
JP2022551607A (en) | 2019-10-03 | 2022-12-12 | バイスクルテクス・リミテッド | Heterotandem bicyclic peptide complexes |
EP4274597A1 (en) * | 2021-01-11 | 2023-11-15 | BicycleTX Limited | Methods for treating cancer |
WO2022253051A1 (en) * | 2021-06-01 | 2022-12-08 | 南京明德新药研发有限公司 | Polypeptide conjugated drug and use thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019025811A1 (en) * | 2017-08-04 | 2019-02-07 | Bicycletx Limited | Bicyclic peptide ligands specific for cd137 |
US11306123B2 (en) * | 2019-07-30 | 2022-04-19 | Bicycletx Limited | Heterotandem bicyclic peptide complex |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1452868A2 (en) | 2003-02-27 | 2004-09-01 | Pepscan Systems B.V. | Method for selecting a candidate drug compound |
WO2006078161A1 (en) | 2005-01-24 | 2006-07-27 | Pepscan Systems B.V. | Binding compounds, immunogenic compounds and peptidomimetics |
EP2653545A1 (en) | 2008-02-05 | 2013-10-23 | Bicycle Therapeutics Limited | Methods and compositions |
GB0913775D0 (en) | 2009-08-06 | 2009-09-16 | Medical Res Council | Multispecific peptides |
WO2012057624A1 (en) | 2010-10-25 | 2012-05-03 | Pepscan Systems B.V. | Novel bicyclic peptide mimetics |
CN103906865B (en) | 2011-10-07 | 2017-12-08 | 拜斯科医疗有限公司 | The regulation and control of structuring polypeptid specificity |
JP7065567B2 (en) * | 2014-06-10 | 2022-05-12 | スリービー・ファーマシューティカルズ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Conjugates containing neurotensin receptor ligands and their use |
SG11201702845QA (en) * | 2014-10-29 | 2017-05-30 | Bicycle Therapeutics Ltd | Bicyclic peptide ligands specific for mt1-mmp |
MA45328A (en) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF |
KR102426765B1 (en) | 2016-04-22 | 2022-07-29 | 엘리게이터 바이오사이언스 에이비 | Novel bispecific polypeptide for CD137 |
GB201607827D0 (en) | 2016-05-04 | 2016-06-15 | Bicycle Therapeutics Ltd | Bicyclic peptide-toxin conjugates specific for MT1-MMP |
AU2018224094A1 (en) | 2017-02-24 | 2019-09-19 | Macrogenics, Inc. | Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof |
GB201721265D0 (en) | 2017-12-19 | 2018-01-31 | Bicyclerd Ltd | Bicyclic peptide ligands specific for EphA2 |
TWI825046B (en) | 2017-12-19 | 2023-12-11 | 英商拜西可泰克斯有限公司 | Bicyclic peptide ligands specific for epha2 |
SG11202007678QA (en) | 2018-02-23 | 2020-09-29 | Bicycletx Ltd | Multimeric bicyclic peptide ligands |
MX2020010444A (en) * | 2018-04-04 | 2021-01-08 | Bicycletx Ltd | Heterotandem bicyclic peptide complexes. |
US11180531B2 (en) | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
GB201810316D0 (en) | 2018-06-22 | 2018-08-08 | Bicyclerd Ltd | Peptide ligands for binding to EphA2 |
US10919937B2 (en) | 2018-10-23 | 2021-02-16 | Bicycletx Limited | Bicyclic peptide ligands and uses thereof |
JP2022514618A (en) | 2018-12-21 | 2022-02-14 | バイスクルテクス・リミテッド | Bicyclic peptide ligand specific for PD-L1 |
CA3135569A1 (en) | 2019-04-02 | 2020-10-08 | Bicycletx Limited | Bicycle toxin conjugates and uses thereof |
KR20220007098A (en) | 2019-05-09 | 2022-01-18 | 바이사이클티엑스 리미티드 | Bicyclic peptide ligand specific for OX40 |
CN114787197A (en) | 2019-08-13 | 2022-07-22 | 拜斯科技术开发有限公司 | Modified multimeric bicyclic peptide ligands |
JP2022551607A (en) | 2019-10-03 | 2022-12-12 | バイスクルテクス・リミテッド | Heterotandem bicyclic peptide complexes |
-
2020
- 2020-10-05 JP JP2022520570A patent/JP2022551607A/en active Pending
- 2020-10-05 US US17/062,662 patent/US11332500B2/en active Active
- 2020-10-05 WO PCT/GB2020/052445 patent/WO2021064428A1/en unknown
- 2020-10-05 CN CN202080069454.8A patent/CN114867753A/en active Pending
- 2020-10-05 EP EP20789240.7A patent/EP4038096A1/en active Pending
-
2022
- 2022-03-22 US US17/655,822 patent/US20220306694A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019025811A1 (en) * | 2017-08-04 | 2019-02-07 | Bicycletx Limited | Bicyclic peptide ligands specific for cd137 |
US11306123B2 (en) * | 2019-07-30 | 2022-04-19 | Bicycletx Limited | Heterotandem bicyclic peptide complex |
US20220242911A1 (en) * | 2019-07-30 | 2022-08-04 | Bicycletx Limited | Heterotandem bicyclic peptide complex |
US20230129258A1 (en) * | 2019-07-30 | 2023-04-27 | Bicycletx Limited | Heterotandem bicyclic peptide complexes |
Non-Patent Citations (8)
Title |
---|
Johnson et al. NATURE COMMUNICATIONS | 7:10582, Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy (Year: 2015) * |
Medical news today by Christina Chun, https://www.medicalnewstoday.com/articles/322700 Accessed May, 8, 2020 (Year: 2018) * |
Merck manual, cancer treatment principles, by Robert Gale, https://www.merckmanuals.com/home/cancer/prevention-and-treatment-of-cancer/cancer-treatment-principles?query=Cancer%20treatment Accessed May 8, 2020 (Year: 2018) * |
Merck manual, overview of cancer therapy, by Robert Gale, https://www.merckmanuals.com/professional/hematology-and-oncology/principles-of-cancer-therapy/overview-of-cancer-therapy?query=Cancer Accessed May 8, 2020 (Year: 2018) * |
National cancer institute, cancer prevention, https://www.cancer.gov/about-cancer/causes-prevention/patient-prevention-overview-pdq accessed May 8, 2020 (Year: 2020) * |
National cancer institute, what is cancer? https://www.cancer.gov/about-cancer/understanding/what-is-cancer accessed on May 8, 2020 (Year: 2015) * |
Nishiwada et al. Journal of Experimental & Clinical Cancer Research (2015) 34:30, Nectin-4 expression contributes to tumor proliferation, angiogenesis and patient prognosis in human pancreatic cancer (Year: 2015) * |
Sausville et al. Contributions of Human Tumor Xenografts to Anticancer Drug Development. Cancer Res 2006; 66: (7). April 1, 2006 (Year: 2006) * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11833211B2 (en) | 2017-12-19 | 2023-12-05 | Bicycletx Limited | Methods of suppression and treatment of disease comprising administering bicycle peptide ligands specific for EphA2 |
US11912792B2 (en) | 2018-06-22 | 2024-02-27 | Bicycletx Limited | Bicyclic peptide ligands specific for nectin-4 |
US11970553B2 (en) | 2019-07-30 | 2024-04-30 | Bicycletx Limited | Heterotandem bicyclic peptide complex |
Also Published As
Publication number | Publication date |
---|---|
WO2021064428A1 (en) | 2021-04-08 |
US20210101937A1 (en) | 2021-04-08 |
US11332500B2 (en) | 2022-05-17 |
JP2022551607A (en) | 2022-12-12 |
EP4038096A1 (en) | 2022-08-10 |
CN114867753A (en) | 2022-08-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11332500B2 (en) | Heterotandem bicyclic peptide complexes | |
US11453703B2 (en) | Heterotandem bicyclic peptide complexes | |
US11312749B2 (en) | Heterotandem bicyclic peptide complex | |
US11261214B2 (en) | Bicyclic peptide ligand specific for CD137 | |
EP3755725A1 (en) | Multimeric bicyclic peptide ligands | |
US11613560B2 (en) | Bicyclic peptide ligands specific for OX40 | |
US20220054646A1 (en) | Bicyclic peptide ligands specific for psma | |
US20220008545A1 (en) | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR FAPa | |
US20220088118A1 (en) | Bicyclic peptide ligands specific for caix | |
WO2023057758A1 (en) | Bicyclic peptide ligand drug conjugates | |
US20220064218A1 (en) | Bicyclic peptide ligands specific for cd38 | |
WO2021123771A1 (en) | Bicyclic peptide ligands specific for il-17 | |
WO2021123767A1 (en) | Bicyclic peptide ligands specific for il-17 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: BICYCLETX LIMITED, UNITED KINGDOM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MUDD, GEMMA;UPADHYAYA, PUNIT;MCDONNELL, KEVIN;REEL/FRAME:059340/0967 Effective date: 20201014 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |